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 Science is not done in a vacuum.  In fact, I believe that the best science is done 
collaboratively, in an environment where researchers of all different disciplines and 
backgrounds share ideas and formulate (or preferably conjugate…) solutions to problems 
as a team, drawing on the expertise of each individual.    
 Team Khvorova was not only the best research team I have ever worked with, but 
they have been my family as well.  I first joined the lab as a research associate, unsure if 
the PhD path was the right one for me.  But from the very beginning Anastasia had an 
enormous amount of confidence in me and quickly became my biggest fan and the 
greatest mentor I have ever had.  From there my family only grew…  Matthew Hassler, 
Marie Didiot, Mehran Nikan and Jasmine Abraham took be under their wings and began 
teaching me the ropes of oligonucleotide chemistry, cell biology, and neuroscience.  
 After that, we gained Soki Ly, Reka Haraszti, Andrew Coles, Anton Turanov, 
Maire Osborn, Loic Roux, Annabelle Biscans, Dimas Echeverria, and Bruno Godinho.  
We weren’t just colleagues we were great friends.  With heart to heart conversations, 
lunchtime chats, late nights with beers in the lab, paintball, lake parties, and skiing trips 
we were like a nerdy gang.  It was during this time that my scientific knowledge also 
began to bloom.  With many different brilliant minds and many varied expertise, I felt so 
lucky to be in this lab.  In particular I need to acknowledge Matt and Bruno, my partners 
in crime in developing the Di-siRNA chemical scaffold, and Bruno and Marie, for letting 
me be part of their growing families.  And to Annabelle, who edited this dissertation. 
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 Then we gained Ken Yamada, Yann Thillier, and the group I like to call “the 
kids”:  Chantal Ferguson, Sarah Davis, James Gilbert, Emily Knox, Sam Hildebrand, 
Jacquelyn Sousa and Lorenc Vangjeli.  While newer students to the lab, it quickly 
became clear that they were always meant to be a part of our family.  They were not only 
thoughtful and intelligent but also funny, kind, and willing to do anything for their fellow 
lab mates.   
 And where would any of us be without Mary Beth Dziewietin....  Like a second 
mother to us she has not only helped with everything administrative but has generally 
ensured that we make it through our time here in one piece. Life in the lab would have 
been much more difficult and far less pleasant without her. 
 As our lab family grew so did our extended lab family…enter, the Khvorova lab 
babies; Jules, Leonor, Emma, Louise, and of course the lab dogs; have brought so much 
joy to all of our lives.  These additions to our extended family just made all of us feel 
more full of love. 
 But my family is not limited to the Khvorova lab.   So many labs at UMass 
supported me during my graduate studies including the Aronin Lab, the Watts lab, the 
Esteves lab, the Muller lab, and many more.  UMass is truly a family in and of itself.   
 I would also like to acknowledge my classmates.  When we all first started we 
were in the same boat. We quickly banned together and ensured that we would carry each 
other, not only through core, but through our entire degrees.  To this day my classmates 
still support me and look out for me.   
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 Last but not least, my family, Mom, Dad, Emma, and all my extended family and 
“feels like family” friends.  They have supported me through thick and thin, in good 
times and bad, and I cannot thank them enough for all they have given me. 




 Small interfering RNAs (siRNAs) are a promising class of drugs for treating 
genetically-defined diseases. Therapeutic siRNAs enable specific modulation of gene 
expression, but require chemical architecture that facilitates efficient in vivo delivery. 
siRNAs are informational drugs, therefore specificity for a target gene is defined by 
nucleotide sequence. Thus, developing a chemical scaffold that efficiently delivers 
siRNA to a particular tissue provides an opportunity to target any disease-associated gene 
in that tissue. The goal of this project was to develop a chemical scaffold that supports 
efficient siRNA delivery to the brain for the treatment of neurodegenerative diseases, 
specifically Huntington’s disease (HD). 
 HD is an autosomal dominant neurodegenerative disorder that affects 3 out of 
every 100,000 people worldwide. This disorder is caused by an expansion of CAG 
repeats in the huntingtin gene that results in significant atrophy in the striatum and cortex 
of the brain. Silencing of the huntingtin gene is considered a viable treatment option for 
HD. This project: 1) identified a hyper-functional sequence for siRNA targeting the 
huntingtin gene, 2) developed a fully chemically modified architecture for the siRNA 
sequence, and 3) identified a new structure for siRNA central nervous system (CNS) 
delivery—Divalent-siRNA (Di-siRNA). Di-siRNAs, which are composed of two fully 
chemically-stabilized, phosphorothioate-containing siRNAs connected by a linker, 
support potent and sustained gene modulation in the CNS of mice and non-human 
primates. In mice, Di-siRNAs induced potent silencing of huntingtin mRNA and protein 
throughout the brain one month after a single intracerebroventricular injection. Silencing 
persisted for at least six months, with the degree of gene silencing correlating to guide 
 viii 
strand tissue accumulation levels. In Cynomolgus macaques, a bolus injection exhibited 
significant distribution and robust silencing throughout the brain and spinal cord without 
detectable toxicity. This new siRNA scaffold opens the CNS for RNAi-based gene 
modulation, creating a path towards developing treatments for genetically-defined 
neurological disorders.
 9 
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CHAPTER I:  INTRODUCTION 
 
1.1 OLIGONUCLEOTIDES: INFORMATIONAL DRUGS 
 Informational drugs such as oligonucleotides are a new class of 
therapeutics that depend on sequence complementarity for target specificity1. They allow 
for the separation of “dianophore” from “pharmacophore” (Fig. 1.1).  The 
pharmacophore of an informational drug is its sequence, which is responsible for 
targeting a specific disease-related gene, while the dianophore is the chemical scaffold 
that impacts distribution, retention, efficacy, potency, clearance, stability, and 
immunogenicity of the drug.  Their advantages over conventional small molecule drugs 
include: (i) ease of design—rationally achieved based on sequence information and 
straightforward screening, leading to drug candidates within a short period of time; (ii) 
ability to target disease-related genes previously considered “undruggable”; and (iii) 
unprecedented potency and duration of effect.  This dissertation focuses on the 





Figure 1.1 A comparison of traditional small molecules to informational drugs  
(This image is adapted from Nat. Biotech. 2017 and used with permission). The target 
specificity and pharmacokinetic, pharmacodynamics of small molecules are all encoded 
within the molecule’s structure.  Informational drugs allow for the separation of these two 
characteristics increasing their versatility and applicability to new diseases. 
 
1.2 CLASSES OF OLIGONUCLEOTIDE THERAPEUTICS 
 There are many categories of oligonucleotide therapeutics.  Each works through a 
different mechanism2 and can target different nucleic acid families3 or proteins4, but all 
rely on a particular sequence to specifically influence their intended target.  The two main 
classes of therapeutic oligonucleotides that have shown success in the clinic are antisense 
oligonucleotides (ASOs) and small interfering RNAs (siRNAs).   
ASOs can be used to target mRNA for degradation5, and for splice switching6.  
For the former, these molecules are typically designed as “GapmeRs”, wherein a DNA 
gap is flanked by modified RNA nucleotides.   The ASO mediated cleavage involves 
recognition by the protein RNAse H of a DNA/RNA hybrid formed by the binding of the 
GapmeR and the target mRNA7.  The flanking regions serve to enhance binding affinity 
and stability when modified.  For splice switching ASOs, there is no requirement for a 
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particular type of base chemistry1, 8. These oligonucleotides need only to bind tightly to 
the target mRNA, remain stable, and to influence splicing. 
 siRNAs are a newer RNA-based informational therapeutic, described by Fire and 
Mello in C. elegans in 20069 and subsequently shown to work in human cells10, 11. They 
are double stranded RNAs that can be recognized by the protein AGO2 in cells (Fig. 
1.2)12. After recognition, the dissociation of the siRNA strands occurs; the passenger 
stand is discarded and the guide strand is retained in the RNA induced silencing complex, 
or RISC (Fig. 1.2)13. The selection of the guide strand by the RISC can be determined by 
the thermodynamic stability of its 5’end, with a decrease in thermodynamic stability 
being favored14.  Loading of the guide strand can be encouraged by increasing AU 
content or by using destabilizing modifications at the 5’ end. Once the passenger strand is 
discarded and degraded, the remaining RISC/guide strand complex is able to recognize 
the target mRNA complementary to the guide strand in order to cleave it with great 
efficiency13. The catalytic site, PIWI domain, in the AGO2 protein, carries out cleavage15, 
16.  Following degradation, the mRNA will no longer make its encoded protein. What 
makes this mechanism remarkable for therapeutic use is the long lasting and recyclable 




Figure 1.2 Mechanism of siRNA mediated mRNA cleavage, RNA interference 
(RNAi) 
 
1.3 CHEMICAL MODIFICATION OF SIRNA 
  Natural RNA has limitations in its use as a therapeutic. It is hydrophilic and 
cannot cross the cell membrane, readily degradable by exonucleases and endonucleases17, 
18, and may elicit an immune response when delivered to the cell19.  Over the past few 
decades, the scientific community has been working to overcome these obstacles by 
introducing chemical modifications to sugars and backbones of these molecules, as well 
as changing structure and adding conjugates1.  These various modifications have led to a 




Figure 1.3 The primary modifications used for an siRNA chemical scaffold. 
  
 Starting with the sugars, 2’-O-Methyl (2’OMe) and 2’-Fluoro (2’F) are the most 
commonly used modifications for siRNA20 (Fig. 1.3).  Both are “RNA-like” with a 
C3’endo conformation21, 22, and will maintain an A-form helix that is essential for them to 
be recognized by AGO223.  In addition to stabilizing the molecule against base cleavage, 
2’-OMe incorporation has also been shown to prevent recognition by the immune 
system24, 25.   
 Modifications to the phosphodiester backbone also provide exo- and 
endonuclease resistance.  These include phosphorothioates26, phosphorodithioates27, and 
boranophosphates28.  Phosphorothioate (PS) is the most commonly used of these 
modifications; it replaces one of the non-bridging oxygen atoms in the phosphodiester 
with a sulfur atom (Fig. 1.3), which significantly protects against nuclease attack29.  In 
addition to providing stability, PS shows a high binding affinity to proteins, which allows 
them to associate not only with blood proteins but also with cellular membranes30.  In 
fact, ASOs rely primarily on PS content for delivery and retention in tissues and all of the 
ASOs in the clinic contain PS linkages5, 26, 31-34. 








 Lastly the crystal structure of RISC indicates that a phosphate at the 5’end (5’P) 
(Fig. 1.3) of the siRNA guide strand is essential for AGO2 recognition and thus 
efficiency of siRNA23. Therefore stabilizing the 5’ phosphate can be beneficial.   5’ vinyl 
phosphonate (5’VP) (Fig. 1.3) has been investigated to mimic the 5’ terminal phosphate 
modification. This analog stabilizes the 5’ phosphate and has been shown to enhance 
stability and efficacy of siRNAs in vivo35, 36. 
 While these modifications abrogate many issues of instability, incorporation of 
the modifications can significantly affect compound efficacy and can be highly sequence 
specific20.  A modified siRNA must be recognized by AGO2, must be able to disassociate 
from the sense strand, and must be able to recognize their target mRNA and coordinate 
cleavage. 
 For example, 2’-OMe is slightly bulkier than the natural 2’OH and is not tolerated 
at particular positions20, 37.  2’-Fluoro promotes very tight base-pairing and can lead to an 
enhancement of off target effects38. Finally, extensive PS content can lead toxicity in the 
form of platelet activation and potential thrombocytopenia39, 40.  Therefore, while 
modifications are essential, great care must be taken to investigate tolerated chemical 
modification patterns. 
1.4 SIRNA IN VIVO DELIVERY 
 Despite advances in sugar and backbone modifications, one main challenge that 
remains is how to deliver these compounds to a specific cell type or tissue of interest.  
Delivery of these compounds can be achieved either with formulation, including lipid 
nanoparticles41, dendrimers42, spherical nucleic acids and gold nano particles43-46, or by 
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chemical conjugation.  The only approved siRNA currently in the clinic, patisiran 
(ONPATTROTM), is partially modified and formulated within a lipid nanoparticle41.  
 In the case of conjugate mediated delivery, which will be the primary focus of this 
section, the N-acetylgalactosamine (GalNAc) conjugate has revolutionized the field for 
liver delivery.  This trivalent conjugate binds with high specificity and affinity to the 
asialoglycoprotein receptor on hepatocytes47. This receptor is present at high 
concentrations and is quickly recycled into the cell and back to the cell surface making it 
an ideal target for ligand mediated siRNA delivery48. Indeed, there are many compounds 
in the clinic today that utilize this conjugate for liver delivery49.  
 While there have been many attempts to identify a ligand for targeting other 
organs or cell types, finding a ligand receptor pair that has the right properties is very 
difficult.  Not only does the receptor have to be present in relatively high concentrations, 
it also needs to recycle quickly to ensure efficient delivery of hundreds of siRNAs into 
the cell.  Additionally, ensuring that the ligand retains functional binding while 
conjugated to a siRNA can also be very difficult.  Other conjugation strategies have 
included antibody conjugation (Avidity Biosciences)50, 51 and aptamer conjugation52-54 
but both require the development of a high affinity binding moiety and selection of 
regularly recycled target receptor. 
 Hydrophobic conjugation is not receptor specific but takes advantage of the fact 
that cells have a hydrophobic membrane, which allows these compounds to interact or 
intercalate.  Examples of these conjugates include polyunsaturated fatty acids55, 56, 
cholesterol57-60, vitamins61, 62, etc.  Since they are not organ or cell type specific, they can 
be used to target different organs than the liver such as the kidney, spleen, heart, muscle, 
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fat, adrenal glands lungs, and brain56, 63, 64. However, while these types of conjugates are 
much more versatile, their high hydrophobicity leads to a very steep gradient of diffusion 
away from the site of injection58.  For organs such as the brain this means significant 
retention at the site of injection with little or no distribution to more distal regions of the 
brain and spinal cord. While this could be useful for the treatment of various 
glioblastomas or neuroblastomas65 it may lead to toxicity at the site of injection, and 
diseases that affect the entire organ would require multiple brain injections for treatment.   
1.5 ASOS IN THE CNS 
 The most advanced oligonucleotide therapeutics for delivery to the brain and 
spinal cord are ASOs66, 67.  These oligonucleotides rely on phosphorothioate content to 
promote protein association and cellular internalization.  Nusinersen (SPINRAZA®) was 
the first approved oligonucleotide therapeutic delivered to the central nervous system66, 
68.  This splice switching oligonucleotide has a pharmacophore targeting the SMN2 gene 
for the treatment of spinal muscular atrophy and a dianophore of complete PS and 
2’Methoxyethyl sugar modifications68.  Currently the dosing scheme for Nusinersen 
requires four loading doses followed by an additional dose every 4 months for 
maintenance66.  Since Nusinersen there have been many new ASOs in the clinic including 
those that rely on the RNAse H mechanism for mRNA cleavage, such as C9ORF72 
(Clinical Trial ID: NCT03626012) or SOD1 (Clinical Trial ID: NCT02623699) targeting 
for amyotrophic lateral sclerosis, TAU targeting for Alzheimer’s disease (Clinical Trial 
ID: NCT03186989), and HTT targeting for Huntington’s disease (Clinical Trial ID: 
NCT03342053).  The most advanced ASOs in the clinic show distribution to various 
areas of the brain but have trouble penetrating to deeper regions of the brain including the 
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caudate, putamen, and hippocampus5.  Therefore there is space in this field to improve 
the versatility of informational drug delivery. 
1.6 SIRNAS IN THE CNS 
 After discovering the power of GalNAc conjugation, most siRNA efforts were 
focused on liver indications leaving other organ indications to alternative oligonucleotide 
groups.  There are some companies that have focused efforts on local administration 
(eye59, skin69, muscle60), but there is no question that liver delivery predominates the 
field.  The academic community continued to explore the potential for siRNA 
therapeutics in the brain (Table 1.1).  Attempts at natural siRNA injection are limited but 
show some activity 24 hours after a single intracerebroventricular (ICV) injection with 
50% silencing70. Due to the instability of these compounds it is not surprising that longer 
term studies were not carried out. One strategy to improve distribution and silencing in 
the brain is by infusing the natural siRNA over a longer period of time71.  While infusion 
did increase the overall spread of the compound, silencing was still short lived.  A similar 
attempt was made with repeated intranasal delivery but also yielded minimal silencing 
and spread72. In an attempt to achieve better silencing, the DiFiglia Lab and the Sah Lab 
injected partially modified siRNA conjugated to cholesterol into the brain (also 
investigated in Chapter III)57, 58, 73.  In these cases, the partial modification (PS and 
2’OMe) did increase duration of effect up to one week but including hydrophobic 
conjugation limited the spread to around the site of injection and did not result in major 
improvements in gene silencing.  At this point the field began to realize that siRNAs 
require full chemical stabilization for meaningful and long-lasting siRNA in vivo 
silencing (discussed in Chapter IV).   Once full chemical stabilization was employed, 
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conjugate mediated delivery began to offer a much longer-term duration of effect and 
superior silencing55, 56.   
 In the last few years there has been a boom in siRNAs being pushed towards the 
clinic for neuro indications, with both Dicerna Pharmaceuticals (dicerna.com), 
Arrowhead Pharmaceuticals (arrowhead.com) Alnylam Pharmaceuticals (alnylam.com) 
initiating neurodegeneration projects.  In fact, recently, Alnylam Pharmaceuticals has 
released a side-by-side study that shows superior target silencing with their new siRNA 
chemical scaffold relative to ASOs74.  However while silencing in outer brain regions 
persists for months in both rat and non-human primate, penetration and silencing in 
deeper brain regions still remains elusive.   
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Table 1.1 Unformulated siRNA delivery to the brain. 
MMP-9 – metallopeptidase 9, SERT – Serotonin transporter, HTT – huntingtin, CNPase 
– 2',3'-Cyclic-nucleotide 3'-phosphodiesterase, dT – deoxy thymine, 2’OMe – 2’O-
methyl, PS – phosphorothioate, Chol – cholesterol conjugated, DHA – Docosahexaenoic 
acid conjugated, PC-DHA – phosphatidylcholine Docosahexaenoic acid conjugated 
 
1.7 ROUTES OF ADMINISTRATION FOR CNS TARGETING 
OLIGONUCLEOTIDES 
 When targeting the central nervous system (CNS) there are a number of additional 
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Depression SERT Intracerebroventricular infusion dTdT 
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injection into the blood stream can potentially support targeting of many other 
extrahepatic organs given the right conjugation strategy, targeting the brain with these 
routes of administration would require crossing of what is referred to as the Blood Brain 
Barrier (BBB)76.   The blood brain barrier is very selective and serves to prevent 
potentially harmful substances in the blood from entering into the CNS.  While the BBB 
serves a very important role, it makes delivering therapeutics to the CNS much more 
difficult.   There have been multiple attempts to deliver oligonucleotides systemically to 
cross the BBB. One strategy is to use an entity that will be recognized and trafficked by 
the BBB.  Examples include the use of rabies virus glycoprotein (RVG) and transferrin77, 
78.  Another strategy is to disrupt the BBB temporarily (e.g. by using mannitol) to allow 
for transport of oligonucleotide across the barrier79.  Unfortunately repetitive disruption 
of the BBB could open the brain to other unwanted intruders.   While some papers have 
shown success with these methods, direct brain injection or infusion into the CSF is 
currently the favored route of administration.  These methods can include 
intraparenchymal injection55-57, intracerebroventricular injection (ICV)5, 80, intrathecal 
injection (IT) (Clinical Trial ID: NCT03342053), and intranasal delivery72.  In the clinic 
the preferred route of administration is an IT injection as it is the least invasive.  However 
there have been no side-by-side comparisons of different routes of administration of 
oligonucleotides to the CNS so it is unclear if an alternative route could provide enhanced 
distribution.  Obviously, multiple brain injections are not a viable option but there is an 
alternative way to target a specific parenchymal region or a ventricle, by use of an 
Ommaya reservoir.  An Ommaya reservoir is a small reservoir attached to a catheter that 
can be placed under the skin of the skull and a catheter can be driven down into the 
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lateral ventricle81, 82.  Once healed the compound can simply be injected directly into 
reservoir, which could be far simpler than regular lumbar punctures, and would be less 
painful.  This procedure has been used for cancer and pain patients and could be an 
alternative to regular intrathecal injections.  
1.8 AN SIRNA DIANOPHORE FOR THE BRAIN 
 In this dissertation I describe the development of a new chemical scaffold for 
siRNA delivery to the brain.  The first step in this project was to identify a functional 
sequence to a valid neurological target.  Huntington’s disease (HD) is an autosomal 
dominant neurodegenerative disorder that is caused by a CAG-repeat expansion in exon 1 
of the huntingtin gene83.  Due to the monogenicity of HD, targeting the huntingtin gene is 
an ideal model for testing out new CNS targeting siRNAs.  This dissertation (i) identifies 
a functional siRNA sequence, or pharmacophore for targeting huntingtin mRNA (Chapter 
III), (ii) identifies a full chemical modification pattern that increases stability of the 
siRNA while maintaining efficacy and potency (Chapter IV), and (iii) identifies a new 
conjugation strategy creating a novel dianophore for siRNA delivery to the brain that 




CHAPTER II:  METHODS 
 
2.1 HTT COMPOUND SCREEN DESIGN 
 We designed and synthesized a panel of 94 hsiRNA compounds (Table 3.1) 
targeting the human huntingtin gene. These sequences span the gene and were selected to 
comply with standard siRNA design parameters including assessment of GC content, 
specificity and low seed compliment frequency84 elimination of sequences containing 
miRNA seeds, and examination of thermodynamic bias14, 85. 
2.2 OLIGONUCLEOTIDE SYNTHESIS 
 Oligonucleotides were synthesized using standard phosphoramidite, solid-phase 
synthesis conditions using a MerMade 12 (BioAutomation, Irving, Texas), Expedite 
DNA/RNA synthesizer, or AKTA Oligopilot 100 (GE Healthcare Life Sciences, 
Pittsburgh, PA). Oligonucleotides with unmodified 3′ ends were synthesized on 
controlled pore glass (CPG) functionalized with long-chain alkyl amine and a 
Unylinker® terminus (Chemgenes, Wilmington, MA). Oligonucleotides with 3’ 
modifications were synthesized on modified solid support synthesized in house.   
Phosphoramidites (ChemGenes, Wilmington, MA) were prepared at 0.1M (MerMade 12) 
and 0.2M (AKTA) in ACN with added 15% DMF in the 2`-OMe U amidite.  5-
(Benzylthio)-1H-tetrazole was used as the activator at 0.25M.  Detritylations were 
performed using 3% trichloroacetic acid (TCA) in dichloromethane on the MerMade 12 
and 3% DCA in toluene (AIC Wilmington, MA) on the AKTA Oligopilot.  Capping was 
done with non-THF containing reagents CAP A: 20% NMI in CAN and CAP B: 20% 
Ac2 O, 30% 2,6-lutidine in CAN (AIC Wilmington, MA).  Sulfurization was performed 
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with 0.1 M solution of DDTT in Pyridine (ChemGenes, Wilmington, MA) for 3 minutes. 
Phosphoramidite coupling times were 8 minutes for all amidites used. 
2.3 DEPROTECTION 
 The CPG was removed from the solid phase column and air dried. 40% 
methylamine (16 minutes at 65°C) was used to deprotect small scale 1 umol synthesis.  
Large scale, 10-300 umol, was deprotected using AMA (3 hours at RT). The solution was 
then frozen and lyophilized to dryness. Oligonucleotides with 2′–TBDMS protecting 
groups were desilylated by desolving the crude oligonucleotide in DMSO followed by 
triethylamine trihydrofluoride and incubated for 60 min at 65°C. The triethylamine 
trihydrofluoride was quenched with 3M sodium acetate and precipitated with 1-butanol. 
The vinylphosphonate (VP) containing oligo, while still on solid support, was treated 
with a mixture of trimethylsilyl bromide/DMF/pyridine (1:9:0.5) for 1 hour at room 
temperature with gentle agitation.  The CPG is then rinsed with DMF followed by of 
water, ACN and allowed to dry. Before being deprotected as described above.  
2.4 PURIFICATION 
 The purification of antisense strands was performed on an Agilent 1100 series 
system, equipped with an Agilent PL-SAX, polymer ion exchange column, or sourceQ 
anion exchange resin (GE healthcare, Chicago, IL) using the following conditions, Eluent 
A: 20% ACN 20mM NaAc pH 8, Eluent B: 1M sodium perchlorate in 20% ACN, 
gradient: 0% B 2min, 35% B 12min, clean and re-equilibration to initial conditions, 
temperature 50°C. Purification of sense strands was performed with a PRP-C18 
(Hamilton, Reno, NV), a polymer reverse phase column, using the following conditions, 
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Eluent A: 50 mM sodium acetate in 5% ACN, and eluent B: ACN. Gradient: 0% B 2min, 
0-40% B 1min, 40-70% B 8min, clean and re-equilibration 6min. Temperature 70°C. 
Peaks were monitored at 280nm. The pure oligonucleotides fractions were collected, 
individually characterized by LCMS, combined, frozen and dried in a speedvac 
overnight. Oligonucleotides were re-suspended in 5% ACN, and desalted through fine 
Sephadex® G-25 columns (GE healthcare, Chicago, IL), and lyophilized.  All reagents 
mentioned above were purchased form Sigma Aldrich and used as is, unless otherwise 
stated.   
2.5 LC-MS ANALYSIS OF OLIGONUCLEOTIDES 
 The identity of oligonucleotides were established by LC-MS analysis on an 
Agilent 6530 accurate mass Q-TOF LC/MS machine using the following conditions, 
Buffer A: 100mM HFIP/9mM TEA in LC/MS grade water, Buffer B: 100mM 
HFIP/9mM TEA in LC/MS grade methanol, column: Agilent AdvanceBio 
oligonucleotides C18,  gradient antisense: 0% B 1min, 0-30% B 8min, clean and re-
equilibration 4min, gradient sense: 0% B 1min, 0-50% B 0.5min, 50-100% B 8min, clean 
and re-equilibration 4min, temperature: 45°C, flow rate: 0.5mL/min, UV (260nm). MS 
parameters, Source: ESI, ion polarity: negative mode, range: 100-3200 m/z, scan rate: 2 
spectra/s, VCap: 4000, fragmentor: 180V. All reagents mentioned above were purchased 
form Sigma Aldrich and used as is, unless otherwise stated.   
2.6 CELL CULTURE 
 HeLa cells (ATCC, Manassas, VA; #CCL-2) were maintained in DMEM 
(Cellgro, Corning, NY; #10-013CV) supplemented with 10% fetal bovine serum (Gibco, 
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Carlsbad, CA;  #26140) and 100 U/mL penicillin/streptomycin (Invitrogen, Carlsbad, 
CA; #15140) and grown at 37°C and 5% CO2. Cells were split every 2 to 5 days, and 
discarded after fifteen passages. 
 Primary cytotrophoblast cells (CTB) from human placenta were a gift from Dr. S 
Ananth Karumanchi. CTBs were maintained in Medium 119 (Gibco, #11043) 
supplemented with 10% FBS (Gibco, #26140) and 100 U/mL penicillin/streptomycin 
(Invitrogen, #15140) at 37°C and 5% CO2. 
 Human primary hepatocytes (Gibco, #HMCPUS) were thawed and plated in 
Cryopreserved Hepatocytes Recovery Medium (Gibco, #CM7000), consisting of 
Williams E Medium (Gibco, #A12176-01) supplemented with 5% fetal bovine serum, 1 
µM dexamethasone in DMSO, 100 U/ml penicillin and streptomycin, 4 µg/ml human 
recombinant insulin, 2 mM GlutaMAX™, and 15 mM HEPES pH 7.4. Plated 
hepatocytes were allowed to recover for 6 h at 37°C and 5% CO2 and subsequently 
maintained in Williams E Medium supplemented with the Hepatocyte Maintenance 
Supplement Pack (Gibco, #CM4000), containing 0.1 µM dexamethasone in DMSO, 
50U/ml penicillin and streptomycin, 6.25 µg/ml human recombinant insulin, 6.25 µg/ml 
human transferrin, 6.25 µg/ml selenous acid, 6.25 µg/ml bovine serum albumin, 6.25 
µg/ml linoleic acid, 2 mM GlutaMAX™,15 mM HEPES pH 7.4, and 5 mM CaCl2 . 
2.6 ANIMAL STUDIES 
 All experimental studies involving animals were approved by the University of 
Massachusetts Medical School Institutional Animal Care and Use Committee (IACUC 
Protocol #A-2411 and #A-2515) and performed according to the guidelines and 
regulations therein described. 
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2.7 PREPARATION OF PRIMARY NEURONS 
 Primary cortical neurons were obtained from FVB/NJ mouse embryos at 
embryonic day 15.5. Pregnant FVB/NJ females were anesthetized by intraperitoneal 
injection of 250 mg Avertin (Sigma, St Louis, MO; #T48402) per kg weight, followed by 
cervical dislocation. Embryos were removed and transferred into a Petri dish with ice-
cold DMEM/F12 medium (Invitrogen, Carlsbad, CA; #11320). Brains were removed, and 
meninges carefully detached. Cortices were isolated and transferred into a 1.5-ml tube 
with pre-warmed papain solution for 25 minutes at 37˚C, 5% CO2, to dissolve tissue. 
Papain solution was prepared by suspending DNase I (Worthington, Lakewood, NJ; 
#54M15168) in 0.5 ml Hibernate E medium (Brainbits, Springfield, IL; #HE), and 
transferring 0.25 ml DNase I solution to papain (Worthington, Lakewood, NJ; 
#54N15251) dissolved in 2 ml Hibernate E medium and 1 ml Earle’s balanced salt 
solution (Worthington, Lakewood, NJ; #LK003188). After the 25 minute incubation, 
papain solution was replaced with 1 mL NbActiv4 medium (Brainbits, Springfield, IL; 
#Nb4-500) supplemented with 2.5% FBS. Cortices were dissociated by repeated pipetting 
with a fire-polished, glass, Pasteur pipet. Cortical neurons were counted and plated at 1 × 
106 cells per ml. 
 For live-cell imaging, culture plates were pre-coated with poly-L-lysine (Sigma, 
St Louis, MO; #P4707), and 2 × 105 cells were added to the glass center of each dish. For 
silencing assays, neurons were plated on 96-well plates pre-coated with poly-L-lysine 
(BD BIOCOAT, Corning, NY; #356515) at 1 × 105 cells per well. After overnight 
incubation at 37°C, 5% CO2, an equal volume of NbActiv4 supplemented with anti-
mitotics, 0.484 µL/mL of UTP Na3 (Sigma, St Louis, MO; #U6625) and 0.2402 µL/mL 
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of FdUMP (Sigma, St Louis, MO; #F3503), was added to neuronal cultures to prevent 
growth of non-neuronal cells. Half of the media volume was replaced every 48 hours 
until the neurons were treated with siRNA. Once the cells were treated, media was not 
removed, only added. All subsequent media additions contained anti-mitotics. 
2.8 DIRECT DELIVERY (PASSIVE UPTAKE) OF OLIGONUCLEOTIDES 
 Cells were plated in DMEM containing 6% FBS at 10,000 cells per well in 96-
well tissue culture plates. hsiRNA was diluted to twice the final concentration in 
OptiMEM (Gibco, Carlsbad, CA; #31985-088), and 50 µL diluted hsiRNA was added to 
50 µL of cells, resulting in 3% FBS final. Cells were incubated for 72 hours at 37°C and 
5% CO2. Based on previous experience, we know that 1.5 µM active hsiRNA supports 
efficient silencing without toxicity. The primary screen for active HTT siRNAs, 
therefore, was performed at 1.5 µM compound, which also served as the maximal dose 
for in vitro dose response assays. 
2.9 HSIRNA LIPID MEDIATED DELIVERY 
 Cells were plated in DMEM with 6% FBS at 10,000 cells per well in 96-well 
tissue culture treated plates. hsiRNA was diluted to four times the final concentration in 
OptiMEM, and Lipofectamine® RNAiMAX Transfection Reagent (Invitrogen, Carlsbad, 
CA; #13778150) was diluted to four times the final concentration (final = 0.3 µl/25 
µl/well). RNAiMAX and hsiRNA solutions were mixed 1:1, and 50 µl of the transfection 
mixture was added to 50 µl of cells resulting in 3% FBS final. Cells were incubated for 
72 hours at 37°C and 5% CO2. 
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2.10 MRNA QUANTIFICATION IN CELLS AND TISSUE PUNCHES 
mRNA was quantified using the QuantiGene 2.0 Assay (Affymetrix, Santa Clara, CA; 
#QS0011).  Cells were lysed in 250 µL diluted lysis mixture composed of 1 part lysis 
mixture (Affymetrix, Santa Clara, CA; #13228), 2 parts H2O, and 0.167 µg/µl proteinase 
K (Affymetrix, Santa Clara, CA;  #QS0103) for 30 minutes at 55°C.  
 Tissue punches (5 mg) were homogenized in 300 µl of Homogenizing Buffer 
(Affymetrix, Santa Clara, CA;  #10642) containing 2 µg/µl proteinase K in 96-well plate 
format on a QIAGEN TissueLyser II (Qiagen, Valencia, CA; #85300). Samples were 
then incubated at 65C for 30 minutes. 
 NHP brains were perfused with ice-cold PBS (Fisher, BP2438) prior to 
sectioning.  Brains were sectioned in a brain matrix into 4 mm sections.  2 mm punches 
were taken from various brain regions and placed in RNAlater (Sigma, R0901) for 
mRNA quantification. 
 mRNA was detected according to the Quantigene 2.0 protocol using the following 
probe sets: human HTT (SA-50339), human PPIB (SA-10003), mouse HTT (SB-14150), 
mouse GFAP (SB-14051), mouse IBA1 (SB-3027744), mouse HPRT (SB-15463), mouse 
PPIB (SB-10002), NHP HTT (SF-10209), NHP GFAP (SF-4228397), NHP IBA-1 (SF-
4214274), and NHP HPRT (SF-10356). 
 Luminescence was read on a Tecan M1000. 
2.11 WESTERN BLOT 
 Frozen tissue punches were homogenized 20 strokes on ice in 10mM HEPES 
pH7.2, 250mM sucrose, 1mM EDTA plus protease inhibitors (Roche #11836170001), 
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1mM NaF, 1mM Na3VO4.  Lysates were then sonicated for 10 seconds and protein 
concentration was determined using the Bradford method (BioRad #5000006).  
Western blots were performed as described in reference (Keeler, AM et al. JHD 2016)86.  
Briefly, 10 µg (mouse) or 25 µg (NHP) lysates were separated by SDS-PAGE using 3-8% 
Tris acetate gels (Life Technologies #EA03785BOX), transferred to nitrocellulose, 
blocked in 5% milk/TBS + 0.1% Tween 20, incubated in primary antibody diluted in 
blocking buffer overnight at 4C then washed and incubated in secondary antibody diluted 
in blocking buffer 1 hour at RT.  Blots were washed and signal was detected using Super 
Signal West Pico Plus Chemiluminescent kit (Pierce #34580) and a CCD imaging system 
(Alpha Innotech) or Hyperfilm ECL (GE Healthcare #28906839) and densitometry was 
determined using ImageJ software (NIH).  Bands were manually circled and area and 
mean gray value were meaured.  Total signal intensity for each band was determined by 
multiplying area by mean gray value.  Primary antibodies were rabbit polyclonal anti-
HTT antibody Ab187 (1:2000), mouse monoclonal anti-polyglutamine antibody 1C2 
(1:6000, Sigma MAB1574), mouse monoclonal anti-β-tubulin (1:6000, Sigma #T8328), 
rabbit polyclonal anti-GFAP (1:8000, Millipore AB5804) and rabbit monoclonal anti-
DARPP32 (1:10,000, Abcam AB40801). Secondary antibodies were peroxidase-labeled 
anti-rabbit IgG (1:2500, Jackson Immunoresearch #711035152) or anti-mouse IgG 
(1:5000, Jackson Immunresearch #715035150). 
ApoE protein quantification: 
 For analysis of ApoE protein expression in mouse brain samples, WES by 
ProteinSimple was used. Tissue punches were collected as above and flash-frozen and 
placed at -80 C. After addition of RIPA buffer with protease inhibitors, samples were 
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homogenized and stored at -80C. Protein amount was determined using Bradford Assay. 
Samples were diluted in 0.1x sample buffer (ProteinSimple) to ~0.2-0.4 ug/ul. Anti-ApoE 
antibody (Abcam, 183597) was diluted 1:200 in antibody diluent (ProteinSimple) and 
loading control, anti-Vinculin (Invitrogen, 700062), was diluted 1:600 in antibody 
diluent. Assay was performed as described by ProteinSimple protocol using the 16-230 
kDa plate (SM-W004).  
2.12 LIVE CELL IMAGING  
 To monitor live cell hsiRNA uptake, cells were plated at a density of 2 × 105 cells 
per 35 mm glass-bottom dish. Cell nuclei were stained with NucBlue® (Life 
Technologies, Carlsbad, CA; #R37605) as indicated by the manufacturer. Imaging was 
performed in phenol red-free NbActiv4. Cells were treated with 0.5 µM Cy3-labeled 
hsiRNA, and live cell imaging was performed over time.  All live cell confocal images 
were acquired with a Zeiss confocal microscope, and images were processed using 
ImageJ (1.47v) software.  
2.13 STEREOTAXIC INJECTIONS 
Intrastriatal injections 
 FVB/NJ mice (50% male and 50% female for each dose group, 6-8 weeks old) 
were deeply anesthetized with 1.2% Avertin (Sigma, St Louis, MO; #T48402) and 
microinjected by stereotactic placement into the right striatum (coordinates relative to 
bregma: 1.0 mm anterior, 2.0 mm lateral, and 3.0 mm ventral). For both toxicity 
(DARPP-32 staining) and efficacy studies, mice were injected with either PBS or 
artificial CSF (2 µl per striata), 12.5 µg of non-targeting hsiRNA (2 µl of 500 µM stock 
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per striata), 25 µg of HTT10150 hsiRNA (2 µl of 1 mM stock per striata), 12.5 µg of 
HTT10150 hsiRNA (2 µl of 500 µM stock per striata), 6.3 µg of HTT10150 hsiRNA (2 
µl of 250 µM stock per striata), or 3.1 µg of HTT10150 hsiRNA (2 µl of 125 µM stock 
per striata).  For toxicity studies, n=3 mice were injected per group, and for efficacy 
studies n=8 mice were injected per group.  Mice were euthanized 5 days post-injection, 
brains were harvested, and three 300 µm coronal sections were prepared. From each 
section, a 2 mm punch was taken from each side (injected and non-injected) and placed in 
RNAlater (Ambion®, Carlsbad, CA; #AM7020) for 24 hours at 4°C.  Each punch was 
processed as an individual sample for Quantigene 2.0 assay analysis (Affymetrix, Santa 
Clara, CA), and averaged for a single animal point.  
Intracerebroventrivular injections 
 FVB/NJ females (8-9 weeks old) or BACHD-ΔN17 females (6 weeks old) were 
anesthetized using 1.2% Avertin. Single intrastriatal administrations (2 µL, per injected 
side) were performed as previously described in Nikan et al. 2016 2017 at the following 
coordinates from bregma: +1.0 mm anterior-posterior (AP), +/-2.0 mm medio-lateral 
(ML) and -3.0 mm dorso-ventral (DV). Single bilateral intracerebroventricular injections 
(5 µL, per injected side) were performed at 500 nl/min after needle placement at the 
following coordinates from bregma: -0.2 mm AP, ±0.8 mm ML and -2.5 mm DV. Doses 
of Mono-siRNA and Di-siRNA ranged between 4 nmol (50 µg) and 40 nmol (475 µg) 
according to the goal of the experiment. 
 For biodistribution studies, animals (n = 2-3/group) were euthanized at 48 hours 
after injection and perfused with PBS. Brains were harvested and post-fixed overnight 
with 10% formalin and processed for paraffin embedding. For efficacy studies, animals 
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(n = 6-8/group) were euthanized at different time points, including 1, 2 weeks and 1, 3, 4, 
6 months after single intracranial injections. At harvesting, tissues were kept in RNA 
later overnight (mRNA analysis) and then stored in -80ºC, or snap frozen (western blot 
assessments) and stored. 
2.14 FOR SYSTEMIC ADMINISTRATION OF OLIGONUCLEOTIDES  
 C57BL/6 or FVB/NJ (both form Jackson Laboratory) mice were intravenously 
injected either with phosphate buffered saline (PBS) or with different amounts of 
hsiRNA, resuspended in PBS, through the tail vein (IV) or SC. For in vivo tissue 
distribution C57BL/6 were injected with 10 mg/kg of hsiRNAsFLT1 and euthanized 24 
hours after injection.  For in vivo efficacy FVB/NJ mice were injected with 20 mg/kg 
using the same protocol. Animals were euthanized 7 days after injection and tissues were 
taken for microscopy or for mRNA and hsiRNA quantification (using PNA hybridization 
assay). Animals were euthanized 7 days after the injection and tissues were taken for 
mRNA quantification using QuantiGene assay88. 
2.15 IMMUNOHISTOCHEMISTRY/IMMUNOFLUORESCENCE  
 Organs were fixed in 10% neutral buffered formalin, embedded in paraffin, and 
sliced into 4 µm sections that were mounted on glass slides. Sections were deparaffinized 
by incubating in Xylene twice for 8 min.  Sections were rehydrated in serial ethanol 
dilutions (100%, 95%, 80%) for 4 min each, then washed twice for two minutes with 
PBS.   
 For NeuN staining89, 90, slides were boiled for 5 minutes in antigen retrieval buffer 
(10 mM Tris/ 1mM EDTA (pH 9.0)), incubated at room temperature for 20 minutes, and 
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then washed for 5 minutes in PBS. Slides were blocked in 5% normal goat serum in PBS 
containing 0.05% Tween 20 (PBST) for 1 hour and washed once with PBST for 5 
minutes. Slides were incubated with primary antibody (Millipore, Taunton, MA 
MAB377, 1:1000 dilution in PBST) for 1 hour and washed three times with PBST for 5 
minutes. Slides were then incubated with secondary antibody (Life Technologies, 
Carlsbad, CA; #A11011, 1:1000 dilution in PBST) for 30 minutes in the dark and washed 
three times with PBST for 5 minutes each. Slides were then counterstained with 250 
ng/ml DAPI (Molecular Probes, Life Technologies, Carlsbad, CA; #D3571) in PBS for 1 
minute and washed three times with PBS for 1 minute. Slides were mounted with 
mounting medium and coverslips and dried overnight before imaging on a Leica 
DM5500 microscope fitted with a DFC365 FX fluorescence camera. 
 For toxicity studies, injected brains were harvested after 5 days. For microglial 
activation studies, brains were harvested after 6 hours or 5 days. Extracted, perfused 
brains were sliced into 40 µm sections on the Leica 2000T Vibratome (Leica Biosystems, 
Wetzlar, Germany) in ice cold PBS. Every 6th section was incubated with DARPP-32 
(Abcam, Cambridge, United Kingdom; #40801; 1:10,000 in PBS) or IBA1 (Wako, 
Osaka, Japan; #019-19741; 1:1,000 in PBS) antibody, for a total of 9 sections per brain 
and 8 images per section (4 per hemisphere).  IBA-1 sections were incubated in blocking 
solution (5% normal goat serum, 1% bovine serum albumin, 0.2% Triton™-X-100, and 
0.03% hydrogen peroxide in PBS) for 1 hour, and then washed with PBS. Sections were 
incubated overnight at 4ºC in primary antibody, anti-Iba1 (polyclonal rabbit anti-
mouse/human/rat; dilution: 1:1,000 in blocking solution) (Wako, Osaka, Japan; #019-
19741).  Sections were then stained with goat anti-rabbit secondary antibody (1:200 
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dilution) (Vector Laboratories, Burlingame, CA), followed by a PBS wash, the 
Vectastain ABC Kit (Vector Laboratories, Burlingame, CA), and another PBS wash.  
IBA-1 was detected with the Metal Enhanced DAB Substrate Kit (Pierce, Rockford, IL).  
For DARPP32 staining, sections were washed for 3 minutes in 3% hydrogen peroxide, 
followed by 20 minutes in 0.2% TritonX-100, and 4 hours in 1.5% normal goat serum in 
PBS.  Sections were incubated overnight at 4ºC in DARPP32 primary antibody (1:10,000 
dilution) (Abcam, Cambridge, United Kingdom; #40801) made up in 1.5% normal goat 
serum.  Secondary antibody and detection steps were conducted as described for IBA-1 
staining.  DARPP-32 sections were mounted and visualized by light microscopy with 20x 
objective on a Nikon Eclipse E600 with a Nikon Digital Sight DSRi1 camera (Nikon, 
Tokyo, Japan). The number of DARPP-32-positive neurons was quantified manually 
using the cell counter plug-in on ImageJ for tracking. Activated microglia were 
quantified by morphology of IBA1-positive cells91-94from the same number of sections 
captured with 40x objective.  Counting of both IBA1 and DARPP-32 positive cells was 
blinded.  Coronal section images were taken with a Coolscan V-ED LS50 35mm Film 
Scanner (Nikon, Tokyo, Japan).  
2.16 IN VITRO RISC LOADING AND CLEAVAGE ASSAY 
 S100 cell extract from ago2−/− + Ago2 (overexpressing Ago2) MEF cells were 
incubated with 50 nM chemically modified or unmodified let 7a siRNA for 30 minutes at 
37°C. After 30 minutes, 100 nM of 32P capped labeled RNA was incubated at 23°C for 
10 minutes to measure RISC concentration. After 10 minutes, temperature was shifted to 
37°C (multi-turnover condition).  Cell extract, RNA labeling, and cleavage assay were 
performed as previously described in:  Salomon et al12 
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2.17 PNA (PEPTIDE NUCLEIC ACID) BASED ASSAY FOR DETECTION OF 
HSIRNA IN MOUSE TISSUES 35 
 hsiRNA guide strand in tissues were quantified using PNA hybridization assay. 
Tissues were lysed in MasterPure™ Tissue Lysis Solution (EpiCentre®) in the presence 
of proteinase K (2mg/ml) (Invitrogen, #25530-049) in TissueLyser II (Quiagen) (10mg 
tissue in 100 µl lysis solution). Sodium dodecyl sulphate (SDS) from lysate was 
precipitated with KCl (3M) and pelleted at 5000 g. hsiRNA in cleared supernatant was 
hybridized to a Cy3-labeled PNA fully complementary to guide strand (PNABio, 
Thousand Oaks, CA) and injected into HPLC DNAPac® PA100 anion exchange column 
(Thermo Fisher Scientific Inc.) and Cy3 fluorescence was monitored and peaks 
integrated. Mobile phase for HPLC was 50% water 50% acetonitrile, 25 mM Tris-HCl 
(pH 8.5), 1mM EDTA and salt gradient was 0 to 800mM NaClO4. For the calibration 









1-(2,2-dimethyl-1,3-dioxolan-4-yl)-2,5,8,11-tetraoxatridecan-13-ol (1)  
 
 Commercially available tetraethylene glycol (CAS: 112-60-7) (146.4g, 
753.9mmol) was co-evaporated with Dry Pyridine/Toluene mixture (50:50)x2 by rotovap 
to remove residual water.  The mixture was then dissolved in THF (700 ml) and cooled to 
0°C in an ice bath with stirring.  Sodium hydride, 60% dispersion in mineral oil (CAS: 
7646-69-7) (4.3g, 107 mmol) was then added slowly to the cooled solution. Once 
hydrogen gas visibly ceased,  2,2-Dimethyl-1,3-dioxolan-4-ylmethyl p-toluenesulfonate 
(CAS: 7305-59-1) (30.8g, 107mmol) was added slowly.  The mixture was removed from 
the ice bath and allowed to warm to room temperature before being refluxed for 16h 
under inert atmosphere.  The solution was rotovapped to near dryness and the excess 
sodium hydride was quenched with a saturated sodium bicarbonate solution dropwise 
with stirring and finally extracted with chloroform x3 300ml and 10% NaCl soluiton.  
The organic layers were combined and dried over magnesium sulfate.  The crude product 
was purified by flash chromatography on silica gel using hexanes/ethylacetate (75:25 to 




 To a solution of (1) in THF, equal volumn of a 1M HCl solution was added at 
room temperature and allowed to stir for 2h until all starting material was consumed by 
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TLC. The mixture was then evaporated to dryness on rotovap and then co-evaporated 
with 100ml (2x) dry pyridine to both remove excess water and quenched any residual 





 The triol (2) (17.2g, 64.2mmol) was then dissolved in 50:50 THF:pyridine 
(600ml) and triethylamine (44ml, 317mmol).  To this solution solid dimethoxytrityl 
chloride (CAS# 40615-36-9) (43g, 126.9mmol) was added slowly over 5min. This 
mixture was allowed to stir at room temperature overnight (16h).  By TLC all starting 
material was consumed (50:50 hexanes:ethylacetate).  The reaction was concentrated to 
near dryness diluted with 600ml of ethylacetate and extracted with 5% sodium 
bicarbonate (x3) and once with brine (x1).  The organic layer was dried over magnesium 
sulphate and concentrated to dryness as a yellow viscous liquid.  The crude product was 
purified by flash chromatography on silica gel using hexanes/ethylacetate (100 to 25:75) 
and 1% triethylamine, in three batches as a colorless viscous oil.  Yield: 42.2g, 76%. 
 
16-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-1,1-bis(4-methoxyphenyl)-18-oxo-




 To a stirring solution of (3) (12.9g, 14.86mmol) in dry DCM and dry 
triethylamine (3.8ml, 29.7mmol) with catalytic 4-dimethylamino pyridine (DMAP, CAS# 
1122-58-3) (200mg, 1.5 mmol) dry solid succinic anhydride (CAS# 108-30-5) (2.23g, 
22.3mmol) was added directly to the solution.  The mixture was heated to a gentle reflux 
under an inert atmosphere overnight (16h).  The reaction was confirmed complete by 
TLC (50:50 hexanes/ethylaceate) and concentrated to near dryness.  The crude sample 
was dissolved in ethylaceate and extracted with a triethylammonium bicarbonate solution 
(300ml, 0.1M, pH 8) (x3) freshly prepared.  The organic layer was dried over magnesium 
sulfate and concentrated to dryness.  The crude product was purified by flash 
chromatography on silica gel quenched with triethylamine using hexanes/ethylacetate 
(100 to 25:75) and 1 % triethylamine as a colorless oil.  Yield: 13.1 g, 82%. 
 
Controlled pore glass loading (5) 
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 Compound (3) was dissolved in 50:50 THF/DMF along with 1.5 equivalents of 
HCTU (CAS# 330645-87-9) (g, mmol) and 0.1 eq of DMAP (g,mmol) and stirred until 
dissolved.  To this solution 0.25 eq (to the amine content on the CPG) of long chain alkyl 
amine CPG (Chemgenes, Cat. N-5100-05) (500Å) was added and gently circulated 
overnight.  The CPG was then filtered and rinsed first with DMF followed by DCM. The 
unreacted amines on the solid support were capped with an equal part mixture of CAP A 
(Acetic Anhydride/lutidine/ACN) CAP B (16% N-Methylimidazole in ACN).  The CPG 
is then rinsed with ACN and diethylether and allowed to dry under reduced pressure.  The 
loading of the support was calculated as previously described by Damha et al95.  In brief: 
weigh CPG (5-10 mg) and treat with exactly 10 mL of 5% trichloroacetic acid in DCM in 
a volumetric flask. Measure absorbance at 504 nm (DMT λ max) and the amount of trityl 
cation determined by using extinction coefficient of 76 mL/(cm*µmol) (DMT) 
2.20 STEREOTACTIC INJECTION IN NON-HUMAN PRIMATES 
 Cynomolgus macaques (2.5-4.5 Kg) were sedated using Ketamine (15 mg/kg), 
Xylazine (0.5 mg/kg) and Glycopyrolate (0.01 mg/kg), and a tracheal tube placed. 
Anesthesia was maintained by isoflurane 1 – 3% carried by oxygen (1 L/minute). 
Animals received intravenous lactate ringer solution (LRS) at a rate of 5-10 ml/kg/hr and 
were placed on a heating blanket. Meloxicam (0.15 mg/kg) and buprenorphine (0.01 
mg/kg) were given for analgesia. Respiratory rate, end tidal CO2, body temperature, 
spO2 and heart rate were monitored and recorded. 
 Standard surgical aseptic technique was used throughout the procedure. Macaques 
were positioned on a stereotaxic frame for non-human primates (KOPF Model 1530M) 
and skin cleaned with alternating applications of betadine and alcohol. The skull was 
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exposed by a transverse incision and the periosteum removed from the surgical area. 
Based on the positioning of Bregma a burr hole (3-5 mm) was drilled using a Stryker 
high-speed drill (Core Powered Instrument Driver and Precision Neuro drill bit (Cat. 
#5820-107-530)). Real-time Cone Beam Computerized Tomography (CBCT) images 
were registered on pre-operative Magnetic Resonance Imaging (MRI) data sets (see 
details on MRI acquisition below) for determination of correct positioning of the 
manipulator for cannula placement. Cannula was lowered to the left lateral ventricle, 50 
µL of iodohexal contrast agent was administered followed by high-resolution CBCT to 
confirm correct positioning of the device. FDA-approved SmartFlow™ neuroventricular 
cannulas (16 ga, 0.008'' ID x 4 ft, MRI Interventions, Inc) were used for all 
intracerebroventricular (ICV) injections. Cannulas were attached to a syringe fitted in a 
programmable PhD Ultrapump (Harvard Apparatus). 
 Di-siRNAs (25 mg/750 µL) were injected at a rate of 50 µL/min for 15 minutes, 
and anesthesia switched to Propofol (1 mL/hour). Cannulas were withdrawn 5-10 minutes 
after the end of the injections. The skull was irrigated with ~50 mL of 0.9% saline and 
scalp sutured with absorbable sutures (3-0 or 4-0 Vicryl Rapide) in an interrupted pattern. 
Animals were kept under anesthesia for ~2 hours following the end of the ICV injection 
and were given prophylactic antibiotics (Cephazolin, IV). Macaques were returned to 
their home cage to recover and monitored for signs of pain and distress. 
 Complete Blood Counts (CBC) and a comprehensive blood chemistry panel was 
carried out on pre-operative blood and after 2 days (distribution study), or 15-days and 30 
days post-injection (efficacy studies). For siRNA guide strand quantification, blood 
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samples were collected pre-operatively and at the following time points after Di-siRNA 
injection: 5, 15, 30 minutes, 1 and 2 hours. 
 At necropsy, animals where heparinized and euthanized with an intravenous 
injection of pentobarbital (150 mg/kg). CSF samples were immediately collected from 
the cisterna magna after euthanasia. Animals were then perfused with 4 L of sterile cold 
PBS, and tissues collected for mRNA, protein and histology. 
2.19 BRAIN MAGNETIC RESONANCE IMAGING 
 Pre-operative and 30-day MRI scans were acquired using a Philips Achieva 
3Tesla Whole Body Scanner. Animals were anesthetized as previously described and 
placed on a MRI-compatible stereotaxic frame in ventral recumbency (head first into the 
magnet). Axial T1 unenhanced spin-echo, axial T2 fast spin-echo, diffusion weighted 
imaging, magnetic resonance angiography and magnetization prepared rapid gradient 
echo sequences. In-plane resolution was 0.4 to 1mm, slice thickness 1-4mm, and 
256x256 acquisition matrix. Total MR imaging time was approximately 60-90 minutes 
per subject. Following imaging, the animal was recovered from anesthesia and monitored 
in cage. 
2.20 RNASEQ 
 Total RNA was isolated from 3 brain punches each from 4 animals per naïve and 
Di-siRNAHTT treated condition using Monarch® Total RNA Miniprep Kit (NEB, 
T2010S) following manufacturer protocol. Briefly, tissue was submerged in DNA/RNA 
protection reagent, homogenized by passing through a 27G hypodermic needle, and 
incubated for 30 minutes at 55C with proteinase K. RNA was bound to column, subjected 
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to on-column DNase treatment, washed, and eluted in nuclease free water. Library 
preparation was performed using TruSeq® Stranded mRNA Library Prep (Illumina, 
20020594) following manufacturer protocol. Single end sequencing was performed for 
75 cycles on the Illumina NextSeq 500, for a total of 271.6 million reads (average of 33.9 
million reads per animal). 
 The resulting 75nt reads were mapped to the cynomolgus macaque genome 
(Macaca fascicularis 5.0) with STAR/2.5.3a. Reads mapping to annotated exons were 
counted using HTseq/0.10.0 and differential expression analysis was performed with 
DESeq2/1.22.2. Genes that had less than 10 reads across all samples or were only 
expressed in one animal were excluded from further analyses. Seed complementary 
matches and enriched 6-mers within 3’ UTRs (for genes with annotated 3’ UTRs in 
Macaca fascicularis Ensembl 95 annotations) were identified using a custom python 
script. Gene set enrichment analysis was conducted using PANTHER/14.0, conditioning 
on biological process gene ontology categories. 
2.21 STATISTICAL ANALYSIS 
 Data were analyzed using GraphPad Prism 6 software (GraphPad Software, Inc., 
San Diego, CA). Concentration-dependent IC50 curves were fitted using a log(inhibitor) 
vs. response – variable slope (four parameters). The lower limit of the curve was set at 
zero, and the upper limit of the curve was set at 100. For each independent mouse 
experiment, the level of knockdown at each dose was normalized to the mean of the 
control group (the non-injected side of the PBS or artificial CSF groups). In vivo data 
were analyzed using a Two-way RM ANOVA with Tukey’s multiple comparisons test 
for dose and side of brain. Differences in all comparisons were considered significant at 
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P-values less than 0.05 compared with the non-targeting control (NTC) injected group.  
P-values reported represent significance of the entire dose group relative to NTC and are 
not specific to the ipsilateral or contralateral side. For microglial activation, significance 
was calculated using a parametric, unpaired, two-tailed t-test for comparison between 
dose groups, and paired t-test for comparison between ipsilateral and contralateral 




CHAPTER III:  HYDROPHOBICALLY MODIFIED SIRNAS SILENCE 
HUNTINGTIN MRNA IN PRIMARY NEURONS AND MOUSE BRAIN 
3.1 PREFACE 
 
Text and figures are reproduced from 
 
• Alterman, J.F., Hall, L.M., Coles, A.H., Hassler, M.R., Didiot, M.C., Chase, K., 
Abraham, J., Sottosanti, E., Johnson, E., Sapp, E. et al. (2015) Hydrophobically 
Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse 
Brain. Mol Ther Nucleic Acids, 4, e266. 
 
Anastasia Khvorova designed the study and the screen.  Matthew Hassler synthesized all 
of the compounds.  I performed all in vitro screening and dose responses.  Lauren Hall, 
Marie Didiot, and I performed primary neuron experiments.  Kathy Chase and Andrew 
Coles did mouse injections.  Andrew Coles and I processed tissue samples and I did 
mRNA quantification.  Ellen Sapp ran western blots.  Emily Sottosanti, Emily Johnson , 
and Lauren hall counted cells.  I made graphs and performed statistical analyses.  
Anastasia Khvorova and I wrote the manuscript. 
3.2 ABSTRACT 
 Applications of RNA interference for neuroscience research have been limited by 
a lack of simple and efficient methods to deliver oligonucleotides to primary neurons in 
culture and to the brain. Here, we show that primary neurons rapidly internalize 
hydrophobically modified siRNAs (hsiRNAs) added directly to the culture medium 
without lipid formulation. We identify functional hsiRNAs targeting the mRNA of 
huntingtin, the mutation of which is responsible for Huntington’s disease, and show that 
direct uptake in neurons induces potent and specific silencing in vitro. Moreover, a single 
injection of unformulated hsiRNA into mouse brain silences Htt mRNA with minimal 
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neuronal toxicity. Thus hsiRNAs embody a class of therapeutic oligonucleotides that 
enable simple and straightforward functional studies of genes involved in neuronal 
biology and neurodegenerative disorders in a native biological context. 
3.3 INTRODUCTION 
 RNA interference (RNAi) is a highly efficient gene silencing mechanism in which 
a small interfering RNA (siRNA) binds a target mRNA, guiding mRNA cleavage via an 
RNA-induced silencing complex (RISC)9, 96. This biological phenomenon is widely used 
as a genetic tool in biomedical research. Advances in RNA chemistry have expanded 
siRNA applications toward therapeutic development, with robust efficacy seen in Phase 
II clinical trials for liver diseases (e.g. TTR amyloidosis)59, 97, 98.  
 Despite its prevalence in biomedical research, the use of RNAi in 
neurodegenerative research has been limited99. There is a significant unmet need for 
simple, effective, and non-toxic siRNA delivery methods to modulate gene expression in 
primary neurons and brain. A range of approaches has been evaluated100, including AAV 
viruses101, 102, peptide conjugates103, oligonucleotide formulations104 , infusion of naked 
or slightly modified siRNAs57, 105, ultrasound106 and convection-enhanced based 
delivery107. None of these approaches has received wide acceptance due to toxicity, a 
requirement for extensive repetitive dosing, and/or limited spatial distribution. 
Lipofection and electroporation of siRNAs are challenging in primary neurons due to low 
transfection efficiencies and their extreme sensitivity to external manipulation108. 
Delivery of siRNA precursors (Lentiviruses and AAV) has been used successfully, but 
viral transduction cannot readily be turned off and requires extensive formulation and 
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experimental optimization to achieve reproducible, non-toxic silencing in neuronal cells 
109-114. 
 In this study, we describe the delivery, distribution, and silencing capacity of 
hydrophobically modified siRNAs (hsiRNAs) in primary neurons and in mouse brain. 
hsiRNAs are siRNA-antisense hybrids containing numerous chemical modifications (see 
Fig. 3.1 and Table 3.1 for exact chemical composition of compounds used) designed to 
promote bio-distribution and stability while minimizing immunogenicity. As a model for 
our studies, we silenced the huntingtin (Htt) gene, the causative gene in Huntington’s 
disease (HD). HD is an autosomal dominant neurodegenerative disorder caused by a 
toxic expansion in the CAG repeat region of the huntingtin gene leading to a variety of 
molecular and cellular consequences. Tetrabenazine, the only FDA-approved therapy for 
HD, seeks to alleviate disease symptoms but does not treat the actual problem: the gain of 
toxic function caused by mutant Htt. Recent studies suggest that transient neuronal 
knockdown of Htt mRNA can reverse disease progression without compromising normal 
cellular function in vivo5. At present, RNA interference via siRNA or ASO is one of the 
most promising therapeutic approaches for transient Htt mRNA silencing. 
 We performed a screen of hsiRNAs targeting Htt mRNA and identified multiple 
functional compounds.  We showed that primary neurons internalize hsiRNA added 
directly to the culture medium, with membrane saturation occurring by one hour. Direct 
uptake in neurons induces potent and long-lasting silencing of Htt mRNA for up to three 
weeks in vitro without major detectable effects on neuronal viability.  Additionally, a 
single injection of unformulated (without cationic lipid or AAV formulation) Htt hsiRNA 
into mouse brain silences Htt mRNA with minimal neuronal toxicity.  
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 Efficient gene silencing in primary neurons and in vivo upon direct administration 
of unformulated hsiRNA represents a significant technical advance in the application of 
RNAi to neuroscience research, enabling technically achievable genetic manipulation in a 
native, biological context.  
3.4 RESULTS 
3.4.1 HSIRNAS ARE EFFICIENTLY INTERNALIZED BY PRIMARY NEURONS 
 Hydrophobically modified siRNA (hsiRNA) is an asymmetric compound 
composed of a 15-nucleotide modified RNA duplex with a single-stranded 3′ extension 
on the guide strand (Fig. 3.1a, Table 3.1)115, 116.  Pyrimidines in the hsiRNA are modified 
with 2′-O-methyl (passenger strand) or 2′-fluoro (guide strand) to promote stability, and 
the 3′ end of the passenger strand is conjugated to a hydrophobic teg-Chol (tetraethylene 
glycol cholesterol) to promote membrane binding and association59.  The single-stranded 
tail contains hydrophobic phosphorothioate linkages and promotes cellular uptake by a 
mechanism similar to that of antisense oligonucleotides117. The presence of 
phosphorothioates, ribose modifications, and a cholesterol conjugate contribute to overall 





Table 3.1 hsiRNA sequences, chemical modification patterns, and efficacy  

































































































































  yes 68.2 N/A N/A 











































































































































































































































































  yes 83.5 N/A N/A 














































































































































































































    102.0 N/A N/A 
Detailed sequence, chemical modification patterns, and efficacy of hsiRNAs.  Huntingtin 
accession number - NM_002111 .6, PPIB accession number - NM_009693.2.  Chemical 
modifications are designated as follows.  “.” – phosphodiester bond, “#” –
phosphorothioate bond, “m” – 2’-O-methyl, “f” – 2’-Fluoro, no prefix – ribonucleotide, 
“P” – 5’ Phosphate, “tegChol” – tetraethylene glycol (teg)-cholesterol, um – unmodified.  
All sequences are homologous to human huntingtin.  IC50 calculated as described in 






Figure 3.1 hsiRNAs are efficiently internalized by primary cortical neurons.  
(a) Schematic structure of hsiRNAs. A double stranded oligonucleotide with single 
stranded, phosphorothioated tale. 2’-O-methyl and 2’-Fluoro modifications, conjugated to 
teg-chol.  (b) Fluorescent images of primary cortical neurons incubated with 0.5 µM 
Cy3-PPIB hsiRNA (red). Nuclei counterstained with Hoechst dye (blue), imaged on 
Zeiss confocal microscope, 63x.  A 10 µm scale bar is shown. Images are representative, 
results confirmed in 5 separate experiments.  (c) Primary cortical neurons incubated for 
72 hours with hsiRNA targeting Ppib at concentrations shown. Level of Ppib mRNA was 
measured using QuantiGene® (Affymetrix) normalized to housekeeping gene, Htt, 
presented as percent of untreated control (n=3 wells, mean ± SD). NTC – non-targeting 
control (0.75 µM).  Graph is representative, results confirmed in 3 separate experiments. 
 
 Previous studies have shown that hydrophobically modified siRNAs bind to a 
wide range of cells and is readily internalized without the requirement for a transfection 
reagent59, 118, 119.  Here, we evaluated whether asymmetric hydrophobically modified 
siRNAs are efficiently internalized by primary neurons.  We found that, when added to 
the culture medium, Cy3-labeled hsiRNAs rapidly associated with primary cortical 
neurons (Fig. 3.1b). These Cy3-labeled hsiRNAs were observed in every cell in the 
culture, demonstrating efficient and uniform uptake. Initially hsiRNAs mainly associate 
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hours, Fig. 3.1b). Treatment of primary neurons with a previously identified hsiRNA 
targeting Ppib59, 118 (encodes cyclophilin B) reduced target mRNA levels by 90%, further 
supporting that the observed compound internalization results in potent gene silencing 
(Fig. 3.1c).   
3.4.2 IDENTIFICATION OF HSIRNAS THAT SILENCE HUNTINGTIN MRNA 
 Robust uptake and efficacy observed with hsiRNAs in primary cortical neurons 
encouraged us to identify functional compounds that target Htt mRNA, the single gene 
responsible for the development of Huntington’s disease.  The hsiRNA extensive 
chemical scaffold59, 118 is essential for stability, minimization of innate immune 
response25, 120, and cellular internalization but imposes significant restrictions on 
sequence space by potentially interfering with the compound’s RISC-entering ability. To 
maximize the likelihood of identifying functional HTT hsiRNAs and to evaluate the hit 
rate for this type of chemistry, we designed (using conventional criteria described in 
Materials & Methods) and synthesized hsiRNAs targeting 94 sites across the human HTT 
mRNA (Table 3.1). The panel of hsiRNAs was initially screened for efficacy in HeLa 
cells by adding hsiRNA directly to the culture medium (without lipofection or 
electroporation) to a final concentration of 1.5 µM and evaluating impact on levels of 
HTT and housekeeping (Ppib) gene mRNA expression using the QuantiGene® 
(Affymetrix) assay.  At this concentration, 24 hsiRNAs reduced HTT mRNA levels to 
less than 50% of control levels, including 7 hsiRNAs that reduced HTT mRNA levels 
below 30% of control (Fig. 3.2a). Unlike unmodified siRNA libraries, creating a library 
with extensive 2’-O-methyl and 2’-fluoro modifications introduces additional constraints 
on sequence selection.   As a result, hit rates for modified siRNA screens are lower than 
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that seen for conventional unmodified siRNA121-124.  Functional hsiRNAs targeted sites 
distributed throughout the mRNA, except the distal end of the 3′ UTR, which later was 
shown to be part of the alternative HTT gene isoform125 not expressed in HeLa cells (data 
not shown). Discounting the ~32 hsiRNAs targeting long 3′ UTR sites absent from the 
HTT isoform in HeLa cells, almost 40% of hsiRNAs showed some level of activity at 1.5 
µM, demonstrating that the evaluated chemical scaffold is well tolerated by the RNAi 









Figure 3.2 Systematic screen identifies functional hsiRNAs targeting huntingtin 
mRNA. 
(a) Huntingtin mRNA levels in HeLa cells treated for 72 hours with 94 hsiRNAs (1.5 
µM) were quantified using QuantiGene® and normalized to the housekeeping gene PPIB. 
Data are presented as percent of untreated control (n=3 wells, mean ± SD).  Grey area 
represents range of huntingtin mRNA levels encompassing untreated and non-targeting 
hsiRNA controls. Red bars indicate compounds selected for further analysis. Compound 
sequence, chemical composition and level of silencing are shown in Table 3.1.  Graph is 
representative, results confirmed in 2 separate experiments.  (b,c) Dose-response analysis 
of huntingtin mRNA levels in HeLa cells treated with HTT10150 hsiRNA (circles) or 
unmodified siRNA (squares) added to culture medium in the absence (modified 
HTT10150 IC50 = 82.2 nM) (b), or presence (modified HTT10150 IC50 = 0.004 nM, 
unmodified HTT10150 IC50 = 0.013 nM) (c), of cationic lipids for 72 hours. Huntingtin 
mRNA was measured as described in a (n=3 wells, mean ± SD). IC50 values were 
calculated as described in Materials and Methods and are presented in Table 3.1.  Graph 
is representative, results for modified siRNA confirmed in 3 separate experiments (in 
both absence and presence of cationic lipids), results for unmodified siRNA confirmed in 
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 Half-maximal inhibitory concentrations (IC50) for passive uptake of hsiRNAs 
ranged from 82 to 766 nM (Table 3.1, Fig. 3.3).  In lipid-mediated delivery, eight of the 
most active hsiRNAs had IC50 values ranging from 4 to 91 pM (Table 3.1). The best 
clinically active siRNAs are usually characterized by IC50 values in the low pM range126. 
An ability to identify highly potent compounds with low picomolar IC50 values suggests 
that the hsiRNA chemical scaffold does not interfere with siRNA biological activity for 
certain sequences. The most potent hsiRNA targeting position, 10150 (HTT10150), and 
an unmodified conventional siRNA version of HTT10150 showed similar IC50 values in 
lipid mediated delivery (4 pM and 13 pM respectively, Fig. 3.2c), further confirming that 
the hsiRNA chemical scaffold does not interfere with RISC loading or function. Only the 
modified hsiRNA, and not the unmodified version, silenced HTT mRNA by passive 
uptake (Fig. 3.2b). Thus, the chemical scaffold described here does not interfere with 
RISC assembly and is sufficient to support unformulated compound uptake and efficacy.  









Figure 3.3 Active hsiRNAs silence 
huntingtin mRNA in a concentration 
dependent manner in HeLa cells. 
Level of huntingtin mRNA was 
measured using QuantiGene® 
(Affymetrix) at 72 hours normalized to 
housekeeping gene, PPIB (cyclophillin 
B), and presented as percent of untreated 
control (n=3 wells, mean ± SD). NTC – 
non-targeting control. (a) Dose response 
of 16 active sequences in passive uptake 
(no cationic lipid formulation). (b) Dose 
response of 8 selected sequences in 




3.4.3 POTENT AND SPECIFIC SILENCING WITH UNFORMULATED HSIRNAS IN 
PRIMARY NEURONS 
 HTT10150 induced a concentration dependent silencing at 72 hours and one week 
after unformulated addition to either primary cortical or primary striatal neurons isolated 
from FVB/NJ mice (Fig. 3.4a).  At 1.25 µM, HTT10150 induced maximal silencing, 
reducing both Htt mRNA levels and HTT protein levels by as much as 70% and 85%, 
respectively (Fig. 3.4a,b, and c for original westerns).  
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Figure 3.4 HTT10150 shows dose-dependent silencing of huntingtin by passive 
uptake in primary neurons. 
(a) Huntingtin mRNA levels in primary striatal (black) or cortical (gray) neurons one 
week after treatment with the indicated concentrations of HTT10150. Huntingtin mRNA 
levels were normalized to Ppib mRNA. Data are expressed as percent of untreated 
control (n=3 wells, mean ± SD). NTC – non-targeting control (1.25 µM).  (b) Huntingtin 
protein levels in primary neurons one week after treatment with the indicated 
concentrations of HTT10150. Huntingtin and β-tubulin proteins were quantified by 
densitometry of western blots, and huntingtin protein levels were normalized to β-tubulin. 
Data are expressed relative to the level of huntingtin protein in untreated control cells. 
(n=5 neuronal preparations from separate pups, mean ± SD).  NTC – non-targeting 
control (1.25 µM).  Graph of silencing in primary cortical neurons after one week is 
representative, results confirmed in 5 separate experiments.  (c) Original western blots 
from graph in b.  Primary cortical neurons were cultured from 5 individual pups (#1-5) 
and incubated with HTT10150 at concentrations shown for one week. Huntingtin protein 
levels were detected by Western Blot using antibody AB1 (Huntingtin 1-17). NTC – non-
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 HTT10150 hsiRNA did not affect the expression levels of housekeeping controls 
(Ppib and Tubb1, Fig.3.4c) or the overall viability of primary neuronal cells, as measured 
by the alamarBlue assay, up to a 3 µM concentration (Fig. 3.5).  Similar results were 
obtained with another hsiRNA targeting Htt mRNA (Fig. 3.4d), supporting that the 
observed phenomena is not unique to HTT10150. These experiments, in conjugation with 
the results seen from targeting Ppib (Fig. 3.1c), indicate that a diversity of genes and 
target sequences can be silenced by hsiRNAs in primary neurons simply upon direct 
addition of compounds into cellular media.   
Figure 3.5 HTT10150 does not affect 
primary cortical neuron viability.   
Cell viability was tested using alamar Blue 
® (Life Technologies) after incubation of 
HTT10150 and non-targeting control with 
primary cortical neurons for 72 hours and 
one week.  Data presented as percent of 
untreated control (n=3 wells, mean ± SD).  
NTC – non-targeting control. 
 
 Since loaded RISC has a typical half-life of weeks110, silencing is expected to be 
long lasting in non-dividing cells. To evaluate duration of silencing after a single 
HTT10150 treatment of primary cortical neurons, Htt mRNA levels were measured at 
one-, two-, and three-week intervals (Fig. 3.4e). A single treatment with hsiRNA induced 
Htt silencing that persisted for at least 3 weeks, the longest time that primary cortical 
neurons can be maintained in culture. Together, these data demonstrate that hsiRNAs are 
a simple and straightforward approach for potent, specific, non-toxic, and long-term 











































3.4.4 HSIRNA DISTRIBUTION IN VIVO IN MOUSE BRAIN AFTER 
INTRASTRIATAL INJECTION 
 Having shown that hsiRNAs effectively silence their targets in primary neurons in 
vitro, we sought to evaluate the ability of HTT10150 to silence Htt mRNA in the mouse 
brain in vivo. The distribution of HTT10150 was evaluated in perfused brain sections 
prepared 24 hours after intrastriatal injection with 12.5 µg Cy3-labeled hsiRNA in 
artificial cerebral spinal fluid (ACSF). We observed a steep gradient of fluorescence 
emanating from the injection site and covering most of the ipsilateral striatum (Fig. 
3.6a,b), while no fluorescence was visually detectable in the contralateral side of the 
brain.  In high magnification images of the ipsilateral side, hsiRNAs appeared 
preferentially associated with the tissue matrix and fiber tracts. In addition, efficient 
internalization was observed in a majority of cell bodies (Fig. 3.6c,d). Consistent with in 
vitro studies, we observed Cy3-labeled hsiRNA in neuronal processes and as punctae in 
the perinuclear space of multiple cell types, including NeuN-positive neurons89, 90 (Fig. 
3.6d,e). In summary, a single intrastriatal injection delivers hsiRNA to neurons in the 
striatum of the injected side. 
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Figure 3.6 A single intrastriatal injection of HTT10150 is localized to neurons and 
fiber tracts ipsilateral to the injection site after 24 hours. 
25 µg CY3-HTT10150 (red) was unilaterally injected into the striatum of WT (FVB/NJ) 
mice. Brains were collected after 24 hours, paraffin imbedded, and sectioned.  (a) Tiled 
image of coronal brain section (16x). Majority of HTT10150 is localized at site of 
injection with sharp gradient of diffusion.  (b) Tiled image of sagittal brain section (16x), 
injected side.  (c), Image of coronal brain section (40x), injected side. (d) Image of 
coronal brain section (60x), injected side, with NeuN stained neurons. (e) NeuN stained 
neurons from injected side (60x) zoomed in.  Solid arrow, NeuN staining.  Open arrow, 
Cy3-HTT10150 punctae in perinuclear space.  Images are representative, results 
confirmed in 2 separate experiments. 
 
3.4.5 HSIRNA EFFECTIVELY SILENCES HTT IN VIVO WITH MINIMAL 
CYTOTOXICITY OR IMMUNE ACTIVATION 
 To measure HTT10150 efficacy in vivo, we performed dose-response studies in 
wild type FVB/NJ mice injected intrastriatally with 3.1, 6.3, 12.5, or 25 µg of HTT10150. 
As controls, we injected mice with a non-targeting control hsiRNA (NTC), artificial 
cerebrospinal fluid (ACSF), or PBS. In punch biopsies taken from the ipsilateral and 
a b 
c d e 
50 µm 25 µm 
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contralateral striatum, HTT10150 reduced Htt mRNA levels in a dose-dependent manner 
(Fig. 3.7a).  
Figure 3.7 HTT10150 effectively silences huntingtin mRNA ipsilateral to the site of 
injection. 
HTT10150 was unilaterally injected into the striatum of WT (FVB/NJ) mice (2 µl). Mice 
were sacrificed at 5 days. Brains were sliced into 300 µm sections and six - 2mm punch 
biopsies of the striatum (a) and cortex (b) were collected from both ipsilateral and 
contralateral sides.   Level of huntingtin mRNA was measured using QuantiGene® 
(Affymetrix) normalized to housekeeping gene, Ppib (cyclophillin B), and presented as 
percent of untreated control (n=8 mice, mean ± SD, 3 biopsies per region).  P values are 
all calculated for each dose group relative to NTC by Two-way RM ANOVA:  25 µg 
striatum p<0.0001, 12.5 µg striatum p<0.0001, p=0.0002, 6.3 µg cortex p=0.0009. NTC – 
non-targeting control. 
 
 This experiment was repeated several times with similar results. The Htt mRNA 
was significantly reduced in the ipsilateral side of striatum in all experiments. We 
observed robust dose-dependent silencing with up to 77% (one way Anova, p<0.0001) 
reduction in Htt mRNA expression levels at the highest dose. Interestingly we observe 
statistically significant, but less pronounced silencing in the contralateral striatum and the 
cortex (Fig.3.7b). The silencing reaches statistical significance with both One-way and 
Two-way Anova (values for Two-way Anova are presented in Fig. 3.7). While some 
level of fluorescence is detectable on the contralateral side with high laser intensity, it is 
very close to the tissue auto-fluorescence and thus is not reported here.  While the 
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phenomenon of potential transport across hemispheres can be investigated further, it is 
clear that the level of silencing is at least correlative to the sharp gradient of diffusion 
from the injection site. 
 Finally, Htt mRNA silencing was observed with HTT10150 but not with NTC or 
ACSF (Fig. 3.7). In addition, the HTT10150 did not affect expression of several 
housekeeping genes (PPIB, HPRT). In combination, this is indicative of Htt mRNA 
silencing being caused by HTT10150 hsiRNA.  
 Nucleic acids, including siRNAs, are potent stimulators of the innate immune 
response127, but extensive chemical modifications, like 2′-O-methyl, are found to 
suppress the immunostimulatory effects of siRNAs in vitro and in vivo91. To assess innate 
immune response activation by hsiRNAs in vivo, we quantified IBA1-positive microglial 
cells in brain sections from mice injected with 12.5 µg HT10150 or artificial CSF.  IBA-1 
is specific to microglial cells and is up-regulated following injury to the brain, allowing 
us to distinguish between resting and activated microglia92-94. In the case of a major 
innate immune response, an increase of 200-300% in total microglia is typical128. Total 
microglia counts showed only a 25% increase in the ipsilateral striatum at five days post 
injection indicating a lack of any major inflammatory response (Fig. 3.8). Thus the 
observed activation is relatively minor, but reaches statistical significance, indicating 
some level of response.   
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Figure 3.8 HTT10150 causes a slight increase in total resting microglia 5 days post 
injection.  
HTT10150 was unilaterally injected into the striatum of FVB/NJ mice. Brains were 
collected 6 hours and 5 days post injection, fixed, sectioned, and stained with antibodies 
against IBA-1.  Total microglia were quantified 6 hours (a) and 5 days (b) post-injection 
of ACSF (n=6 mice, mean ± SD) (a), n=4 mice, mean ± SD (b)), and 12.5 µg HTT10150 
(n=3 mice, mean ± SD (a,b)).  For (a), P values calculated by paired t-test, t=2.915, df=5: 
ACSF ipsilateral vs ACSF contralateral p=0.0332.  For (b), P values calculated by 
unpaired t-test (between groups), t=5.272, df=5: ACSF vs HTT10150 ipsilateral 
p=0.0033; and by paired t-test (between ipsilateral and contralateral sides within the same 
group), t=4.845, df=2: HTT10150 ipsilateral vs contralateral p=0.0401. Images are 
representative, results confirmed in separate images of all injected brains. 
 
 Levels of innate immune response might be more pronounced immediately 
following compound administration. To assess the level of stimulation in more detail, we 
separately evaluated the number of activated and resting microglia at both 6 hours and 5 
days post- injection. At 6 hours post-injection we observed a significant increase in the 
number of activated microglia in the injected side of the brain with both ACSF and 
HTT10150. The injection event itself causes trauma and induces a major increase in 
activated microglia (nine fold) compared to the contralateral side of the brain (Fig. 
3.8b)57, 129. In the presence of HTT10150, the number of activated microglia was 
additionally increased two fold compared to ACSF, indicating enhancement of trauma-
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related microglia activation in the presence of oligonucleotide, although the relative 
contribution of the oligonucleotide to the trauma related induction is minor. HTT10150-
treated mice also showed some elevation of activated microglia in the contralateral 
striatum 6 hours post injection (Fig. 3.9b), however, after 5 days, all changes in number 
of microglia in the contralateral side of the brain disappeared (Fig. 3.9c, Fig. 3.9a for 
representative images), suggesting that HTT10150-dependent activation of microglia in 






Figure 3.9 HTT10150 shows a two-fold increase in microglial activation at the site of 
injection.  
HTT10150 was unilaterally injected into the striatum of WT (FVB/NJ) mice. Brains were 
collected after 6 hours (b) and 5 days (a, c) fixed, sectioned, and stained with antibodies 
against IBA-1. (a) Representative images of activated (black arrow) and resting (open 
arrow) after injection of 12.5 µg HTT10150 and ACSF 5 days post injection, 40x 
magnification.  (b) Quantification of activated and resting microglia 6 hours post-
injection of ACSF (n=6 mice, mean ± SD) and 12.5 µg HTT10150 (n=3 mice, mean ± 
SD). P values calculated by unpaired t-test, t=9.996, df=7: ACSF vs HTT10150 activated 
microglia ipsilateral striatum p=0.0239.  ACSF vs HTT10150 activated microglia 
contralateral striatum p<0.0001.  (c) Quantification of activated and resting microglia 5 
days post-injection of ACSF (n=4 mice, mean ± SD) and 12.5 µg HTT10150 (n=3 mice, 
mean ± SD).  Images are representative, results confirmed in separate images of all 
injected brains.  P values calculated by unpaired t-test, t=2.700, df=5: ACSF vs 
HTT10150 activated microglia ipsilateral striatum p=0.0428. 
 
 Despite the mild immune stimulation in the brains of animals injected with 
HTT10150, we did not observe any overall significant reduction of DARPP-32, an 
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Figure 3.10 HTT10150 shows no toxicity in DARPP-32 positive neurons around the 
site of injection.  
HTT10150 was unilaterally injected into the striatum of WT (FVB/NJ) mice. Brains were 
collected after 5 days, fixed, sectioned, and stained with antibodies against DARPP-32 
(a-d).  Representative image of striatum after injection of ACSF, full brain scan and 60x 
magnification (a,b) or 12.5µg HTT10150, full brain scan and 60x magnification (c,d). (a) 
Quantification of DARPP-32 positive neurons (n=3 mice, mean ± SD).  Images are 
representative, results confirmed in separate images of all injected brains. 
 
 The only observed effect was at a small area directly around the injection site in 
animals treated with 25 µg HTT10150 (Fig. 3.11).  Taken together, our data shows that a 
single intrastriatal injection of hsiRNA induces potent gene silencing with a mild immune 
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Figure 3.11 HTT10150 shows 
limited toxicity at the site of 
injection at the 25 µg dose. 
HTT10150 was unilaterally 
injected into the striatum of 
FVB/NJ mice.  
Brains were collected after 5 
days, fixed, sectioned, and 
stained with antibodies against 
DARPP-32.  Representative 
image of striatum after 
injection of 25 µg, full brain scan (a), 10x and 20x magnification at injections site (b), 
and 60x magnification directly adjacent to injection site, and contralateral to injection site 
(c).  Images are representative, results confirmed in separate images of all injected brains. 
 
3.5 DISCUSSION 
 Achieving simple, effective, and non-toxic delivery of synthetic oligonucleotides 
to primary neurons and brain tissue represents a challenge to the use of RNAi as a 
research tool and therapeutic for neurodegenerative diseases like HD100. We have shown 
that hsiRNAs elicit potent and specific silencing of Htt mRNA in primary neurons in 
culture with minimal toxicity at effective doses, while the non-targeting control hsiRNA 
has no effect on Htt or housekeeping mRNA levels.  These data taken together suggests 
that hsiRNAs are both sequence specific and on target. Additionally, we do not see 
knockdown of housekeeping genes following treatment with HTT10150, suggesting that 
HTT silencing by this compound is both sequence specific and on target.  Interestingly, 
the level of silencing is more pronounced on the protein level (>90%) compared to the 
mRNA level (>70%).  The mRNA plateau effect is reproducible and is specific to Htt 
mRNA, as housekeeping genes like PPIB can be silenced by 90%. One potential 
explanation is that some fraction of huntingtin mRNA is translationally inactive and 
poorly accessible by RNAi machinery. We are continuing to investigate this 
10x Injection site 20x Injection site 




phenomenon. Silencing in primary neurons persists for multiple weeks after a single 
administration, consistent with the expected half-life of active RISC131. Moreover, 
efficient intracellular delivery of hsiRNAs does not require the use of lipids or viral 
packaging. 
 Currently, the most impressive in vivo modulation of Htt mRNA expression is 
demonstrated with 2'-O-methoxyethyl (MOE) GapmeR antisense oligonucleotides 
(ASO). A single injection of 50 µg of ASO or infusion of around 500 µg results in potent 
and specific Htt mRNA silencing in mouse and marked improvement in multiple 
phenotypic endpoints5, 132-134. However, MOE GapmeR ASOs are not readily 
commercially available making them inaccessible for the majority of academic labs. 
 Here, we show Htt mRNA silencing in the ipsilateral striatum and cortex, two 
brain areas significantly affected in HD disease progression, with a single intrastriatal 
injection of 12.5-25 µg. As a considerably reduced level of silencing was observed on the 
contralateral side of the brain, bilateral injections might be necessary to promote equal 
gene silencing in both hemispheres.  
 The limited distribution profile observed in vivo restricts immediate adoption of 
this technology for use in larger brains and eventually as a therapeutic for 
neurodegenerative disease. Tissue distribution can be improved by tailoring the chemical 
scaffold (e.g. number and type of sugar modifications, position of phosphorothioate 
linkages) or by changing the conjugation moiety to promote receptor-mediated cellular 
internalization. Formulation of hsiRNA in exosomes, exosome-like liposomes, or 
shielding the compounds with PEG may also provide an alternative strategy to improve 
tissue distribution135, 136. 
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 Here, we identify an active siRNA sequence targeting Huntington’s disease and 
describe a class of self-delivering therapeutic oligonucleotides capable of targeted, non-
toxic, and efficient Htt silencing in primary neurons and in vivo. This chemical scaffold 
can be specifically adapted to many different targets to facilitate the study of neuronal 
gene function in vitro and in vivo. The development of an accessible strategy for genetic 
manipulation in the context of a native biological environment represents a technical 





CHAPTER IV:  COMPARISON OF FULLY AND PARTIALLY 
CHEMICALLY-MODIFIED SIRNA IN CONJUGATE-MEDIATED 
DELIVERY IN VIVO 
4.1 PREFACE 
 
Text and figures are reproduced from 
 
• Hassler MR*, Turanov AA*, Alterman JF*, Coles AH, Haraszti RA, Osborn 
MF, Godinho BM, Lo A Rajakumar A, Golebiowski D, Echeverria D, Nikan M, 
Salomon WE, Davis SM, Morrissey DV, Sena-Esteves M, Zamore PD, 
Karumanchi SA, Moore MJ, Aronin N, Khvorova A.  Comparison of fully and 
partially chemically-modified siRNA in conjugate-mediated delivery in vivo.  
NAR, 2018.  *These authors contributed equally to this work. 
 
Anastasia Khvorova, Matthew Hassler, Anton Turanov, and I conceived of the project.  
Matthew Hassler and I designed the sequences.  Matthew Hassler and Dimas Echeverria 
synthesized all of the compounds.  Andrew Coles and Anton Turanov did injections.  
Maire Osborn, Sarah Davis, Anton Turanov, and I contributed to in vitro dose responses.  
Wes Salomon did Ago2 loading and turnover experiments. Reka Haraszti ran the PNA 
assay.  Anton Turanov and I processed in vivo tissue samples, and graphed and analyzed 
the data.  Matthew Hassler, Anton Turanov, Anastsia Khvorova and I wrote the 
manuscript.   
4.2 ABSTRACT 
 Small interfering RNA (siRNA)-based drugs require chemical modifications 
and/or formulation to promote stability, minimize innate immunity, and enable delivery 
to target tissues. Partially modified siRNAs (up to 70% of the nucleotides) provide 
significant stabilization in vitro and are commercially available; thus are commonly used 
to evaluate efficacy of bio-conjugates for in vivo delivery. In contrast, most clinically-
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advanced non-formulated compounds, using conjugation as a delivery strategy, are fully 
chemically modified (100% of nucleotides). Here we compare partially and fully 
chemically modified siRNAs in conjugate mediated delivery. We show that fully 
modified siRNAs are retained at 100x greater levels in various tissues, independently of 
the nature of the conjugate or siRNA sequence, and support productive mRNA silencing. 
Thus, fully chemically stabilized siRNAs may provide a better platform to identify novel 
moieties (peptides, aptamers, small molecule) for targeted RNAi delivery. 
4.3 INTRODUCTION 
 A variety of chemical modification patterns have been explored to improve 
siRNA stability123, ranging from the simple introduction of a dTdT overhang to highly 
complicated patterns that remove the chemical nature of RNA137.  Commonly used, 
commercially available scaffolds include modification of every other nucleotide138 or all 
pyrimidines in a given sequence139.  These “conventional” modification patterns 
substantially enhance siRNA stability in vitro140 and block innate immune activation in 
vivo25. 
 Partially modified siRNAs have been extensively used to study the impact of 
conjugates on siRNA distribution and in vivo efficacy.  A wide range of conjugate 
modalities have been tested: steroids141, lipids142, folate143, vitamins62, aptamers54, and 
antibodies51 all demonstrating only marginal efficacy.  All of these conjugates were 
evaluated in the context of naked or partially modified siRNA, miRNAs, and antisense 
oligonucleotides. 
 A recent breakthrough in conjugate-mediated delivery was the development of the 
triple N-acetylgalactosamine (GalNAc) conjugated siRNA144, 145, which drives efficient, 
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receptor-mediated uptake into hepatocytes.  The GalNAc-conjugated siRNAs were fully 
modified using an advanced version of an alternating 2ʹ–fluoro, 2ʹ–O–methyl pattern first 
described in 2005138.  Additionally, in the context of single stranded RISC entering 
oligonucleotides chemical stabilization was shown to be absolutely essential for in vivo 
efficacy145, 146. Recently, fine-tuning of the chemical stabilization pattern, including 
increases in the 2ʹ–O–methyl content, incorporation of additional phosphorothioates145 
and 5’ phosphate stabilization147-149 have been shown to even further enhance long-term 
efficacy of conjugated siRNAs.  
  Here we systematically compare the distribution, tissue accumulation, and 
efficacy of partially and fully modified siRNA scaffolds and show that full chemical 
stabilization of siRNA is preferred for in vivo applications, independently of the siRNA 
sequence or the nature of the conjugate used. 
4.4 RESULTS 
4.4.1 FULL CHEMICAL STABILIZATION ENABLES EFFICIENT CONJUGATE-
MEDIATED SIRNA EFFICACY IN VITRO.  
 To compare the impact of fully or partially modified scaffolds on conjugate-
mediated distribution and silencing in vivo, we used asymmetric, cholesterol-modified 
siRNAs as a model (Fig. 4.1a).   
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Figure 4.1 Chemical composition and cellular efficacy of fully modified hsiRNAs.   
(a) Chemical structure, modification pattern, and molecular model of partially (hsiRNA) 
and fully modified (FM-hsiRNA) hydrophobic siRNA.  (b,c) Comparison of hsiRNA and 
FM-hsiRNA activity in vitro.  HeLa (b) or primary cytotrophoblasts (c) were incubated 
with hsiRNA or FM-hsiRNA at concentrations shown for one week.  mRNA levels were 
measured using QuantiGene® (Affymetrix) normalized to housekeeping gene (human 
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Ppib for (b) and human Ywhaz for (c)), and presented as percent of untreated control 
(n=3, mean ± SD).  UNT – untreated cells.  (d,e) Preferential RISC loading of fully 
modified hsiRNA.  (d) Concentration of loaded RISC with unmodified, naked-siRNALet7, 
or FM-hsiRNALet7 (e) Multiple turnover cleavage rate normalized to amount of loaded 
RISC with unmodified, naked-siRNALet7, or FM-hsiRNALet7. 
 
 The asymmetric design, termed hsiRNAs (15-nucleotide sense strand with a 3ʹ-
conjugate and 20-nucleotide guide strand) lowers the melting temperature of the double-
strand region, to facilitate the dissociation of the non-cleavable modified sense strand 
from the RNA-Induced Silencing Complex (RISC) during loading.  RISC loading can 
occur through passenger strand cleavage150 or dissociation. Full chemical modification of 
the passenger strand blocks the cleavage pathway, leaving dissociation as the only 
functional alternative for RISC loading. This makes Tm of the fully chemically stabilized 
duplex one of the primary activity-limiting factors. The relative impact of asymmetric 
duplex configuration on compound efficacy is sequence dependent. Fig. 4.2a,b shows the 
activity of two siRNA sequences in the context of either the conventional symmetric (20-
mer-20-mer) or asymmetric (15-mer-20-mer) duplex configuration. For the siRNA 
targeting HTT there is no difference between the two configurations, whereas for the 
siRNA targeting sFLT1, reduction in duplex length substantially improves compound 
efficacy.  The single-strand region of the guide strand contains phosphorothioate 
linkages26, providing additional stabilization and enhancing cellular internalization151.  
This chemical scaffold has been extensively characterized including mechanism of 
trafficking, clearance kinetics, systemic and local delivery1, 35, 55, 56, 58, 59, 151, 152.  
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Figure 4.2 A comparison of symmetric and asymmetric siRNAs in vitro and screen 
of alternative FM-hsiRNAHTT patterns.  
(a, b) The effect of duplex chemical configuration on siRNA activity is sequence 
dependent. HeLa cells were treated in the absence of cationic lipids with asymmetric and 
symmetric siRNAs targeting both HTT and sFLT1. HTT expression was measured using 
QuantiGene 2.0 (Affymetrix), normalized to the housekeeping gene HPRT and sFLT1 
expression was measured using a luciferase reporter assay (c) Representative images of 
alternative modification patterns and their corresponding IC50s. IC50s calculated as 
described in Materials and Methods. Cells treated for 72 hours with compound in the (d) 
absence (e) or presence of cationic lipids. HTT mRNA was measured using QuantiGene 
2.0 (Affymetrix), normalized to the housekeeping gene PPIB. All data is expressed as 
percent of untreated control . (n=3 wells, mean ± SD). UNT – untreated cells. 
 
 Cholesterol conjugation to partially modified hsiRNAs results in robust cellular 
uptake in vitro and potent local silencing in vivo58, 59, but marginal systemic efficacy.  
Thus, cholesterol-conjugated siRNAs provide a good starting point to evaluate the impact 
of extensive chemical stabilization on conjugate-mediated hsiRNA delivery. 
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 Using a previously identified, partially modified hsiRNA sequence targeting 
huntingtin (Htt) mRNA58, we synthesized and tested a panel of fully modified hsiRNAs 
(FM-hsiRNAs) based on previously reported patterns137, 138. Though several 
configurations were functional, an alternating 2ʹ–O–methyl, 2ʹ–fluoro pattern, with a 
chemically monophosphorylated, 2ʹ–O–methyl–modified uridine (U) at position 1, and a 
2ʹ-fluoro modified nucleotide at position 14 of the guide strand performed the best (Fig. 
4.1a, Fig. 4.2c and Table 4.1). An alternating pattern with a 2ʹ–fluoro in position 1 of the 
guide strand reduced silencing activity (data not shown), likely due to placement of 2ʹ–
O–methyl groups in positions 2 and 14, which negatively affects potency in the context 
of heavily modified duplexes153.  5ʹ -Chemical phosphorylation of the guide strand was 
performed, as terminal 2ʹ–O–methylated U is not as good a substrate for intracellular 
kinases as natural RNA. We also added two phosphorothioate linkages to both 5ʹ and 3ʹ 
ends of the sense and guide strands to provide additional resistance to exonucleases. 
Figure 4.1a shows the modification patterns and PyMol structure models of the 
conventionally modified hsiRNA and the most active fully modified hsiRNA (FM-
hsiRNA). 
Table 4.1 hsiRNA sequences and chemical modification patterns 
siRNA ID Gene Accession number 
Targeting 

























































































































































































































































































































Chemical modifications are designated as follows.  “.” – phosphodiester bond, “#” – 
phosphorothioate bond, “m” – 2’-O-methyl, “f” – 2’-Fluoro, no prefix – ribonucleotide, 
“P” – 5’ Phosphate, , “V” – 5’ Vinyl phosphonate, “teg-cholesterol” – tetraethylene 
glycol (teg)-Cholesterol, GalNAc  – trivalent N-Acetylgalactosamine, (OO) – O-linker 
(PNA Bio), DHA – docosahexaenoic acid 
 
 The FM-hsiRNA pattern supported similar or improved silencing when applied to 
previously identified functional siRNAs targeting Htt, Ppib, sFlt1, Tie2154, Plk1, and 




Figure 4.3 Comparison of hsiRNA and FM-hsiRNA activity cultured cells.  
Primary neurons (a) or primary cytotrophoblasts (b) were incubated with hsiRNA or FM-
hsiRNA at concentrations shown for one week.mRNA levels were measured using 
QuantiGene® (Affymetrix) normalized to housekeeping gene (mouse PPIB for (a) and 
human Ywhaz for (b)), and presented as percent of untreated control (n=3, mean ± SD). 
UNT – untreated cells. 
 
 Moreover, FM-hsiRNAs improved silencing in cultured primary neurons and 
primary trophoblasts, adherent and suspension cell types, respectively, the latter of which 
are notoriously difficult to transfect by conventional methods109, 155.  The activity 
improvement provided by full chemical stabilization was more pronounced in the non-
adherent primary trophoblasts where cholesterol mediated uptake is generally slower 
(Fig. 4.1c).  When directly compared to an unmodified, unconjugated siRNA, Chol-FM-
hsiRNA showed significantly enhanced efficacy following passive uptake (IC50 of 33.5 
nM) while naked siRNA is inactive.  However, both compounds showed comparable 
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potency (IC50 of 3.5 nM for siRNA and 0.9 nM FM-hsiRNA) following lipid 
transfection, further confirming that full modification is compatible with RISC function 
in cells (Fig. 4.4).   
Figure 4.4 Full chemical modification is essential for unassisted cellular delivery and 
does not compromise siRNA RISC entry.  
HeLa Cells treated for 72 hours with compound in the (a) absence or (b) presence of 
cationic lipids. Htt mRNA was measured using QuantiGene®, normalized to the 
housekeeping gene PPIB, and expressed as percent of untreated control. (n=3 wells, mean 
± SD). UNT – untreated cells. IC50 values were calculated as described in Materials and 
Methods and are presented in table (c). 
 
 Similarly, fully modified GalNAc-conjugated siRNAs were more active in 
primary hepatocytes than partially modified GalNAc-conjugated siRNAs (Fig. 4.5), 
indicating that improvement in potency is not specific to the nature of the conjugate or 




Figure 4.5 Full chemical modification enhances GalNAc-mediated mRNA silencing 
in human primary hepatocytes.  
Cells treated for 72 hours with compound in the (a) absence or (b) presence of cationic 
lipids. Htt mRNA was measured using QuantiGene®, normalized to the housekeeping 
gene Ppib, and expressed as percent of untreated control. (n=3 wells, mean ± SD). UNT – 
untreated cells. IC50 values were calculated as described in Materials and Methods and 
are presented in table (c). 
 
4.4.2 FULLY CHEMICALLY MODIFIED SIRNAS ARE EFFICIENTLY LOADED 
INTO RISC COMPLEX 
 The loading and cleavage rates of FM-hsiRNA were compared to a completely 
non-modified Let-7 siRNA in a loading and cleavage assay described earlier156. The FM-
hsiRNA loaded almost three times more RISC complex compared to the naked siRNA 
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(Fig. 4.1d), which is likely associated with the enhanced stability of FM-hsiRNA.  Once 
the loaded RISC was under multiple turnover conditions (37°C), the in vitro cleavage 
rates of both the FM-hsiRNA and the non-modified oligo were similar (after normalizing 
to equal numbers of loaded RISC) (Fig. 4.1e).  Thus, full modification does not interfere 
with the ability of the tested oligonucleotide to be recognized by, and functionally load 
the RISC complex. 
4.4.3 COMPARISON OF PARTIALLY AND FULLY CHEMICALLY MODIFIED 
SIRNAS IN CONJUGATE-MEDIATED SYSTEMIC DELIVERY. 
 Both partially modified (e.g., all pyrimidines) and fully modified siRNAs have 
increased stability in vitro (from minutes to days in 50% serum) over non-modified 
siRNAs138, 139.  In vivo, however, oligonucleotides are exposed to an aggressive nuclease 
environment that cannot be adequately mimicked in vitro.  Thus the stability of partially 
and fully modified siRNAs might be quite different from one another in vivo.  To 
compare the distribution of partially modified and fully modified hsiRNAs in vivo, we 
administered 10 mg/kg of Cy3-labeled Chol (cholesterol)-hsiRNA and Chol-FM-hsiRNA  
by intravenous (IV) or subcutaneous (SC) injection (Fig. 4.6a,b).  Twenty-four hours 
after injection, we harvested tissues from mice and visualized the siRNA distribution by 
fluorescence microscopy. Injection of partially modified Cy3-Chol-hsiRNA resulted in 
minimal levels of fluorescence, observed only in liver and kidney.  By contrast, injection 
of Cy3-Chol-FM-hsiRNA resulted in intense accumulation of fluorescence in tissues 
throughout the body, including liver, kidney, spleen, fat, and skin (Fig. 4.6a, b and Data 
not shown).   
 93 
Figure 4.6 Systemically administered fully modified hsiRNA shows enhanced tissue 
distribution.   
Tissue distribution of Cy3-Chol-hsiRNA sFLT1 and Cy3-Chol-FM-hsiRNA sFLT after 10 
mg/kg intravenous (IV) tail vein injection (a) or 10 mg/kg subcutaneous (SC) injection 
(b).  Tissue distribution of Cy3-DHA-hsiRNA sFLT1 and Cy3-DHA-FM-hsiRNA sFLT after 
10 mg/kg intravenous (IV) tail vein injection (c) or 10 mg/kg subcutaneous (SC) injection 
(d).  Tissue distribution of Cy3-GalNAc-hsiRNA sFLT1 and Cy3-GalNAc-FM-hsiRNA sFLT 
after 10 mg/kg intravenous (IV) tail vein injection (e) or 10 mg/kg subcutaneous (SC) 
injection (f).  Cy3-hsiRNA (red), nuclei stained with DAPI (blue).   For every chemistry 
the left panels are tiled tissue images (scale bar – 1 mm) and the right panels are higher 























































































 To evaluate whether a significant enhancement in retention upon full chemical 
stabilization is not specific to the cholesterol conjugate, we evaluated two other 
conjugates with potential for tissue delivery: Docosahexaenoic acid (DHA)150, and 
GalNAc144. The fully modified and partially modified GalNAc and DHA conjugate 
compounds were synthesized and their tissue distribution evaluated 24 hours post IV and 
SC injection (Fig. 4.6 c-f). As with cholesterol, we observed a substantial increase in 
compound tissue accumulation with the FM-hsiRNA, independently of the nature of the 
conjugate. It is important to notice that changing the conjugate resulted in a change in 
tissue distribution profile, which could only be visualized in the context of fully modified 
hsiRNA. 
 To insure that qualitative robust difference observed in fluorescence distribution 
between partially and fully modified hsiRNAs is not an artifact of tissue processing or 
presence of the fluorescent label, we used a PNA hybridization-based assay152, 157 to 
evaluate the accumulation of these compounds quantitatively.  This method allows for the 
detection of intact guide strands present in tissue biopsies and is not dependent on the 
presence of the fluorescent label.  
 Figure 4.7 shows the quantification data for the three different conjugates 
(Cholesterol, DHA, and GalNAc) attached to fully and partially modified hsiRNA 
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Figure 4.7 Systemic administration of fully modified hsiRNAs shows enhanced 
tissue accumulation  
Guide strand tissue quantification by PNA hybridization-based assay in tissues from 
Figure 4.6.  Guide strand quantification of Cy3-Chol-hsiRNA sFLT1 and Cy3-Chol-FM-
hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein injection (a) or 10 mg/kg 
subcutaneous (SC) injection (b).  Guide strand quantification of Cy3-DHA-hsiRNA sFLT1 
and Cy3-DHA-FM-hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein injection (c) or 
10 mg/kg subcutaneous (SC) injection (d).  Guide strand quantification of Cy3-GalNAc-
hsiRNA sFLT1 and Cy3-GalNAc-FM-hsiRNA sFLT after 10 mg/kg intravenous (IV) tail vein 
injection (e) or 10 mg/kg subcutaneous (SC) injection (f).  Data presented as mean ± SD 
(n=3 mice). 
 
 In all cases, independently of the route of administration, or the type of conjugate, 
over 100x tissue accumulation was observed of fully chemically modified siRNAs 
relative to the partially chemically modified siRNAs. FM-hsiRNA guide strands 
accumulated to relatively high levels, 20-200 ng/mg in liver, kidney, and spleen (Fig. 4.6 
b,c).  Consistent with the imaging data, the tissue distribution profile was effected by the 
type of conjugate used, with cholesterol preferentially accumulating in liver (~ 150 
ng/mg), DHA in kidney (300-400 ng/mg) and GalNAc in both liver and kidney (~200 
ng/mg). While cholesterol and DHA show distribution to tissues beyond the liver and 
kidney, such as the spleen, skin, and fat (data not shown), GalNAc distribution was 
effectively exclusive to liver and kidney (Fig. 4.6e,f).  Hence, full chemical stabilization 
significantly enhances conjugate-mediated tissue accumulation independent of the 
conjugate nature, or route of administration, and is heavily reliant on the full chemical 
modification of the siRNA. 
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4.4.4 FULL CHEMICAL STABILIZATION ENABLES PRODUCTIVE SILENCING IN 
VIVO. 
 The poor accumulation and retention of partially modified hsiRNAs is consistent 
with published studies showing that systemic silencing by partially modified siRNA 
lipophilic conjugates requires repetitive delivery with high doses (50 to 80 mg/kg)142. 
Consistently, when cholesterol-conjugated partially modified hsiRNA was delivered 
systemically at 2x50 mg/kg dose levels we were unable to detect silencing, even in the 
liver, a primary tissue where cholesterol modified siRNAs distribute.   
 To confirm that significant FM-hsiRNA tissue accumulation results in functional 
gene silencing, we evaluated silencing efficiency in the liver and the kidney.  For this 
experiment, we selected the following targets:  Ppib, a commonly used housekeeping 
gene expressed in all cell types, Htt, a key target in Huntington’s Disease, also expressed 
in all cell types, and sFlt1 (soluble fms-like tyrosine kinase 1 or VEGFR1), which is 
primarily expressed in endothelial cells and kidney proximal tubules epithelia, where 
Chol-FM-hsiRNAs tend to accumulate (Fig. 4.6 a, b). 
 We, and others, have recently demonstrated that chemical stabilization of the 5’ 
phosphate of the guide strand increases in vivo efficacy of siRNA conjugates35, 36, 149.  
Thus for evaluation of targeted gene silencing in vivo, partially and fully modified siRNA 
scaffolds were synthesized with a 5’-(E)-VP (vinyl phosphonate).  Animals were injected 
with 20 mg/kg of fully and partially modified hsiRNAs. The level of targeted gene 
expression was evaluated a week post injection using the QuantiGene® Assay. We also 
injected a non-targeting control (NTC), compounds of the same chemical composition 
but not targeting the intended mRNA, and PBS (phosphate buffered saline) as controls. 
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For all three genes tested, injection of controls resulted in no significant changes in gene 
expression. In contrast, all three genes were significantly silenced in liver after injection 
of a fully chemically stabilized variant (Fig. 4.9 a-c).   
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Figure 4.8 Fully modified hsiRNAs are more efficacious than partially modified 
hsiRNAs following systemic administration.   
(a, b, c) Quantification of target (Ppib, Htt, sFlt1, respectively) mRNA silencing in liver 
7 days after SC administration of cholesterol-conjugated VhsiRNANTC, VFM-hsiRNANTC, 
VhsiRNATarget, VFM-hsiRNATarget at 20 mg/kg. (d) Quantification of Ppib mRNA 
silencing in kidney 7 days after SC administration of cholesterol-conjugated VhsiRNANTC, 
VFM-hsiRNANTC, VhsiRNAsFLT1, VFM-hsiRNAsFLT1 at 20 mg/kg.  FVBNj mice (n=6 per 
group).  mRNA levels were measured with QuantiGene® (Affymetrix) assay.  Htt, Ppib, 
and sFlt1 mRNA levels normalized to housekeeping gene, Hprt.  All data presented as 
percent of PBS treated control. All error bars represent mean ± SD. *, P<0.05, ***, 
P<0.001; ****, P<0.0001 as calculated by One Way ANOVA with Tukey’s test for 
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 The same phenomenon was observed in kidney, where sFlt1 was significantly 
downregulated by Chol-FM-hsiRNAs (Fig. 4.10d).  In both liver and kidney partially 
modified hsiRNA did not support efficient silencing.  The degree of silencing varies from 
target to target and is likely due to differences in cell types and levels of target mRNA 
expression. While distribution and efficacy are significantly enhanced by full chemical 
modification, injection of cholesterol, DHA and GalNAc-conjugated, fully chemically 
modified, siRNAs were well tolerated at the doses injected, with animals showing no 
observable adverse events or changes in blood chemistry (data not shown).   
 To confirm that this phenomenon also holds true with local delivery, both 
hsiRNAHTT and FM-hsiRNAHTT were injected unilateral into the brain striatum.  FM-
hsiRNA showed not only greater potency (Fig. 4.11a) but also maintains silencing for up 




Figure 4.9 Fully modified hsiRNAs are more efficacious than partially modified 
hsiRNAs following intrastriatal injection.   
(a) Quantification of Htt mRNA silencing in brain 7 days after intrastriatal administration 
of cholesterol-conjugated hsiRNAHTT, FM-hsiRNAHTT  (b) Quantification of Htt mRNA 
silencing in brain at different timepoints. FVBNj mice. mRNA levels were measured with 
QuantiGene® (Affymetrix) assay. mRNA levels normalized to housekeeping gene, Hprt.  
All data presented as percent of PBS treated control. All error bars represent mean ± SD. 
*, P<0.05, **, P<0.01, ***, P<0.001; ****, P<0.0001 as calculated by One Way 
ANOVA with Tukey’s test for multiple comparisons. 
 
 This confirms that full chemical stabilization enables both siRNA tissue 
accumulation and productive silencing. 
4.5 DISCUSSION 
 Here we have compared partially and fully chemical modified siRNA scaffolds in 
conjugate mediated delivery in vitro and in vivo. We have utilized a simple siRNA 
scaffold, utilizing an alternating 2ʹ-fluoro, 2ʹ-O-methyl modification138 pattern in the 
context of an asymmetric siRNA.  We have shown that full chemical modification does 
not interfere with RISC assembly and target cleavage in vitro and supports the activity of 
previously identified, functional siRNA sequences in cell culture. In fact, this chemical 
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duplex) and target cleavage in vitro, allows productive RISC assembly and function in 
cells and in vivo in animals. 
 Historically, extensive chemical modifications of siRNAs were shown to 
negatively impact siRNA efficacy, resulting only in a small fraction of functional, naked 
siRNAs being successfully converted to modified scaffolds123, 158, 159.  The two major 
contributors to modification-related negative impact on silencing activity are 
modifications forcing the nucleic acid into a suboptimal geometry (both for loading and 
target cleavage) and/or making the duplex too stable, interfering with guide strand 
loading150.  Indeed, complete modification of the guide strand with 2ʹ-fluoro resulted in 
almost three-fold drop in silencing efficacy in vitro.   Both, 2ʹ-fluoro and 2ʹ-O-methyl 
modifications favor the C3ʹ-endo ribose conformation, but 2ʹ-fluoro modifications 
slightly over-wind the duplex and 2ʹ-O-methyl slightly under-wind the RNA duplex. In 
addition, 2ʹ-fluoro modification is more hydrophobic and thus might contribute to 
enhancement in cellular uptake and in vivo distribution160. Alternating these two types of 
modifications supports formation of an A-form helical structure, the geometry required 
for guide strand-based positioning of the targeted mRNA into the cleavage center of 
RISC161. This is consistent with the recently published crystal structure of fully modified 
guide strand showing ability to adopt variety of confirmations23 Alternating 2ʹ-fluoro and 
2ʹ-O-methyl modifications on both strands pairing 2ʹ-fluoro on one strand with 2ʹ-O-
methyl on the other weakens the modification-induced thermodynamic gain137, 138 and 
reduces the sequence related biases.  The shorter (15-nucleotide) duplex region will also 
help to promote release of the non-cleavable sense strand, alleviating a major 
thermodynamic limiting step in RISC assembly with fully modified, FM-hsiRNAs161.  
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Our findings suggest that RISC assembled with the asymmetric fully modified-siRNA is 
as effective as RISC assembled with non-modified siRNAs (Fig. 4.1d, e) and potentially 
load more efficiently.  This modification pattern can be applied to previously validated 
siRNA sequences, as the Htt and Ppib sequences used in this study were originally 
discovered using a partially modified scaffold.  By switching the sequence to the fully 
modified pattern we effectively reduced the IC50 by almost 2.5x in vitro.  We are in a 
process of evaluating the exact impact of these chemistries on RISC assembly and 
cleavage kinetics using single molecule approaches12.  
 Interestingly, the relative impact of full chemical modification on in vitro efficacy 
was significantly less pronounced than in vivo. Similar effects have been seen for 5’ 
phosphate stabilization where in vitro, 5ʹ-vinyl phosphate and 5ʹ phosphate hsiRNAs 
show similar efficacy, while in vivo phosphate stabilization clearly enhances efficacy35. It 
is likely that in the harsh biological environment of systemic delivery, chemical 
stabilization impact on efficacy is much more pronounced than in vitro or upon local 
delivery.  
 Systemically administered FM-hsiRNAs accumulate in tissues throughout the 
body, including liver, kidney, spleen, fat, and skin.  As expected, all oligonucleotides, 
including lipophilic conjugated siRNAs119, 142 preferentially accumulated in the liver and 
silencing of the target genes was observed in those tissues.  Additionally, significant 
levels of compound accumulated in the kidneys and spleen (Fig. 4.2a-d and Fig. 4.3), but 
importantly the substantial differences observed between the fully and partially modified 
siRNAs were not dependent on the nature of the conjugates themselves but rather the 
modification pattern of the siRNA.  
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 The increase in tissue accumulation (50-250 ng/mg) by full chemical modification 
was observed with different conjugates, but it was predominantly the nature of conjugate 
that had an impact on tissue distribution profile.  This is consistent with a recently 
published paper demonstrating that cholesterol modified siRNAs can silence genes in 
muscle, although dose levels necessary to achieve this effect were high (50mg/kg)60. 
DHA-conjugates accumulate to a higher extent in the kidneys, indicating that changing 
the nature of the conjugate can be used as a strategy to alter tissue distribution. 
Interestingly, with GalNac-hsiRNAs we observed similar distribution between kidneys 
and liver, specifically after SC administration. This was surprising, as GalNAc 
internalization is believed to be dependent on ASGPR (asialoglycoprotein receptor) 
overexpressed in hepatocytes. It is possible that partial kidney delivery is due to the 
presence of the single stranded phosphorothioated tail or the oversaturation of the 
ASGPR receptors at the dose levels used in this study (10 mg/kg).     
 With increased accumulation we observed an increase in productive silencing. 
However, the level of silencing was not directly proportional to the increase in siRNA 
tissue accumulation. It is well understood that for both antisense and siRNAs a significant 
fraction of internalized compounds is trapped nonproductively and different cells 
accumulate oligonucleotides to different degrees. This phenomenon is the subject of 
active investigation.  
 While the nature of the conjugate clearly effected tissue accumulation, these 
effects can be observed only in the context of a fully chemically modified scaffold. This 
demonstrates that some previously discarded or dismissed siRNA conjugates evaluated in 
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the context of partially or non-modified siRNAs might have served as viable delivery 




CHAPTER V:  DIVALENT-SIRNAS: AN ADVANCED CHEMICAL 
SCAFFOLD FOR POTENT AND SUSTAINED MODULATION OF GENE 
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Sapp E, Haraszti RA, Coles AH, Conroy F, Miller R, Roux L, Yan P, Knox EG, 
Turanov AA, King RM, Gernoux G, Mueller C, Gray-Edwards HL, Moser RP, 
Bishop NC, Jaber SM, Gounis MJ, Sena-Esteves M, Pai AA, DiFiglia M, Aronin 
N, Khvorova A.  Divalent-siRNAs: an advanced chemical scaffold for potent and 
sustained modulation of gene expression in the CNS.   Nat. Biotech, in review.  
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Matthew Hassler, Bruno Godinho, Anastasia Khvorova, and I conceived of this project. 
Matthew Hassler, Dimas Echeverria, and Loic Roux synthesized the compounds.  Bruno 
Godinho and I did all of the mouse surgeries and tissue processing with help from Emily 
Knox.  Bruno and I did the mouse mRNA processing, and Ellen Sapp did all of the HTT 
western blots.  Chantal Ferguson did the APOE western blot and we both processed the 
monkey tissue.  Robert King did the MRI.  Paul Yan and Athma Pai did the RNAseq.  All 
remaining authors contributed to large animal studies. I performed the majority of data 
analysis and statistical analysis.  Bruno Godinho, Matthew Hassler, Chantal Ferguson, 
Anastasia Khvorova and I wrote the manuscript. 
5.2 ABSTRACT 
 Small interfering RNAs (siRNAs) are a promising class of drugs for treating 
genetically-defined diseases. Therapeutic siRNAs enable simple and specific modulation 
of gene expression, but require chemical architecture that facilitates efficient in vivo 
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delivery.  Here we describe an siRNA scaffold—Divalent-siRNA (Di-siRNA)—that 
supports potent and sustained gene silencing in the central nervous system (CNS) of mice 
and non-human primates, following a single injection into cerebrospinal fluid. Di-siRNAs 
are composed of two fully chemically stabilized, phosphorothioate containing siRNAs 
connected by a linker. In mice, Di-siRNAs induced potent silencing of huntingtin 
(causative gene in Huntington’s disease) mRNA and protein throughout the brain one 
month after injection. Silencing persisted for at least six months, with the degree of gene 
silencing correlating to guide strand tissue accumulation levels.  In Cynomolgus 
macaques, a bolus injection of 25 mg Di-siRNA exhibited significant distribution and 
robust silencing throughout the brain and spinal cord without detectable toxicity and 
minimal off-targeting effects. Broad distribution and efficacy of Di-siRNA likely 
depends on the cooperative binding of phosphorothioate-driven cellular interactions and 
its large size, contributing to favorable pharmacokinetic properties. This new siRNA 
architecture opens the CNS for RNAi-based gene modulation, creating a path towards 
developing treatments for genetically-defined neurological disorders. 
5.3 INTRODUCTION 
 Oligonucleotide therapeutics are an emerging class of drugs that enable potent 
and efficient modulation of gene expression in vivo. Unlike traditional small molecules 
and biologics, oligonucleotides are informational drugs, meaning that they are designed 
using the informational sequences (RNA and DNA) present within the cell1. The 
development of a chemical architecture that enables robust, productive, and non-toxic 
delivery to a particular tissue is a prerequisite for therapeutic oligonucleotide 
intervention. 
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 Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are the 
two most clinically advanced oligonucleotide modalities for modulating mRNA 
expression.  While both platforms work effectively in liver162, 163, applications of ASOs 
have been expanded to the central nervous system (CNS)5, with one drug approved66 and 
several others undergoing clinical evaluation (Clinical Trial ID: NCT03342053). The 
broad distribution of ASOs, both systemically and within the CNS, is primarily driven by 
phosphorothioate (PS) backbone modifications26, which facilitate cellular uptake via 
mechanisms that are not fully understood164. PS modifications are also critical for 
clinically-advanced siRNA configurations37, 165. However, siRNAs are large, negatively-
charged, and double-stranded, and thus require additional modifications—formulation166 
or chemical conjugation55, 56, 58, 167—for meaningful in vivo delivery. 
 The development of the multivalent N-acetylgalactosamine (GalNAc) ligand144 
was a breakthrough for siRNAs37, 145 in liver applications. GalNAc-conjugated siRNAs 
have been shown to provide long-term hepatic retention and functional silencing—a 
single subcutaneous (SC) injection can support more than 12 months of efficacy168, 169. 
Importantly, the clinical success of GalNAc as an siRNA conjugate was possible only 
after its development as a trivalent ligand in the context of extensive chemical 
stabilization of the siRNA47. This may be due, in part, to cooperative binding—a 
biological phenomenon that enables favorable binding kinetics through multivalent 
interactions170. 
 Despite multiple attempts over the last few decades to expand siRNA 
functionality beyond the liver and into the CNS, its distribution and efficacy in this tissue 
remains limited. Even with continuous, monthly administration of siRNAs into the non-
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human primate brain, distribution and efficacy remain near the site of compound 
infusion5, 58.   
 Here we describe a new chemical scaffold—divalent, fully chemically stabilized, 
PS-containing siRNAs (Di-siRNAs)—which provide widespread distribution and 
sustained gene silencing in rodent and NHP brain after a single administration into 
cerebrospinal fluid (CSF). 
5.4 RESULTS 
5.4.1 CHEMICAL ARCHITECTURE AND SYNTHESIS OF DI-VALENT, FULLY 
CHEMICALLY MODIFIED SIRNAS.  
 Full chemical stabilization of siRNAs is essential for conjugate-mediated 
delivery37. We utilize fully chemically stabilized asymmetric siRNAs that have a 20-base 
guide strand and 15-base passenger strand. All terminal backbones and the protruding 3' 
end of the guide strand are fully phosphorothioated, resulting in PS modifications to 13 
out of 35 phosphate linkages (~40% PS content) (Fig. 5.1a). When conjugated to 
hydrophobic ligands like cholesterol58, docosahexaenoic acid (DHA)55, or DHA with a 
phosphocholine head group56, the siRNA scaffold is internalized by cells151 and retained 
near the brain injection site, where it induces specific gene silencing. Unconjugated, 


















































































P B S V D i-s iR N A H T T
6 0  µg
V D i-s iR N A H T T
4 7 5  µg
V D i-s iR N A N T C



























i Hipp – Hippocampus 
Thal – Thalamus 
Str – Striatum 
PC – Posterior cortex 

































































































P B S V D i-s iR N A A P O E
4 7 5  µg
V D i-s iR N A N T C



















Figure 5.1 A divalent siRNA chemical configuration improves distribution and 
retention and supports significant silencing after a single injection in the mouse 
brain.   
a.  Schematic of the chemical structure of Mono-siRNA.  b.  Biodistribution of Cy3-
labeled Mono-siRNA 48 hours after a single intrastriatal injection of 50 µg.  c.  
Schematic of the chemical structure of Di-siRNA. d.  Biodistribution of Cy3-labeled Di-
siRNA 48 hours after a single intrastriatal injection of 50 µg. e. Image of whole mouse 
brain injected with Di-siRNA (top – PBS, bottom – Di-siRNA).  f. Di-siRNA distributes 
throughout mouse the brain after a bilateral injection of 475 µg (237 µg/ventricle) into the 
lateral ventricles.  Tiled fluorescent images taken 48 hours post injection. (g,h) High 
resolution images of Di-siRNA distribution to various regions of the mouse brain: g. 
Striatum, h. Cortex.  i.  Scale bar – 50 µm. Di-siRNA silences huntingtin (HTT) protein 
at two different doses in multiple brain regions 1 month after bilateral ICV injection.   All 
statistics are One-Way ANOVA with Dunnett’s multiple comparisons test. All results 
compared to PBS control.  Hipp: F(3,17) = 31.92 , HTT 60µg ****P<0.0001, HTT 457µg 
****P<0.0001.  Thal: F(3,17) = 16.875 , HTT 60µg ***P=0.0003, HTT 457µg 
***P=0.0002. Str: F(3,17) = 33.38 , HTT 60µg ****P<0.0001, HTT 457µg 
****P<0.0001. PC: F(3,17) = 12.64, HTT 457µg ***P=0.0001. MC: F(3,17) = 53.58 , 
HTT 60µg ***P=0.0003, HTT 475 µg ****P<0.0001. PBS: n=6, NTC n=5, HTT 60 µg: 
n=5, HTT 475 µg: n=5.  Mean ± SD.  NTC – non-targeting control. j. Di-siRNA silences 
apolipoprotein E (APOE) protein 1 month after bilateral ICV injection.   All statistics are 
One-Way ANOVA with Dunnett’s multiple comparisons test. All results compared to 
PBS control.  Hipp: F(2,14) = 1.991, ****P<0.0001.  Thal: F(2,14) = 4.283, 
****P<0.0001. Str: F(2,15) = 4.781, ****P<0.0001. PC: F(2,14) = 6.618, ****P<0.0001. 
PBS: n=6.  NTC Mean ± SD.  NTC – non-targeting control. 
 
 For ASOs, the most advanced CNS-active scaffold utilizes a mixed backbone 
configuration with ~70-80% PS content. This modification maintains efficacy and 
distribution while reducing the risk of toxic phenotypes39, 171 that can be associated with 
high PS content. Increasing the PS content of individual siRNA duplexes to 80% can 
limit RNA-induced silencing complex (RISC) efficacy172, 173 and will increase toxicity174, 
175.  We examined whether a multi-valent approach— specifically, cooperative 
interactions between two partially PS-modified siRNAs—could enhance siRNA 
distribution and efficacy in the CNS.  
 We synthesized the divalent siRNA (Di-siRNA) compound using a functionalized 
solid support (Fig. 5.2), which allowed for parallel growth of two oligonucleotides. As a 
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result, two sense strands are covalently connected at their 3’end through a tetra-ethylene 
glycol (TEG) linker.  
Figure 5.2 Structure of Di-valent solid 
support used in the synthesis of Di-
siRNA.  
Di-trityl protected support separated by a 
tetraethylene glycol spacer, attached 
through a succinate linker to long chain 
alkyl amine (LCAA) derivatized solid 
support.   
 
 Use of the polymeric spacer was necessary to limit steric hindrance during 
synthesis and functional knockdown. Annealing of the passenger strand to two identical 
20-base guide strands formed a ~ 27 kD compound (Fig. 5.1c). Mono- and Di-siRNAs 
show comparable in vitro IC50 values (Fig. 5.3), suggesting that the linkage of two 
molecules did not compromise RISC loading.   
Figure 5.3 Mono-siRNA and Di-
siRNA show similar gene silencing 
efficiency after lipid mediated 
delivery.   
siRNAs were formulated in RNAiMax 
and delivered to HeLa cells at varying 
concentrations for 72 hours. All graphs 





 The sequences and chemical configuration of all compounds used in this study are 
shown in Table 5.1.  
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Table 5.1 Table of siRNAs sequences and chemical modification patterns. 









































































































PNAHTT HTT NM_002111.6  10150 T*A*T*A*T*C*A*G*T*A*A*A*G*A*G*A* T*T*A*A   
Detailed sequence, chemical modification patterns, and efficacy of siRNAs. Chemical 
modifications are designated as follows, “#” –phosphorothioate bond, “*” – peptide bond, 
“m” – 2’-O-methyl, “f” – 2’-Fluoro, “P” – 5’ Phosphate, “V” – 5’ Vinylphosphonate.  
“DIO” – Di-siRNA, Teg – tetraethylene glycol. 
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5.4.2 DI-SIRNA SHOWS WIDESPREAD RETENTION IN THE MOUSE BRAIN 
FOLLOWING AN INTRA-PARENCHYMAL INJECTION. 
 Intra-parenchymal injection of Cy3-labeled Di-siRNAs significantly enhanced 
distribution and retention in the mouse brain compared to Cy3-labeled monovalent 
siRNAs (Fig. 5.3d), supporting the idea that a cooperative interaction between two 
partially PS-modified siRNAs is sufficient for widespread brain retention. In all 
experiments, the dose of injected compounds (Mono- vs Di-siRNA) was defined by guide 
strand concentration. Thus, each injection contained equal amounts of fluorescent dye 
and active duplex that was independent of valency status (i.e. Di-siRNA injection 
includes half the number of molecules compared to the Mono-siRNA injection). 
 To evaluate if the observed enhancement in brain retention translates into 
functional gene silencing, we synthesized Di-siRNA targeting huntingtin (Htt) mRNA 
using a previously identified siRNA sequence targeting a sequence conserved in mouse, 
non-human primate, and human (Chapter III)58. Huntingtin is the causative gene in 
Huntington’s disease (HD) and its modulation is considered to be a viable clinical 
strategy for HD treatment5. Intra-striatal injection of Di-siRNAHTT in wild type mice 
resulted in potent down-regulation of Htt mRNA (between 50-75%) in the striatum and 





Figure 5.4 Di-siRNAs work in a dose dependent manor and do not require Cy3 
conjugation for activity.   
a.  Di-siRNA shows significant Htt mRNA silencing (% of control) at 10 µg and 50 µg 
doses 2 weeks after a single intrastriatal injection. Statistics calculated by One-Way 
ANOVA with Dunnet’s correction for multiple comparisons. All results compared to 
PBS control.  Striatum: F(3,26) = 71.86, ****P<0.0001; Cortex: F(3,26) = 21.67, 
****P<0.0001. PBS (n = 12), NTC (n=6), 10 µg (n=6) and 50 µg (n=6). b.  Cy3-labelling 
has minimal impact in Di-siRNA efficacy after a single intrastriatal injection of 50 µg. 
Statistics calculated by One-Way ANOVA with Tukey’s correction for multiple 
comparisons. All results compared to PBS control.  Striatum: F(3,20) = 49.41, 
****P<0.0001. Cortex: F(3,17) = 55.36, ****P<0.0001. n=6 for each group, except for 
Di-siRNA in cortex n=3. 
 
 Since Cy3 potentially can alter oligonucleotide retention and distribution, we 
compared Cy3-labeled and non-labeled Di-siRNAHTT efficacy following an intra-
parenchymal injection into the striatum. Both compounds show similar levels of silencing 
in cortex and striatum (~ 80% silencing, p < 0.0001, Fig. 5.4b). The non-targeting control 
(NTC) oligonucleotide of the same chemical configuration did not impact target gene 
expression (Fig. 5.4a-b). Thus, the observed silencing activity was specific to the Htt 
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 To confirm that PS content is essentially contributing to observed efficacy, we 
synthesized Di-siRNAHTT variants containing fewer and no PS backbones (Fig. 5.5a). 
Reduction of number of PS modification led to a reduction in silencing efficacy, and the 
complete removal of PS modification fully abolished activity (Fig. 5.5b) after IS injection 
in mice. Thus, the observed efficacy of Di-siRNAHTT is phosphorothioate mediated, a 
mechanism that is likely shared with traditional antisense oligonucleotides.  
 
 
Figure 5.5 Di-siRNA efficacy is phosphorothioate content dependent.  
Wild-type mice received a single intrastriatal injection of injection of 12.5 µg (237 
µg/ventricle) Di-siRNA.  a.  Schematic of varying phosphorothioate containing Di-
siRNAs.  b.  mRNA scilencing of various PS containing Di-siRNAs reduces efficacy in 
the striatum 2 weeks after an intrastriatal injection. Statistics calculated by One-Way 
ANOVA with Dunnetrs’s correction for multiple comparisons. All results compared to 



































































5.4.3 DI-SIRNA EXHIBITS BROAD DISTRIBUTION AND PRODUCTIVE 
SILENCING IN THE MOUSE BRAIN AFTER A BOLUS CSF INJECTION. 
 To evaluate CSF-driven brain distribution of Cy3-Di-siRNA, we injected 475 µg 
intracerebroventricularly (ICV) into the lateral ventricles of mice.  Forty-eight hours after 
the injection, the mouse brain was uniformly pink to the naked eye (Fig. 5.1e), indicating 
broad distribution. Microscopy confirmed the initial observation (Fig. 5.1f). Di-siRNAs 
distributed to all regions of the brain—from the prefrontal cortex to the cerebellum. High 
magnification images show accumulation in the vast majority of neurons (Fig. 5.1g,h). 
Intracellular distribution followed a perinuclear localization pattern that is characteristic 
of oligonucleotides151.  
 Broad distribution of Di-siRNAHTT supported productive silencing (measured two 
weeks post injection) in all brain regions, including prefrontal, medial and posterior 
cortices, striatum, hippocampus, thalamus, hypothalamus, cerebellum, brain stem and 
cervical, thoracic, and lumbar sections of the spinal cord (Fig. 5.6). To quantitatively 
evaluate guide strand accumulation, we used a PNA hybridization assay, which provides 
quantitative accumulation data and does not depend on the presence of a fluorescent 
label157. Analysis (Fig. 5.6a) confirmed the visual and microscopy-based observations of 
broad Di-siRNA distribution, and correlated with Htt mRNA (Fig. 5.6b) and HTT protein 
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Figure 5.6 Di-siRNAs silence huntingtin throughout the brain and spinal cord of 
mice two weeks after a single ICV injection.  
Wild-type mice received a single bilateral ICV injection of 475 µg (237 µg/ventricle) Di-
siRNA.  Data was collected two weeks post injection.  a. siRNA guide strand 
accumulation (µg/g).  b.  Huntingtin (Htt) mRNA silencing (% of control). All statistics 
are two-tailed unpaired t-tests. MC: t=3.917, df=10, **P=0.0095. PC: t=5.677, df=10, 
***P=0.0002. Str: t=6.663, df=10, ****P<0.0001. Hipp: t=5.948, df=10, ***P=0.001. 
Thal: t=5.312, df=10, ***P=0.0003. n=6/group. c.  Huntingtin (HTT) protein silencing 
(% of control). PFC: t=6.439, df=10, ****P<0.0001. MC: t=11.78, df=10, 
****P<0.0001. PC: t=6.972, df=10, ****P<0.0001. Str: t=8.726, df=10, ****P<0.0001. 
HIPP: t=16.9, df=10, ****P<0.0001. Thal: t=9.356, df=10, ****P<0.0001. HT: t=5.9, 
df=10, ***P=0.0002. Cer: t=2.706, df=10, *P=0.0221. BS: t= 3.335, df=10, **P=0.0076. 
Cerv: t=8.032, df=10, ****P<0.0001. Thor: t=5.918, df=10, ***P=0.0001. Lumb: 
t=6.275, df=10, ****P<0.0001. n=6/group. d.  Western blots from representative brain 
regions (used for quantification in (c)).  n=6/group. 
 
 Next, we compared the efficacy of two different Di-siRNAHTT doses—60 and 475 




Figure 5.7 Di-siRNA shows widespread guide strand accumulation and mRNA 
silencing one month after a single ICV injection.  
Wild-type mice received a single bilateral ICV injection of 475 µg (237 µg/ventricle), 60 
µg (30 µg per ventricle), or NTC Di-siRNA.  a.  Schematic of experiment.  b.  Guide 
strand accumulation (µg/g).  c.  Huntingtin (Htt) mRNA silencing (% of control).  n=5-6 
mice/group. Mean ± SD.  NTC – non-targeting control.  All statistics calculated by One-
Way ANOVA with Dunnet’s correction for multiple comparisons. All results compared 
to PBS control.  Hipp: F(3,17) = 15.45 , HTT 60µg ***P=0.0005, HTT 457µg 
***P=0.0002.  Thal: F(3,17) = 74.57 , HTT 60µg ****P<0.0001, HTT 457µg 
***P<0.0001. Str: F(3,17) = 23.58 , HTT 60µg ****P<0.0001, HTT 457µg 
****P<0.0001. PC: F(3,17) = 41.86 , HTT 60µg ****P<0.0001, HTT 457µg 
****P<0.0001. MC: F(3,17) = 15.83 , HTT 60µg **p=0.0039 , HTT 457µg 
****P<0.0001. PBS: n=6, NTC n=5, HTT 60 µg: n=5, HTT 475 µg: n=5.  Mean ± SD.  
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 The higher dose resulted in approximately a two-fold maximum increase in guide 
strand tissue retention and a wider distribution (0.1 to 4 µg/g at 60 µg; 2-8 µg/g at 475 µg 
dose, Fig. 5.7b). The higher dose silenced HTT protein below level of detection (p < 
0.0001) throughout the brain (Fig. 5.1i; Fig. 5.8).  
 
Figure 5.8 Di-siRNA silences huntingtin protein one month after a single ICV 
injection.  
Wild-type mice received a single bilateral ICV injection of Di-siRNA.  Original western 






























































The lower dose was highly efficacious in the hippocampus, thalamus, and striatum, 
showing 80-99% silencing (p < 0.0001, p < 0.001, p < 0.0001, respectively). In the 
cortical areas located away from the site of injection, efficacy was reduced. This 
observation is consistent with the relatively lower guide strand accumulation measured in 
these regions. NTC and PBS groups showed no difference in HTT expression level. NTC 
was used as a control for all subsequent experiments (Fig. 5.1i).  
5.4.4 DI-SIRNA CHEMICAL SCAFFOLD IS APPLICABLE FOR SILENCING OF 
MULTIPLE GENES IN THE CNS. 
 The base sequence of the siRNA determines its target, but the chemical 
architecture of the oligonucleotide determines pharmacokinetics and tissue delivery. 
Therefore, we decided to evaluate the efficacy of the Di-siRNA scaffold containing 
sequences targeting other mRNAs in the CNS. Indeed, Figure 5.9 shows potent silencing 
(65-85%, p < 0.0001) of another target, Cyclophilin B (Ppib) upon intrastriatal injection. 
The NTC control had no activity, demonstrating that silencing was specific to the PPIB-
targeting sequence. 
Figure 5.9 The Di-siRNA scaffold can be 
applied to alternative sequences after a 
single intrastriatal injection of 50 µg.  
Statistics calculated by One-Way ANOVA 
with Dunnet’s correction for multiple 
comparisons. All results compared to PBS 
control.  Striatum: F(2,15) = 66.24, 
****P<0.0001, except NTC **P=0.0017; 
Cortex: F(2,15) = 27.08, ****P<0.0001, 
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 While the direct cause of many neurological disorders remains unclear, some have 
clear genetic components, in which certain genes or mutations increase risk for 
neurodegeneration. Apolipoprotein E (Apo E) is implicated in several neurodegenerative 
diseases including Alzheimer’s disease and Amyotrophic Lateral Sclerosis176-178.  We 
have previously identified functional siRNA sequences targeting Apo E (Ferguson et al, 
manuscript in preparation). To determine if Di-siRNA scaffold could be applied to 
another CNS-relevant target, we synthesized Di-siRNAApoE (see Table 5.1 for sequence 
information) and injected mice ICV with PBS and NTC as controls. Figure 5.1j (Fig. 5.10 
for raw westerns) shows that, similar to HTT, a single CSF injection of Apo E targeting 















Figure 5.10 Di-siRNA silences apolipoprotein E protein one month after a single 
ICV injection.  
Wild-type mice received a single bilateral ICV injection of Di-siRNA.  Original western 
blot graphically represented in Figure 5.1j. n=6. 
 
Again, NTC had no impact on ApoE expression, indicating that observed silencing is 
sequence specific and not caused by the Di-siRNA chemical scaffold. In addition, the 










Di-siRNA chemical scaffold can be reprogrammed to modulate gene expression in vivo 
for a number of other targets implicated in the pathogenesis of neurological conditions.   
 
Figure 5.11 Di-siRNA silences apolipoprotein E (ApoE) mRNA 1 month after a 
single bilateral ICV injection of 475 µg (237 µg/ventricle).    
All statistics are One-Way ANOVA with Dunnett’s multiple comparisons test. All results 
compared to PBS control.  Hipp: F(2,15) = 6.025, ****P<0.0001.  Thal: F(2,15) = 5.084, 
****P<0.0001. Str: F(2,15) = 1.382, ***P=0.0002. PC: F(2,15) = 2.251, ****P<0.0001. 
PBS: n=6.  NTC Mean ± SD.  NTC – non-targeting control. 
 
5.4.5 THE DURATION OF EFFECT OF HIGH-DOSE DI-SIRNA EXCEEDS SIX 
MONTHS FOLLOWING A BOLUS CSF INJECTION. 
 To evaluate the duration of Di-siRNA efficacy, we delivered a high dose (475 µg) 
of Di-sRNAHTT or Di-siRNANTC to mice via a single ICV injection in wild type mice. We 
then measured guide strand accumulation levels, Htt mRNA, and HTT protein in key 
brain regions (cortex, striatum, thalamus, hippocampus) at one, four, and six months post 
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Figure 5.12 Di-siRNA efficacy is sustained for up to 6 months after a single bilateral 
ICV injection in the mouse brain.   
Mice were injected with 475 µg siRNA (bilaterally) (237 µg/ventricle) and data was 
collected at 1, 4 and 6 months post injection.  a.  Schematic of the duration of effect study 
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mRNA silencing (% of control) in five brain regions.  All statistics are two-tailed 
unpaired t-tests. All results compared to NTC control.  1 month. Hipp: t=9.56, df=8, 
****p<0.0001. Thal: t=10.59, df=8, ****p<0.0001. Str: t=10.63, df=8, ****p<0.0001. 
PC: t=11.45, df=8, ****p<0.0001. MC: t=8.082, df=8, ****p<0.0001. HTT: n=5, NTC: 
n=5. 4 month. Hipp: t=14.26, df=9, ****p<0.0001. Thal: t=8.577, df=9, ****p<0.0001. 
Str: t=6.606, df=9, ****p<0.0001. PC: t=2.561, df=9, *p=0.0306. HTT: n=6, NTC: n=5. 
6 month. Hipp: t=6.998, df=7, ***p=0.0002. Thal: t=9.865, df=7, ****p<0.0001. Str: 
t=4.264, df=7, **p=0.0037. HTT: n=5, NTC: n=4. d.  Huntingtin (HTT) protein silencing 
(% of control) in five brain regions. 1 month. Hipp: t=10.58, df=8, ****p<0.0001. Thal: 
t=14.092, df=8, **p=0.0035. Str: t=12.05, df=8, ****p<0.0001. PC: t=9.834, df=8, 
****p<0.0001. MC: t=10.85, df=8, ****p<0.0001. HTT: n=5, NTC: n=5. 4 month. Hipp: 
t=6.117, df=9, ***p=0.0002. Thal: t=5.661, df=9, ***p=0.0003. Str: t=6.261, df=9, 
***p=0.0001. PC: t=4.651, df=9, **p=0.0012, MC: t=3.46, df=9, **p=0.0072. HTT: 
n=6, NTC: n=5. 6 month. Hipp: t=19.01, df=7, ****p<0.0001. Thal: t=93.536, df=7, 
**p=0.0095. Str: t=3.479, df=7, *p=0.0103. HTT: n=5, NTC: n=4.  e.  Di-siRNA Htt 
mRNA silencing shows a strong correlation with siRNA guide strand accumulation.  f.  
Di-siRNA HTT protein silencing shows a strong correlation with siRNA guide strand 
accumulation (IC50 ~ 0.5 µg/g).  g.  siRNA guide strand retention shows strong, two 
phase tissue clearance kinetics.  The majority of the compound is cleared within the first 
month. Clearance slows between 4 and 6 months. Mean ± SD.  NTC – non-targeting 
control.   
 
 Guide strand accumulation in different brain regions ranged between 2-7 µg/g at 
one month, 0.8-2.5 µg/g at four months, and 0.2- 1.8 µg/g at six months, suggesting 
relatively slow clearance (Fig. 5.12b).  We also noticed that the extent of HTT protein 
modulation was always greater than Htt mRNA (> 99% vs ~70%) (Fig. 5.12c,d). This 
discrepancy is due to a fraction of Htt mRNA being localized to the nucleus, and thus 
more resistant to RNAi-based modulation179.  More than 80% silencing of HTT protein 
was maintained at four months in all brain regions analyzed (Fig. 5.12d, Fig. 5.8, and 
5.13 for raw westerns).  At six months, the degree of silencing differed between brain 
regions: > 90% in hippocampus, ~50% in thalamus and striatum, and high variability in 





Figure 5.13 Di-siRNA shows sustained huntingtin protein silencing after a single 
ICV injection.  
Wild-type mice received a single bilateral ICV injection of 475 µg (237 µg/ventricle) Di-
siRNA.   a.  Huntingtin (HTT) protein silencing at 4 months (% of control). Naïve n=3,  
HTT n=6, NTC n=5, b.  HTT protein silencing at 6 months (% of control). HTT n=5, 




















































































































5.4.6 DI-SIRNA GUIDE STRAND RETENTION IN TISSUE IS CORRELATED TO 
THE DEGREE OF MRNA AND PROTEIN SILENCING. 
 Using data from all time points in the duration of effect study, we observed strong 
correlations between the level of residual guide strand accumulation and the degree of Htt 
mRNA (Fig. 5.12e) and HTT protein (Fig. 5.12f) silencing.  We estimate the protein 
silencing IC50 value to be ~0.5 µg/g and the IC90 value to be ~2 µg/g.  
Figure 5.12g shows guide strand clearance over time for individual brain regions. Initial 
(one month) hippocampal accumulation of ~7 µg/g resulted in ~2 µg/g present at 6 
months. Both levels of guide strand accumulation are sufficient to silence HTT protein 
below the level of detection. In the cortical regions, initial accumulation at one month 
was 3-4 µg/g and fell below the 0.5 µg/g threshold by six months, resulting in loss of 
silencing in some animals. This suggests that siRNA tissue accumulation at early time 
points can be used to estimate duration of effect. 
5.4.7 DI-SIRNA INJECTION AT DIFFERENT DOSES IS SAFE AND WELL-
TOLERATED IN MICE 
 To evaluate overall safety and tolerability of Di-siRNA at 475 µg over 6 months, 
we measured DARPP32 protein expression, innate immune response activation markers, 
and blood biochemistry. Loss of DARPP32, an established marker for medium spiny 
neurons in the striatum130, indicates neuronal death. Injection of Di-siRNA had no impact 
on DARPP32 expression, indicating maintenance of neuronal viability (Fig. 5.8, Fig. 
5.13). To evaluate impact of Di-siRNA injection on microglia activation and gliosis we 
measured two well-established markers of immune stimulation, IBA-1 and GFAP. IBA-1 
 131 
is located within a major histocompatibility complex and increases as a result of 
microglial activation180.  GFAP is an intermediate filament protein and increases as a 
result of astrocyte proliferation181.  We observed only minor changes in Iba-1 expression 
(< 1.5 fold from control) at both dose levels and at all three time points. At the higher 
dose, we observed transient activation of Gfap at one month, which was absent by four 
months (Fig. 5,14, 5.15).  
 132 
 
Figure 5.14 Di-siRNA does not cause Iba-1 upregulation after a single bilateral ICV 
injection.  
Wild-type mice received a single bilateral ICV injection of 475 µg (237 µg/ventricle) Di-
siRNA.  a.  Iba-1 mRNA expression 1 month post injection.  Statistics calculated by One-
Way ANOVA with Dunnet’s correction for multiple comparisons. All results compared 
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n=5, HTT 475µg: n=5. b.  Iba-1 mRNA expression 4 months (HTT: n=6, NTC: n=5) and. 
c. 6 months (HTT: n=5, NTC: n=4) after injection. Statistics for 4 and 6 months 






Figure 5.15 Di-siRNA causes transient Gfap mRNA up-regulation 1 month after a 
single ICV injection.  
Wild-type mice received a single bilateral ICV injection of 475 µg (237 µg/ventricle) Di-
siRNA. a.  Gfap mRNA expression 1 month after injection.  Statistics calculated by One-
Way ANOVA with Dunnet’s correction for multiple comparisons. All results compared 
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HTT475µg *p=0.0154, PC: F(3,17) = 4.287, HTT475µg *p=0.0259. (PBS: n=6, NTC: 
n=5, HTT 60µg: n=5, HTT 475µg: n=5). b.  Gfap mRNA expression 4 months (HTT: 
n=6, NTC: n=5) and c. 6 month after injection (HTT: n=5, NTC: n=4).  Statistics for 4 
and 6 months calculated by two-tailed unpaired t-test, compared to NTC control Mean ± 
SD. 
 
Additionally, a comprehensive blood chemistry panel showed no detectable changes at 
any time point, suggesting a systemic tolerability of Di-siRNA administration to the CNS 
(Fig. 5.16). Overall, Di-siRNA injection in the CSF appears to be well tolerated in mice 







Figure 5.16 Di-siRNA does not show any significant blood toxicity after a single 
bilateral ICV injection in mouse.   
Wild-type mice received a single bilateral ICV injection of 475 µg (237 µg/ventricle) Di-
siRNA. A comprehensive diagnostic blood chemistry profile of 14 biochemical markers 
was analyzed 30 days post-injection using a VetScan 2. 1 Month, PBS n=6, 60 µg n=5, 
475 µg n=5, NTC n=5. 4 month, Naïve n=3,  HTT n=6, NTC n=5. 6 months, HTT n=5, 
NTC n=4. Mean ± SD. 
 
5.4.8 DI-SIRNA SILENCES BOTH WILD TYPE AND MUTANT HTT PROTEIN 
WITH SIMILAR EFFICIENCY. 
 Di-siRNAHTT has perfect homology to both human and mouse Htt genes58. To 
evaluate the ability of Di-siRNAHTT to silence mutant HTT, we measured efficacy in the 
BAC∆N17 mouse model of HD. This HD model contains both wild type mouse HTT and 
mutant human HTT (97 CAG repeats) with 17 N-terminal amino acids removed182. At 













ALB 3.3±0.77 3.4±0.19 3.9±0.13 3.5±0.27 3.5±0.23 3.6±0.16 3.6±0.17 3.8±0.17 3.6±0.18 
ALP 35±12.02 24.2±15.55 24.8±12.72 26.6±15.24 57.7±5.51 28.4±24.88 46.5±7.26 28.3±12.95 36.2±20.55 
ALT 99±54.07 85.6±54.27 92.8±43.86 61.2±31.96 54.3±11.02 75.4±28.61 72±23.54 61.8±19.41 120.2±143.74 
AMY 744.6±95.53 746.4±80.6 837±45.78 751.8±78.3 871.7±22.12 846±149.35 888.5±52.39 926.3±56.02 950.4±40.53 
TBIL 0.2±0 0.2±0.06 0.2±0 0.2±0 0.2±0 0.2±0 0.2±0 0.2±0.06 0.2±0.05 
BUN 24.6±3.21 25.4±2.7 19.8±2.05 22.4±7.8 23.7±4.04 19.4±4.56 20.7±2.8 24.5±3 23.6±2.88 
CA 9.2±1.17 8.4±0.33 10.2±0.41 8.5±0.52 9.8±0.31 9.8±0.47 9.6±0.29 10.1±0.29 10±0.58 
PHOS 8.8±1.65 6.3±0.78 7.8±0.87 6.8±1.88 7.1±0.5 7.9±0.5 8±0.69 8.1±0.61 8±1.23 
CRE 0.3±0.13 0.2±0.04 0.2±0.05 0.2±0.09 0.2±0 0.3±0.1 0.2±0 0.2±0 0.2±0 
GLU 273.2±72.42 200±35.48 223.2±29.07 197.4±32.85 225±10.44 202.4±27.18 186±22.34 201±18.11 210.8±29.51 
NA+ 4.5±0.99 4.4±0.21 5.2±0.25 4.5±0.37 5±0.31 5±0.23 5±0.23 5.3±0.18 5.1±0.31 
GLOB 1.1±0.23 1±0.11 1.2±0.13 1±0.18 1.5±0.1 1.4±0.18 1.5±0.12 1.5±0.08 1.5±0.19 
1 month 4 months 6 months 
Supp. Fig.15 
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seven weeks of age, animals were injected with 475 µg Di-siRNA targeting HTT or 
NTC, or injected with PBS. Levels of HTT protein expression were evaluated at five 
months of age (~three months post injection). We used a combination of two antibodies 
(Ab1 and 1C2) to evaluate specific knockdown of wild type mouse and mutant human 
HTT protein. The Ab1 antibody only detects wild type HTT protein, as its epitope is 
located in exon 187. The 1C2 antibody detects polyQ expansions183, and thus is specific to 
the mutant protein.  A single injection of Di-siRNAHTT showed potent down-regulation of 
both mutant and wild type HTT protein (Fig. 5.17), with a silencing efficiency similar to 
observations in wild type mice at four months post injection (Fig. 5.12d). This finding 






Figure 5.17 Di-siRNA silences 
mutant huntingtin protein in the 
BACHD-ΔN17 mouse model of 
Huntington’s disease.   
a.  Quantification of wild type 
huntingtin protein silencing in 
BACΔN17 mice. All statistics are 
One-Way ANOVA with Dunnett’s 
multiple comparisons test.  Hipp: 
F(2,11) = 11.25, HTT **P=0.0017. 
Str: F(2,11) = 10.67, HTT 
**P=0.0017. PC: F(2,11) = 12.21, 
HTT **P=0.0024. MC: F(2,11) = 
4.363, HTT *P=0.0361. PBS n=4, 
NTC n=5, HTT n=5. b. 
Quantification of mutant huntingtin 
protein silencing in BACdeltaN17 
mice. All statistics are One-Way 
ANOVA with Dunnett’s multiple 
comparisons test.  All results 
compared to PBS control.  Hipp: 
F(2,11) = 34.66, NTC ***P=0.0005, HTT ****P<0.0001. Str: F(2,11) = 8.112, HTT 
**P=0.0037. PC: F(2,11) = 8.6, HTT *P=0.0136. MC: F(2,11) = 9.885, HTT *P=0.014. 
PBS n=4, NTC n=5, HTT n=5. Mean ± SD.  NTC – non-targeting control. 
 
5.4.9 DI-SIRNA SHOWS WIDESPREAD DISTRIBUTION AND SUSTAINED 
SILENCING IN NON-HUMAN PRIMATE BRAIN. 
 Rodent systemic distribution is generally predictive of large mammal distribution. 
However, this is not necessarily the case for the CNS.  Complexity of brain structure, 
CSF volume, rate of clearance, and the overall distance of brain regions from the CSF 
may contribute to oligonucleotide distribution and retention. ASO delivery to deep brain 




































































































Hipp – Hippocampus 
Thal – Thalamus 
Str – Striatum 
PC – Posterior cortex 




















safety of a single CSF injection of Di-siRNA in the Cynomolgus macaque, whose siRNA 
targeting region in the Htt sequence is homologous to both mouse and human. 
 We delivered Di-siRNAHTT via ICV injection, using MRI and CT to confirm 
needle placement in the lateral ventricle. A 25 mg dose in 750 µl of PBS was infused 
over 10 minutes (see Methods). Animals woke up within 15 minutes after anesthesia was 
discontinued, with no observable adverse events. Figure 5.18a shows a schematic of the 
study timeline. Forty-eight hours after unilateral injection, we observed uniform 
distribution throughout the non-human primate (NHP) brain, similar to mice. The 
injected oligonucleotide was fluorescently labeled, allowing for visual and microscopy-
based distribution evaluation. The brain appeared visibly pink with no obvious difference 
in the degree of oligonucleotide distribution in injected vs. non-injected sides (Fig. 
5.18b). Upon sectioning of the brain, we observed uniform cortical distribution with 
evident delivery to deep brain structures, including the striatum (caudate and putamen) 
and hippocampus (Fig. 5.18c). Fluorescent microscopy confirmed the visual distribution, 
with significant delivery to the cortex, caudate, and hippocampus.   
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Figure 5.18 Di-siRNA shows widespread distribution, retention, and efficacy in the 
non-human primate brain.   
Cynomolgus macaques received a unilateral ICV injection of Di-siRNAs (25 mg). 
Samples were collected at 48 hours for biodistribution and at 30 days for gene silencing 
and toxicity assessments. a.  Schematic of NHP study.  b.  Image of whole NHP brain 










































* * * *
* * * *
* * *





C o rte x H ip p o c a m p u s C a u d a te P u ta m e n










































C tx H ip p C a u d P u t W M C e r Tha l
 141 
siRNA in various regions of the NHP brain (bottom).  c.  Immunofluorescence of the   
NHP cortex and hippocampus.  All images acquired 48 hours after a single unilateral ICV 
injection of 25 mg Di-siRNA.  Scale bar – 50 µm.  d.  Quantification of siRNA guide 
strand (n=4 treated animals, µg/g) in seven brain regions, IL – ipsilateral, CL – 
contralateral.  e.  Huntingtin (HTT) protein silencing (% of control) ipsilateral and 
contralateral sides of four brain regions. Statistics calculated by One-Way ANOVA with 
Dunnet’s correction for multiple comparisons. All results compared to naïve control.  
Cortex: F(2,9) = 35.86, ****P<0.0001. Hippocampus: F(2,9) = 35.15, ipsilateral ***P = 
0.0001, contralateral ****P<0.0001. Caudate: F(2,9) = 11.51, ipsilateral **P = 0.0028, 
contralateral **P = 0.0087. Putamen: F(2,9) = 9.08, ipsilateral *P = 0.0385, contralateral 
**P = 0.0043. n=4/group.  1 month (n=4 Di-siRNA treated animals, n=4 naive animals).  
All graphs are mean ± SD.  
 
 
 To evaluate any potential preference for specific cell-types, we performed 
immunofluorescence on sections of Di-siRNA treated NHP brains using neuron specific 
(NeuN)89, 90 and glial cell specific (GFAP)185 antibodies. We observed efficient 
distribution of Di-siRNA to both neurons and glial cells in the hippocampus and cortex, 
and observed co-localization of Di-siRNA (red) with both neurons (green) and glial cells 
(purple) (Fig. 5.18d).  
 Upon evaluation of guide strand accumulation in different NHP brain regions at 
one month post injection (Fig. 5.18e), we observed 1-9 µg/g guide strand accumulation, 
with the highest accumulation detected in the cortex (9 µg/g), hippocampus (6 µg/g), and 
thalamus (6 µg/g), and the lowest accumulation in the caudate (2 µg/g) and putamen (1 
µg/g). Figure 5.19 shows cortical accumulation across seven slices spanning the entire 
brain (both ipsilateral and contralateral biopsies), confirming microscopy observations. In 
all NHP brain regions, guide strand accumulation level was well above the established 
IC50 value of ~0.5 µg/g (Fig. 5.12f).  
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Figure 5.19 Di-siRNA support uniform cortex delivery.   
Cynomolgus macaques received an ICV injection of Di-siRNAs (25 mg). siRNA 
accumulation was measured after 48 hours in the cortex from the anterior to the posterior 
of the brain.  Each bar represents one animal.  IL – ipsilateral.  CL – contralateral. 
 
 One month following injection, we assessed HTT mRNA and protein  
expression in the NHP brain, to evaluate Di-siRNAHTT efficacy. We observed potent 
modulation of mRNA expression in all brain regions, independent of the normalization 
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Figure 5.20 Di-siRNA significantly silences mRNA throughout the non-human 
primate CNS 1 month after a unilateral injection into the CSF.   
Four animals treated with 25mg of Di-siRNA are compared with 4 naïve animals.  a.  
Huntingtin (HTT) mRNA silencing in various regions of the NHP brain.  Normalized to 
housekeeping gene, HPRT.  All statistics are One-Way ANOVA with Dunnett’s multiple 
comparisons test.  Cortex: F(2,9) = 17.3, ipsilateral **P=0.0014, contralateral 
**P=0.0011. Hippocampus: F(2,9) = 54.66, ****P<0.0001. Caudate: F(2,9) = 9.809, 
ipsilateral **P=0.005, contralateral *P=0.0119. n=4/group. b.  HTT mRNA silencing in 
various regions of the NHP brain (injected side).  Normalized to housekeeping gene, 
PPIB. All statistics are two-tailed unpaired t-tests. Cortex, t= 5.085, df=6, **P=0.0023. 
Hippocampus, t= 6.263, df=6, ***P=0.0008. Caudate, t=5.71, df=6, **P=0.0012. 
Putamen, t=2.581, df=6, *P=0.0417. n=4/group.  Mean ± SD.  NTC – non-targeting 
control. 
 
 There was no major difference in silencing between the ipsilateral and 
contralateral sides of the brain, which is consistent with uniform distribution. For protein 
silencing (Fig. 5.18f, Fig. 5.21 for raw westerns), we observed >90% silencing in cortex 
(p < 0.001), >80% silencing in hippocampus (p < 0.01), between 50 and 85% silencing in 
the caudate (p < 0.001), and ~40-70% silencing in putamen (p < 0.05). These data 
indicate that a single injection of Di-siRNA enables modulation of target gene expression 
throughout the NHP brain. 
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Figure 5.21 Di-siRNA shows significant silencing of huntingtin protein one month 
after a single injection into the lateral ventricle of the non-human primate.  
Cynomolgus macaques received an ICV injection of Di-siRNAs (25 mg). mRNA 
silencing was measured at 1 month (n=4).  Densitometry analysis of original western 
blots graphically represented in Figure 5.18d. 
 
5.4.10 DI-SIRNA SHOWS WIDESPREAD DISTRIBUTION AND SUSTAINED 
SILENCING IN NON-HUMAN PRIMATE SPINAL CORD. 
 The cortex and striatum are the two brain regions primarily affected in HD. 
However, treatment of other neurodegenerative disorders (e.g. ALS) may require gene 
modulation in the spinal cord. In ALS, a rapidly progressive and devastating 
neurodegenerative disease, dysfunction and degeneration of motor neurons is a primary 
driver of disease pathogenesis186. Consequently, we evaluated Di-siRNA distribution and 






Figure 5.22 Di-siRNA shows widespread distribution, retention, and efficacy in the 
non-human primate spinal cord.   
a.  Image of the whole NHP spinal cord.  b.  Tiled fluorescent images of cross sections of 
the spinal cord at each segment  c.  Immunofluorescence of the NHP spinal cord 
(cervical, thoracic and lumbar regions).  All images acquired 48 hours after a single 
unilateral ICV injection of 25 mg Di-siRNA.  Scale bar – 50 µm.  d.  Quantification of 
siRNA guide strand (µg/g) in three spinal cord regions, both white and grey matter. e.  
HTT mRNA silencing in various regions of the NHP spinal cord. Statistics calculated by 
two-tailed unpaired t-test: Cervical GM: t=4.686, df=6, **P=0.0034. Thoracic WM: t= 
5.278, df=6, **P=0.0019. Thoracic GM: t=5.757, df=6, **P=0.0012. Lumbar WM: 
t=4.69, df=6, **P=0.0034. Lumbar GM: t=9.853, df=6, ****P<0.0001. 1 month (n=4 Di-
siRNA treated animals, n=4 naive animals).  All graphs are mean ± SD. 
 
 We observed robust distribution to all spinal cord regions, with guide strand 
accumulation ranging from 4-7 µg/g (Fig. 5.22d). Slightly higher accumulation was seen 












































































































WM – White matter 
GM – Grey matter 
d e 
Cervical 
WM GM WM GM WM GM 
Thoracic Lumbar 
Cervical Thoracic Lumbar 







Cerv Thor Lumb 
 147 
delivery to all cell types, including neurons. Figure 5.22c shows immunofluorescence of 
the ventral horn of the lumbar spinal cord segment, indicating robust delivery to lower 
motor neurons, easily identified morphologically by their large soma187.  
 Again, the level of guide strand accumulation was sufficient for significant and 
potent HTT mRNA silencing in all regions tested (p < 0.01), with the exception of a 
single outlier in cervical white matter (Fig. 5.22e). These findings suggest that a single 
Di-siRNA injection supports potent and widespread gene modulation in the NHP brain 
and spinal cord, thus opening all regions of the CNS to RNAi based therapeutics. 
5.4.11 A SINGLE INJECTION OF 25 MG OF DI-SIRNA IN NHP BRAIN DOES 
NOT INDUCE ANY DETECTABLE ADVERSE EVENTS. 
 We next looked at overall safety and tolerability of a single injection of 25 mg Di-
siRNA in NHP. MRI is commonly used to look at brain inflammation and edema. MRIs 
were collected pre-operatively and one month following injection. There was no 
detectable difference between these scans, indicating that Di-siRNA injection did not 
cause a major inflammatory response (Fig. 5.23a). Consistent with this finding, we 
observed no significant up-regulation of IBA-1 and GFAP at one month post injection 
(Fig. 5.23b,c).   
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Figure 5.23 No detectable brain toxicity 1 month after a single ICV injection of Di-
siRNA in pilot non-human primate studies.   
Animals were all dosed with 25 mg Di-siRNA unilaterally into the lateral ventricle.  a.  
Pre-operative and post-operative (30 days) MRI scans.  b.  There is no significant 
increase in GFAP mRNA expression 30 days after a single ICV injection.. c. There is no 
significant increase in IBA-1 mRNA expression 30 days after a single ICV injection. 
Statistics calculated by One-Way ANOVA with Dunnet’s correction for multiple 
comparisons. All results compared to naïve control. F(2,9) = 4.578 iplsilateral 
*P<0.0359.  n=4/group. 
 

















































































































































































































































To determine whether there was any effect on neuronal viability, we examined two 
additional markers by western blot, NeuN188 and BF-1189.  We observed no differences 
between naïve and treated animals (Fig. 5.24).   
Figure 5.24 Di-siRNA does not 
cause cell loss in the cortex 1 
month after a single ICV 
injection.   
Cynomolgus macaques received 
an ICV injection of Di-siRNAs 
(25 mg). Two neuronal markers 
were measured by western blot: 




 In addition, we found no measurable changes in blood chemistry or cell counts 
(Fig. 5.25), which is particularly important because thrombocytopenia (low platelet 
count) has been reported as a PS-mediated rare adverse event39, 171.   
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Figure 5.25 Di siRNA shows no changes in blood chemistry or cell counts.   
Data collected before pre-op, 15 days and 30 days post ICV Di-siRNA injection.  a.  




assay: 4-Apr 19-Apr 3-May 3-Apr 19-Apr 3-May 9-Apr 23-Apr 10-May 30-Apr 15-May 30-May 
1312007 1312019 1401045 1401401 
Units Pre-op 15	days 30	days Pre-op 15	days 30	days Pre-op 15	days 30	days Pre-op 15	days 30	days 
ALB g/dL 4.5 4.7 4.5 4 4.4 4.2 3.6 4.2 3.6 4.3 4.5 4.4 
ALP U/L 381 354 406 267 288 312 231 288 260 419 420 417 
ALT U/L 36 35 39 30 28 32 29 36 26 40 45 35 
AMY U/L 318 408 359 269 295 275 238 196 193 240 222 223 
TBIL mg/dL 0.4 0.4 0.4 0.4 0.4 0.5 0.3 0.4 0.3 0.4 0.3 0.3 
BUN mg/dL 20 18 16 17 11 15 13 10 7 17 17 10 
Ca2+ mg/dL 9.3 9.8 9.5 9.2 10 9.4 8.6 9 8.4 9.7 9.8 9.8 
PHOS mg/dL 7.2 5.6 5.3 6.7 5.9 7.1 7.3 4.5 6.6 6.7 5.5 4.7 
Cre mg/dL 0.9 0.7 0.8 0.8 0.3 0.9 0.9 0.7 0.7 1 0.9 0.9 
GLU mg/dL 65 59 61 112 88 81 81 68 111 95 66 86 
Na+ nmol/L 140 140 141 137 141 140 142 140 140 147 140 138 
K+ nmol/L 4.6 3.9 3.7 4.4 3.8 3.8 4.6 4 4 4.2 4.1 3.8 
TP g/dL 6.4 6.9 6.4 6.2 7.1 6.3 5.9 7 5.7 6.7 7.5 6.9 
GLOB g/dL 1.9 2.3 1.9 2.2 2.7 2.1 2.4 2.8 2.1 2.4 3 2.5 
QC 	 Ok OK OK OK OK OK OK OK OK OK OK OK 
HEM 	 0 0 0 0 2+ 0 0 0 0 0 2+ 0 
LIP 	 0 0 0 0 0 0 0 0 0 0 0 0 
ICT 	 0 0 0 0 0 0 0 0 0 0 0 0 
		
Dates	of	the	
assay:	 8-Jan	 19-Apr	 3-May	 8-Jan	 19-Apr	 3-May	 30-Nov	 23-Apr	 10-May	 30-Apr	 15-May	 30-May	
		 		 1312007	 1312019	 1401045	 1401401	
		 Units	 Pre-op	 15	days	 30	days	 Pre-op	 15	days	 30	days	 Pre-op	 15	days	 30	days*	 Pre-op	 15	days	 30	days	
WBC	 10^9/L	 13.27	 15.5	 14.09	 9.64	 15.96	 9.07	 5.7	 2.46	 	 6.58	 15.35	 14.63	
LYM	 10^9/L	 0.26	 0.25	 0.16	 0.01	 1.27	 0.01	 0.2	 0.04	 	 0.1	 5.73	 0.25	
MON	 10^9/L	 6.48	 7.77	 8.2	 5.78	 11.04	 4.75	 3.34	 1.86	 	 4.62	 2.71	 6.47	
NEU	 10^9/L	 6.54	 7.48	 5.73	 3.85	 3.65	 4.31	 2.16	 0.56	 	 1.86	 6.91	 7.9	
EOS	 10^9/L	 	 	 	 	 	 	 	 	 	 	 	 	
BAS	 10^9/L	 	 	 	 	 	 	 	 	 	 	 	 	
LYM%	 %	 1.9	 1.6	 1.2	 0.1	 7.9	 0.1	 3.5	 1.7	 	 1.5	 37.3	 1.7	
MON%	 %	 48.8	 50.1	 58.2	 60	 69.2	 52.4	 58.6	 75.7	 	 70.2	 17.6	 44.3	
NEU%	 %	 49.2	 48.3	 40.7	 39.9	 22.9	 47.5	 37.9	 22.6	 	 28.3	 45	 54	
EOS%	 %	 	 	 	 	 	 	 	 	 	 	 	 	
BAS%	 %	 	 	 	 	 	 	 	 	 	 	 	 	
RBC	 10^12/L	 5.03	 5.09	 4.89	 5.15	 5.35	 4.71	 4.81	 4.44	 	 5.78	 5.65	 5.48	
HGB	 g/dL	 13.9	 14.2	 13	 14	 14.1	 12.6	 13	 11.3	 	 14.4	 14	 13.7	
HCP	 %	 37.4	 37.83	 36.78	 38.93	 40.11	 35.93	 36.81	 35.1	 	 40.1	 38.77	 38.33	
MCV	 fl	 74	 74	 75	 76	 75	 76	 80	 79	 	 69	 69	 70	
MCH	 pg	 27.7	 27.8	 26.5	 27.1	 26.3	 26.8	 28.1	 25.5	 	 25	 24.8	 25.1	
MCHC	 g/dL	 37.3	 37.5	 35.2	 35.9	 35.2	 35.1	 35.2	 32.2	 	 36	 36.1	 35.9	
RDWc	 %	 15.1	 14.9	 15.1	 14.9	 14.6	 14.8	 14.1	 14.5	 	 15.6	 15.4	 15.7	
RDWs	 fl	 45.3	 44.5	 45.3	 45.3	 43.8	 44.5	 45.3	 46.1	 	 43	 42.2	 43.8	
PLT	 10^9/L	 427	 510	 442	 303	 301	 292	 330	 2	 	 396	 242	 413	
MPV	 fl	 7.9	 7.8	 7.7	 8.2	 9.4	 7.9	 9.2	 6	 	 8.7	 9	 8.5	
PCT	 %	 0.34	 0.4	 0.34	 0.25	 0.28	 0.23	 0.31	 0	 	 0.34	 0.22	 0.35	
PDWc	 %	 36.2	 35.3	 36.2	 36.9	 35.9	 36.7	 38	 22.8	 	 37.8	 36.4	 36.2	
PDWs	 fl	 11.9	 11.2	 11.9	 12.7	 11.7	 12.4	 14.9	 4.5	 	 13.7	 12.2	 11.9	
PrVP	 		 338/342	 340/344	 339/342	 346/349	 344/348	 330/335	 350/354	 348/352	 	 340/344	 348/352	 345/349	
PrVR	 		 334/336	 332/333	 328/330	 337/340	 334/336	 323/325	 343/346	 339/341	 	 334/336	 338/340	 335/337	
PrVE	 		 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 0/0	 	 0/0	 0/0	 0/0	
WBC	Lyse	 ml	 0.5	 0.5	 0.5	 0.5	 0.5	 0.5	 0.5	 0.5	 	 0.5	 0.5	 0.5	





 Finally, we sent treated and naïve NHP brain sections for independent 
neuropathological analysis. The summary of the report is included in Appendix A. No 
histopathological changes, with exception of changes resulting directly from the needle 
track, were identified. 
 Collectively, these findings suggest that a single CSF injection of Di-siRNA 
enables broad, potent, and safe modulation of gene expression throughout the NHP brain 
in the animals tested. It is important to note that the data presented is limited to a short-
term, one-month study. Further evaluation of long-term safety of non-selective HTT 
modulation, as well as repetitive dosing of Di-siRNA, is necessary.   
5.4.12 DI-SIRNA HTT MODULATES HTT EXPRESSION WITH MINIMAL OFF-
TARGET EVENTS. 
 To determine if HTT modulation or Di-siRNA treatment had any major effect on 
the transcriptome, we performed genome-wide RNA sequencing (RNA-seq), comparing 
Di-siRNAHTT-treated to naïve NHP brains. We analyzed three cortical replicates from 
each of 8 animals (4 naïve, 4 treated). We chose to analyze the cortex, because we 
observed the highest accumulation of Di-siRNA in this region; therefore, the chances of 
seeing off-target effects would be maximized.  
 We observe 52 genes with significant differential expression between treated and 
naïve animals, using a 1% FDR significance threshold (Figure 5.26, Table 5.2).   
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Figure 5.26 Di-siRNA shows few off-target effects genome-wide.  
RNA collected from Cynomolgus macaques was subjected to RNA-sequencing to assess 
genome-wide patterns of differential gene expression. a. Volcano plot showing genome-
wide gene expression changes in Di-siRNAHTT treated NHPs, with differentially 
expressed genes (Benjamini Hochberg FDR < 1%) in orange and differentially expressed 
genes with a 3’ UTR seed complementary region in red. Enrichment of 3’ UTR seed 
complementarity down- or up-regulated genes (top-right) was calculated using a Fisher’s 
exact test. b. Volcano plot showing unbiased screen for enriched 6-mer sequences within 
3’ UTRs of differentially expressed gene (FDR < 1%). There are no significantly over- or 
under-represented sequences after Benjamini Hochberg multiple test correction. Seed 
complementary sequence for Di-siRNAHTT is indicated in black. c. Gene expression 
measurements (transcripts per million, x-axis) across 4 naïve NHPs (grey) and 4 Di-
siRNAHTT treated NHPs (red) for the 8 differentially expressed genes with seed 
complementary regions. d. Significant gene ontology categories for differentially 
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ENSMFAG0
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0000043210 
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05 
0 elongator  complex 
protein 1 [Source:NCBI 
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ENSMFAG0
0000045718 
PLD4 -1.90 2.00E-08 2.48E-
05 
3 phospholipase  D family 
member 4 [Source:NCBI 
gene;Acc:102145104]   
ENSMFAG0
0000033464 
BBC3 1.07 3.23E-08 3.53E-
05 




 As expected, HTT stood out as a single outlier with the most significantly 
impacted mRNA levels (75% silencing, P < 10-40). With the exception of HTT, most 
gene expression changes were minimal. Importantly, both the level and consistency of 
modulation for other genes were nowhere near what was observed with HTT. 
 siRNA off-target effects are a major concern in development of siRNA-based 
therapeutics38. siRNA off-target effects are predominantly due to seed (position 2-7 of the 
guide strand) complementarity in the 3’UTR of other targets190. To evaluate if the 
observed non-HTT gene expression changes were due to off target effects of the siRNA, 
we looked at enrichment for seed complementarity in significantly downregulated and 
upregulated targets. Downregulated transcripts were slightly enriched for perfect 
complementarity to the guide strand seed region (P = 0.04) while no enrichment was 
observed in up-regulated genes (P = 0.59). No enrichment was observed for seed reverse 
complement. In comparison to a previous study evaluating RNA-seq in rat livers treated 
with siRNA, the off target effects observed here are minor38.  
 To look more broadly at potential seed enrichment, we performed a novel 
analysis, searching all differentially expressed 3’ UTRs for any combination of six 
nucleotides (seed length) that were overrepresented. For genes differentially expressed at 
a 1 % FDR, there were no significantly over-represented 6-mers and the HTT siRNA 
seed complement “AGAUUA” was present in the middle of distribution (Fig. 5.26b). 
Relaxing the differential expression threshold to 10% FDR, there were several 
overrepresented 6-mers, but none of them match AGAUUA (Fig. 5.27). 
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Figure 5.27 Volcano plot showing 
unbiased screen for enriched 6-mer 
sequences within 3’ UTRs of differentially 
expressed gene (FDR < 10%).  
Significantly over- or under-represented 
sequences (Benjamini Hochberg adjusted p-
value < 0.05) are in red. Seed 
complementary sequence for Di-siRNAHTT 
is indicated in black. 
 
  
 There were 7 differentially expressed genes whose 3’ UTRs contain the 
AGAUUA seed complement. The gene expression values (transcripts per million) for 
individual animals are shown in Figure 5.27c. For five out of seven transcripts, the 
changes were minor and are likely not to be biologically significantly. Thus, there were 
only two potential genes, APOLD1 (~ 40% down) and ANLN (~ 20% down), that might 
be down-regulated due to miRNA-like off-target modulation. 
 Huntingtin expression is essential for embryonic development191, but the 
conditional modulation of huntingtin in adult mice has very minimal phenotype192, 
suggesting that non-selective modulation of HTT might be a reasonable therapeutic 
approach. However, HTT is involved in several cellular processes193, generating the 
potential for transcriptional changes downstream of HTT silencing (“on-target effects” vs 
“off-target”). To determine if changes were due to “on-target effects” of HTT 
modulation, we performed gene ontology analyses on the differentially expressed genes. 
With a 1% FDR, only the “immune system processes” category was significantly 
enriched among differentially expressed genes, with 12 out of 576 expressed genes in this 
category showing differential expression.  
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 With a 5% FDR, three other pathways were slightly significantly enriched (Fig. 
5.26d; G-protein-coupled purinergic receptors signaling, adenosine receptor signaling and 
purinergic receptor signaling), with all changes being minor. 
At this point, we are not able to distinguish if the observed minor transcriptional changes 
are of biological significance and, if so, they are due to the trauma of ICV injection itself, 
a consequence of month-long HTT silencing, or off-target modulation. 
 In general, RNA-seq analyses of Di-siRNA HTT treated NHP brains reveal a lack 
of major transcriptional changes (aside from HTT modulation) and minimal, if any, off-
targeting activity. Thus Di-siRNA enable highly specific modulation of gene expression 
in the CNS. 
5.5 DISCUSSION 
 The ability to modulate gene expression in the CNS opens up a wide range of 
neurological diseases to therapeutic intervention. Many different technologies are being 
explored for gene modulation in the CNS, including ASOs and adeno-associated virus 
(AAV)5, 133, 184, 194. Delivery of AAV via intra-parenchymal injections shows promise, 
with efficient HTT silencing being observed in minipig, sheep, and NHP194-196. However, 
multiple injections of AAV are required due to the limited distribution achieved upon a 
single injection. While this approach would eliminate the need for repetitive dosing, 
major technological advances in the field of AAV delivery are needed to achieve uniform 
silencing throughout the brain. In contrast, ASOs are the most clinically-advanced 
technology, with multiple compounds in different stages of clinical evaluation197.  Recent 
data with HTT-targeting ASOs show ~50% modulation of soluble mutant HTT in the 
CSF of patients following monthly intrathecal injections (Clinical Trial ID: 
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NCT03342053).  However, ASO delivery to deep brain structures is limited5, with no 
significant HTT silencing observed in NHP caudate with multiple injections184. Di-valent, 
PS-containing, fully chemically stabilized siRNA enables wide spread distribution and 
efficacy after a single bolus injection in rodent and NHP brains, and offers a new 
approach for gene modulation in the CNS. 
 The broad distribution and retention of Di-siRNAs in the non-human primate 
brain is likely due to its large size, which may slow the rate of CSF clearance.  Thus, the 
difference in size between ASOs (7 KD) and Di-siRNAs (27 KD) may be partially 
responsible for the observed difference in distribution to deep brain structures. It is 
possible that similar strategies might be employed to enhance deep brain delivery of other 
therapeutic RNA classes. The concept of branching has been explored for ASOs, 
specifically by IDERA Pharmaceuticals. Their approach links two first-generation ASOs 
(fully phosphorothioated DNA and RNA) together via the 5' ends, which results in better 
systemic efficacy compared to monomeric ASO variants198.  
 In addition to size, the Di-siRNAs are comprised of two PS-containing siRNAs, 
with 26 PS modifications per molecule. Elimination of PS content in siRNA scaffold 
completely abolished efficacy (Fig. 5.5), suggesting that enhanced brain retention and 
distribution is dependent on the presence of PS modifications. The mechanism behind 
PS-mediated delivery is not fully understood, but multiple cell surface receptors have 
been recently identified that may be involved in phosphorothioated oligonucleotide 
uptake164.  Optimizing PS content is currently the strategy utilized for fine-tuning ASO 
potency and toxicity profiles. The siRNA scaffold used in this study (13 out of 35 
backbones phosphorothioated or ~40% PS content) is not sufficient to promote 
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significant retention for monomeric compounds. Yet, by increasing the size and linking 
these two compounds together, the cooperativity of weak PS-driven cellular interactions 
produces robust cellular uptake and retention. Increasing the percentage of PS 
modifications, either uniformly (i.e. every other nucleotide linkage) or strategically 
positioned, throughout the siRNA may interfere with RISC assembly172, 173 and reduce 
tolerability.  Therefore, a multi-valency approach may be preferable for achieving siRNA 
uptake without overt toxicity. 
 Mouse studies confirmed that duration of effect could be predicted based on 
compound tissue accumulation at earlier time points (one month). In NHPs, we observed 
potent silencing in all brain regions at one month after injection. Given the level of 
accumulation in cortex and hippocampus, silencing is expected to last 6-9 months in 
these regions, and as long as 2-4 months in the caudate and putamen.  Therefore, 
repetitive injections would be necessary to maintain HTT silencing throughout the brain. 
While a single injection was found to be safe at one month, additional studies would be 
necessary to evaluate long-term safety.  
 Interestingly, animals with a single treatment of Di-siRNA targeting HTT show 
significant silencing of HTT, yet did not exhibit major transcriptional changes. There 
were minimal observed miRNA-like off target effects, with only two genes identified as 
putative candidates for minor off-target based modulation. While seed complementary 
sequences were slightly overrepresented in the 3’ UTRs of downregulated transcripts (P = 
0.04), the overall effect and overall degree of enrichment was minimal compared to 
previously observed off-target effects with siRNA in rat livers38 and in cells199. Off-target 
effects were explored in cortical samples, where guide strands accumulated to more than 
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9 ug/g resulting in more than 90% HTT protein silencing. Significantly lower 
accumulation has been observed to be sufficient for target modulation, so the lack of 
significant off-target effects in this region is likely representative of the transcriptome 
changes at high guide strand concentration. It is unclear if the lack of significant off-
target effects is specific to CNS regions, NHPs or these particular compounds. At this 
point there is no other genome-wide off-targeting data in NHPs available for comparison. 
 The lack of a large number of transcriptome changes at one month following 
potent HTT modulation is consistent with published data that elimination of HTT in adult 
mice has minimal phenotypes192. While encouraging, long-term safety studies need to be 
performed to conclude that non-selective potent HTT modulation is safe. 
 An interesting and often debated consideration is whether non-selective or single 
nucleotide polymorphism (SNP)-selective modulation of Htt expression is a better 
therapeutic strategy for HD. The most clinically-advanced ASO compound targeting Htt 
(Clinical Trial ID: NCT03342053) modulates wild type and mutant HTT non-selectively. 
However, there are other programs (from Wave Life Sciences and IONIS 
Pharmaceuticals) that enable SNP-based discrimination. An argument for a non-selective 
strategy is that it allows for the treatment of all HD patients with a single entity200. 
Furthermore, although HTT knockout is embryonically lethal, its elimination is well 
tolerated in adult mice192.  Di-siRNA compounds deliver to most of the cortical neurons, 
resulting in non-selective, potent silencing of wild type and mutant HTT. The long-term 
safety of such widespread down-regulation must be assessed carefully. 
 In this paper, we characterized Di-siRNA as a new chemical scaffold that enables 
potent modulation of Htt gene expression in the CNS, independent of brain size.  The 
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identified scaffold can be reprogrammed to silence other genes in CNS, opening CNS of 
RNAi-based modulation of gene expression in CNS. Further, in depth, evaluation in 
established disease models is necessary to assess the impact of Di-siRNA-mediated 
silencing of HTT on disease progression.  However, these findings establish a foundation 




CHAPTER VI:  DISCUSSION 
  
 In this dissertation I have described a new siRNA dianophore that enables both a 
long-lasting duration of effect of silencing as well as widespread distribution and 
retention in the non-human primate brain.  This is the first described siRNA to show this 
magnitude of distribution and silencing. 
 ASOs are leading the field of oligonucleotide delivery to the brain5, 133.  While 
siRNAs had been investigated with some local brain delivery55-58, it was difficult to 
achieve widespread long-term distribution not in small part due the limitations in 
chemical structure and modification space20.  siRNAs must be recognized by the AGO2 
protein and their modification pattern must neither interfere with their shape nor effect 
their interactions with the various domains of the AGO223.  However given the efficiency 
of siRNA mediated mRNA silencing12 it seemed important to determine if an alternative 
chemical scaffold could support similar delivery and efficacy with siRNAs than ASOs.   
 In Chapter I of this dissertation the qualities of an informational drug that 
uniquely allow for separation of the pharmacophore, or targeting sequence, from the 
dianophore1, or chemical scaffold that supports delivery characteristics, are laid out.  
Therefore the first step in identifying a new dianophore is to identify an efficient 
pharmacophore to establish the context in which the dianophore efficiency can be 
assessed.  In Chapter III I identify a functional siRNA sequence for targeting 
Huntington’s disease. Partially modified cholesterol conjugated siRNA dianophore did 
not provide ideal distribution, silencing, or duration of effect, thus identification of this 
sequence acted as a jumping off point for further investigation58. 
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 At the start of this research, the standard chemistry in the field for siRNAs was 
partial 2’-O-methyl/2’fluoro modification59.  In Chapter IV of this dissertation I describe 
different versions of fully modified siRNAs in the context of systemic delivery and 
efficacy.  While other labs have published on a fully modified chemical scaffold, there 
has been no side-by-side comparison of retention and efficacy of partially and fully 
modified siRNAs in a multi-organ in vivo study.  This research made it abundantly clear 
that assessing the functionality of new chemical conjugate for siRNA can only be done in 
the context of a fully chemically stabilized siRNA37.  These results are confirmed by 
Alnylam Pharmaceuticals who have continued to improve the efficacy and potency of an 
individual sequence by adjusting even the pattern and position of 2’-O-methyl and 2’-
fluoro modifications20, 163, 165. 
 In my final research Chapter V I describe a new dianophore for delivery of siRNA 
to the brain.  As I mentioned, ASOs are currently leading the field in the treatment of 
neurodegenerative diseases with an informational drug5, 66.  When I joined the lab the 
strategy to support siRNA delivery to the brain was to synthesize a number of different 
hydrophobic conjugates to try to increase distribution while maintaining retention.  
Unfortunately these two aspects of a hydrophobic molecule are tightly linked with 
increased hydrophobicity leading to increased retention but decreased distribution and 
vice versa58.  And while we understood at the time that ASOs rely on phosphorothioate 
mediated delivery to the brain it was unclear as to whether we could incorporate enough 
PS content into siRNAs to ensure retention without toxicity.  As we brainstormed 
different ways of incorporating increased PS content into siRNAs (whether in the 
duplexed region, or in the context of an additional 3’sense PS tail) a failed conjugate 
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synthesis produced the Di-siRNA chemical scaffold.  We were immediately intrigued by 
the properties of this molecule. 
 There are a number of possible explanations for the observed efficacy of the Di-
siRNA chemical scaffold.  One of the most obvious, the potentially enhanced PK 
properties and changes in compound clearance kinetics.  Phosphorothioate content 
supports binding to both circulating proteins as well as cellular membrane proteins30.  By 
linking two molecules together two flexible PS modified single stranded tails may be 
potentially increasing the opportunity for cooperative PS binding, where the presence of 
two PS binding opportunities is possibly increasing overall membrane association.  There 
is another example of this phenomenon in siRNA field.  The GalNAc conjugate consists 
of three identical N-acytalgalactosamine units, which increase the binding of this 
conjugate to the ASGPR receptor47.  Studies have shown that while one unit of GalNAc 
can bind to the receptor and initiate internalization, the presence of additional GalNAc 
units significantly increases receptor binding47.  It is possible that the cooperative 
interaction of the two PS tails has a similar effect, although with non-specific PS protein 
binding. 
 Another unique aspect to the Di-siRNA chemical scaffold is its size.  It is known 
that systemically, a molecule’s size affects the rate at which it is cleared.  For example, 
the kidneys have a cutoff of approximately 70KD201.  Where molecules <70KD are 
cleared by the kidney and molecules >70KD remain in circulation for a longer period of 
time.  This phenomenon has been exploited by adding additional molecular weight to 
compounds in the form of PEGylation to increase overall circulating times which may 
lead to greater tissue exposure202.  Similarly, the increase in size of the Di-siRNA 
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chemical scaffold relative to either the mono-siRNA chemical scaffold or the even 
smaller molecular weight of an ASO could be impacting the rate of CSF clearance, 
increasing the amount of time that the siRNA is exposed to various brain regions.   This 
increased exposure could also explain the ability of Di-siRNA to penetrate to deeper 
regions of the brain such as the caudate and putamen. By increasing the time of 
circulation we may also be increasing the amount of interstitial fluid exchange allowing 
for deeper penetration and increased overall compound retention.  ASO studies in both 
mouse and non-human primate require weekly dosing for one month 66, yet silencing in 
the non-human primate brain is not observed in deeper brain regions such as the caudate, 
putamen or hippocampus184.   The observed deep brain silencing of the Di-siRNA 
chemical scaffold could be a result of changes in PK properties.   
 While the studies performed here suggest robust silencing and duration of effect 
that could offer significant therapeutic value, it is important to think about the potential 
drawbacks to such a potent non-specific down-regulation of a protein whose function is 
not well understood.  Huntington’s disease is autosomal dominant83.  This means that 
there is still a wild type copy of the huntingtin gene.  In mice a huntingtin knockout 
phenotype, while embryonic lethal, has not been shown to have any notable effects in 
adults192.  However with a protein that has been implicated in so many functions193, it is 
hard to know whether near complete silencing of the huntingtin gene will have an effect 
in adult humans.   Therefor an alternative treatment could be to silence only the mutant 
huntingtin transcript leaving expression of the wild type transcript unaltered.  There are 
two main differences between the mutant and the wild type transcript: one is the length of 
the CAG repeats203 and the other is the presence of differing SNPs, or single nucleotide 
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polymorphisms200.  Attempts to silence at the CAG repeats could potentially have off 
target effects as there are other genes that contain this repeat, but our lab and others have 
had success in selectively silencing at SNPs.  While the potential off-target (the wild type 
transcript) is only different by a single nucleotide, introduction of a second mismatch or 
use of alternative backbone and base chemistry can increase the selectivity of the 
informational drug for the mutant HTT transcript.  While the current clinical candidate 
ASO targets both the wild type and mutant huntingtin, exploring the ability to just silence 
a single allele is an important therapeutic question and is currently being investigated 
(Wave Life Sciences)133, 204. 
 There has also been some evidence that it is not even the full-length transcript that 
is causing the disease but a truncated version (exon and intron 1) that is toxic205.  Given 
that the sequence described in this dissertation targets the early 3’UTR, this informational 
therapeutic would not target the short fragment.   In this case it would be necessary to 
identify a new sequence that target both the short fragment as well as the full length 
fragment, or potentially only the short fragment by targeting an intronic sequence.   This, 
like SNP targeting, becomes far easier to attempt given that the dianophore for brain 
delivery has already been identified.   
 Lastly our lab has shown that huntingtin mRNA, especially in Huntington’s 
disease exhibits significant nuclear localization179.   While there is some evidence that 
siRNA can functionally silence mRNA in the nucleus, the more obvious choice for 
nuclear silencing is an ASO approach.  It may be possible to use this branched PS 
scaffold discussed in this dissertation to deliver an ASO as well. Using two 
complementary oligonucleotides attached by a linker, the scaffold could be used to carry 
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two antisense oligonucleotides into cells.  Different chemical modifications could adjust 
the melting temperature of the duplexes to ensure disassociation.  ` 
 With any informational drug or functional genomics study it is important to 
ensure that observed effects are a result of specific silencing of the target gene and not 
non-specific off target gene silencing as a result of seed complementarity with another 
gene.  Additionally it is important to understand whether silencing of huntingtin 
specifically has any major effect on the expression levels of other proteins or transcripts.  
In order to investigate off target effects we chose to do RNAseq.   To ensure that we were 
investigating the most serious off target effects we looked at the cortex where we had the 
most silencing.   After one month no significant off target events were observed.    
However there are a number of considerations to make when extending this limited 
analysis to broad assumptions of off target effects.  For one, while the cortex may have 
the greatest silencing, it is possible that there are other brain regions that have had more 
significant off target effect than the cortex as huntingtin may play a more important role 
in another brain region.  Secondly, the analysis was done after one month.   Given that 
the huntingtin protein has so many functions it is possible that off target effects could 
accumulate and cause issue at a later date.  Therefor it is important that we investigate the 
effect of huntingtin lowering at later time points.  
 With the identification of a new siRNA dianophore for the brain the most obvious 
next question is can this scaffold be applied to alternative genetically defined 
neurodegenerative disease?   This research shows that the chemical scaffold is not 
sequence dependent and can be applied to alternative sequences (APOE and PPIB).  
Additionally the widespread distribution achieved opens other regions of the brain for 
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therapeutic targeting.  For example, Huntington’s disease will primarily require targeting 
of the striatum and cortex, Alzheimer’s disease requires targeting of the hippocampus and 
cortex, cerebellar ataxia requires targeting of the cerebellum, and ALS requires targeting 
of the spinal cord and lower motor neurons as well as targeting of the motor cortex.  With 
full cortical, deep brain, and spinal cord distribution and silencing, this new chemical 
scaffold can potentially be applied to a wide range of neurodegenerative diseases.  
 Although this dissertation primarily focuses on the therapeutic applications of a 
new chemical scaffold it is important to note that there are many basic biological 
applications of such a chemical scaffold as well.  For instance, applying this technology 
for functional genomics to understand the effect of gene or protein silencing on 
neurological function.  At present, many of these studies are done in the context of cell 
culture, but cell culture is unable to recapitulate the complexities of a mouse brain or 
brains more complex like that of the non-human primate.  Even if the studies are carried 
out in the brain, communication between various brain regions may be able to 
compensate for silencing in a single brain region which could make analysis of findings 
in a less robust in vivo study more convoluted206.   
 In conclusion this dissertation has 1) Identified a potent siRNA sequence for 
targeting huntingtin mRNA, 2) identified a fully modified chemical scaffold that enables 
increased systemic accumulation as well as increased silencing in multiple organs and 
increased duration of effect in the brain, and 3) identified a new siRNA dianophore for 
brain delivery that shows not only a six month duration of effect in the mouse but 
supports widespread distribution retention and silencing in the non-human primate brain 
(Fig. 6.1).   These findings suggest a possible new path towards the use of siRNAs for 
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widespread mRNA silencing in larger animals brains and could potentially be translated 
into a robust therapeutic for a number of genetically defined neurodegenerative diseases. 
 



































































APPENDIX A:  NON-HUMAN PRIMATE BRAIN HISTOLOGY REPORT 
 
Test Site Reference No. 20187084 
 Histopathologic changes in the brain were very similar in all four monkeys and 
were primarily localized to the brain regions at the site of the ICV injection. These 
changes included the presence of an injection track; minimal to mild gliosis with 
gemistocytosis; minimal to mild perivascular cuffing of mononuclear cells; and minimal 
to mild axonal degeneration. The nature, severity and distribution of these changes is 
consistent with the ICV procedures employed and/or the resulting reparative processes. 
No evidence is present that suggests an exacerbation due to the presence of the siRNA 
test article. 
 In addition, two monkeys (Nos. 1 and 4) had mild degenerative changes focally in 
the superficial cerebral cortex. The nature, severity and location of these changes is 
consistent with effects due to the surgical procedures used for the ICV injection. 
In conclusion, the histopathologic changes identified, i.e., injection track, gliosis, 
perivascular cuffing of mononuclear cells, axonal degeneration, were localized to the 
immediate region of the injection and were considered related to the experimental 
procedures that were employed and/or the resulting reparative processes. Histopathologic 
changes resulting directly from the administration of the siRNA were not identified. 
 
RESPONSIBLE PERSONNEL 
Study Pathologist James P. Morrison, DVM, DACVP 
Charles River Laboratories, Inc. 
334 South Street 
Shrewsbury, MA 01545 
 
Test Site Management Scott Fountain, PhD  
Charles River Laboratories, Inc. 
334 South Street 
Shrewsbury, MA 01545 
 
INTRODUCTION 
This report presents the pathology findings in Cynomolgus monkeys assigned to Study 
No. 20187084.  The objective of this study was to evaluate the brain from four 
Cynomolgus macaques treated with siRNA once via ICV injection followed by 1 month 
recovery period.   
 
The study was sponsored by University of Massachusetts Medical School, Worcester, 
MA.  Julia Alterman, PhD candidate, served as the Study Monitor. 
 
MATERIALS AND METHODS 
 All animals received an image guided ICV injection of a chemically modified 
siRNA intended to treat Huntington’s Disease unilaterally on study day 1. The animals 
were submitted for necropsy after 1 month (Terminal Euthanasia).  Necropsies were 
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performed by University of Massachusetts Medical School personnel.  Tissues required 
for microscopic evaluation were trimmed, processed routinely, embedded in paraffin, and 
stained with hematoxylin and eosin by University of Massachusetts Medical School.  
Microscopic evaluation was conducted by the Study Pathologist, a board-certified 
veterinary pathologist on select tissues from 3 male and 1 female monkeys.  Tissues were 
evaluated by light microscopy. 
 The brain trimming procedure that was employed resulted in seven transverse 
brain sections for evaluation. The sections were taken unilaterally from the hemisphere of 
the brain that received the ICV injection and included the following regions: frontal lobe, 
temporal lobe, frontoparietal lobe, occipital lobe, mesencephalon, cerebellum and 
medulla oblongata.  
 
RESULTS AND DISCUSSIONS 
Histopathology 
 Histopathologic changes in the brain were similar in all animals and were 
primarily localized to the brain region at the site of the intracerebroventricular (ICV) 
injection. Overall the changes were consistent with those expected from the injection 
procedure and evidence of an exacerbation of the changes resulting from the presence of 
the siRNA test article was not present.  
 The injection track was identified in all four monkeys within the cerebral white 
matter of the frontal lobe.  The subanatomic location of the injection track in the sections 
evaluated ranged from immediately deep to the overlying cerebral cortex to immediately 
dorsal to the lateral ventricle. The variability in the location most likely reflects 
sectioning variability from small differences in the location of the trimming plane, 
although small variations in the site or angle of the injection could have contributed.  
 Histopathologically the injection track was characterized by a small, focal, 
circular to ovoid area in which the parenchyma was absent and replaced by small 
numbers of finely vacuolated macrophages/microglia. Mildly increased numbers of 
astroglia and microglia surrounded the injection tracks and extended into the 
neuroparenchyma a small distance from the track, gradually decreasing in number with 
increasing distance from the injection track. Small numbers of astrocytes surrounding the 
injection track had abundant homogenous eosinophilic cytoplasm and prominent, 
eccentrically placed, open faced nuclei, consistent with a gemistocytic morphology. In 
addition, small numbers of degenerating axons were present throughout the surrounding 
neuroparenchyma, characterized by scattered digestion chambers containing pyknotic 
debris and/or axonal spheroids. Multifocal perivascular cuffs of mononuclear 
inflammatory cells were scattered throughout the section and were minimal to mild in 
severity. These cuffs occasionally had small numbers of macrophages containing golden 
brown pigment, most likely representing lipofuscin.  
 In animals 1 and 4, minimal to mild degenerative changes were focally present in 
the superficial cerebral cortex, presumably near the location of the entry point through the 
skull. These changes included gliosis, minimal neuronal loss/degeneration, edema, 
mononuclear perivascular cuffing, and multifocal axonal spheroids. In animal 4, there 
was also a focal depression in the cerebral cortex at this location that was surrounded by 
mildly hyperplastic meninges. These changes are consistent with and presumably the 
result of minimal trauma resulting from the surgical entry though the skull.  
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 Rare perivascular cuffs of mononuclear cells were present in other brain sections 
and occurred at an incidence and severity typical of non-human primates and thus are 
considered background findings unrelated to the injection procedure. In addition, in 
animal 4, a focal decrease in granule neurons was present in the cerebellar cortex. This 
was consistent with a developmental abnormality and is unrelated to the experimental 
procedures. All other findings are consistent with spontaneous changes. 
 In conclusion, the histopathologic changes identified (i.e., injection track, gliosis, 
perivascular cuffing of mononuclear cells, axonal degeneration) were localized to the 
immediate region of the injection and were considered related to the experimental 
procedures that were employed and/or the resulting reparative processes. Histopathologic 
changes resulting directly from the administration of the siRNA were not identified. 
 
CONCLUSIONS 
 In conclusion, four cynomolgus macaques received an intracerebroventricular 
injection of an siRNA on study day 1. The majority of the histopathologic changes 
identified in the brain were localized to the immediate region of the injection and were 
considered related to the experimental procedures that were employed and/or the 
resulting reparative processes. Histopathologic changes resulting directly from the 
administration of the siRNA were not identified. Other findings occurred at an incidence 




APPENDIX B:  CO-AUTHORED PUBLICATIONS 
 
1. Alterman JF*, Godinho BMDC*, Hassler MR*, Echeverria D, Sapp E, Ferguson 
CM, Haraszti RA, Coles AH, Conroy F, Miller R, Roux L, King, RM, Gernoux 
G, Mueller C, Gray-Edwards HL, Moser RP, Bishop NC, Jaber SM, Gounis MJ, 
Sena-Esteves M, DiFiglia M, Aronin N, Khvorova A.  Divalent-siRNAs: an 
advanced chemical scaffold for potent and sustained modulation of gene 
expression in the CNS. *Authors contributed equally to this work.  Nat. Biotech., 
Submitted. 
2. Turanov A*, Hassler MR*, Lo A*, Makris A*, Ashar-Patel A, Alterman JF, 
Coles AH, Haraszti RA1, Roux L, Godinho BMDC, Echeverria D, Pears S, 
IIiopoulos J, Shanmugalingam R, Ogle R, Hennessy A, Karumanchi SA, Moore 
MJ, and Khvorova A.   RNAi Modulation of Placental sFLT1 for the Treatment of 
Preeclampsia.  *Authors contributed equally to this work.  Nat. Biotech., 2018. 
3. Haraszti RA, Miller R, Didiot MC, Biscans A, Alterman JF, Hassler MR, Roux 
L, Echeverria D, Sapp E, DiFiglia M, Aronin N, Khvorova A.  Optimized 
Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular 
Vesicles.  Mol. Ther., 2018 26(8). 
4. Godinho BMDC, Henninger N, Bouley J, Alterman JF, Haraszti RA, Gilbert JW, 
Sapp E, Coles AH, Biscans A, Nikan M, Echeverria D, DiFiglia M, Aronin N, 
Khvorova A.  Transvascular Delivery of Hydrophobically Modified siRNAs: Gene 
Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier.  Mol. Ther., 
2018. 
5. Mir A, Alterman JF, Hassler MR, Debacker AJ, Hudgens E, Echeverria D, 
Brodsky M, Khvorova A, Watts JK, Sontheimer EJ.  Heavily and Fully Modified 
RNAs for Efficient Cas9-Mediated Genome Editing.  Nat. Commun, 2018, 9:2641. 
6. Hassler MR*, Turanov AA*, Alterman JF*, Coles AH, Haraszti RA, Osborn MF, 
Godinho BM, Lo A Rajakumar A, Golebiowski D, Echeverria D, Nikan M, 
Salomon WE, Davis SM, Morrissey DV, Sena-Esteves M, Zamore PD, 
Karumanchi SA, Moore MJ, Aronin N, Khvorova A.  Comparison of fully and 
partially chemically-modified siRNA in conjugate-mediated delivery in vivo.  
NAR, 2018, 46 (5), 2185-2196.  *Authors contributed equally to this work. 
7. Alterman JF, Coles AH, Hall LM, Aronin N, Khvorova K, Didiot MC. A High-
Throughput Assay for mRNA Silencing in Primary Cortical Neurons With 
Oligonucleotide Therapeutics.  Bio Protoc. 2017 Aug 20; 7(16): e2501 
8. Sharma VK, Singh SK, Krishnamurthy PM, Alterman JF, Haraszti RA, Khvorova 
A, Prasad AK, Watts JK.  Synthesis and biological properties of triazole-linked 
locked nucleic acid.  Chem Commun (Camb). 2017 Aug 3;53(63):8906-8909. 
9. Haraszti RA*, Roux L*, Coles AH, Turanov AA, Alterman JF, Echeverria D, 
Godinho BM, Aronin N, Khvorova A..  5′vinylphosphonate improves tissue 
accumulation and efficacy of conjugated siRNAs in vivo.  Nucleic Acids Res. 2017 
Jul 27; 45(13): 7581–7592. *Authors contributed equally to this work.  
10. Didiot MC, Hall LM, Coles AH, Haraszti RA, Godinho BM, Chase K, Sapp E, Ly 
S, Alterman JF, Hassler MR, Echeverria D, Raj L, Morrissey DV, DiFiglia M, 
 173 
Aronin N, Khvorova A. Exosome-mediated Delivery of Hydrophobically Modified 
siRNA for Huntingtin mRNA Silencing. Mol Ther. 2016 Oct;24(10):1836-1847. 
11. Ly S, Navaroli DM, Didiot MC, Cardia J, Pandarinathan L, Alterman JF, Fogarty 
K, Standley C, Lifshitz LM, Bellve KD, Prot M, Echeverria D, Corvera S, 
Khvorova A. Visualization of self-delivering hydrophobically modified siRNA 
cellular internalization. Nucleic Acids Res. 2017 Jan 9;45(1):15-25.  
12. Coles AH*, Osborn MF*, Alterman JF, Turanov AA, Godinho BM, Kennington 
L, Chase K, Aronin N, Khvorova A. A High-Throughput Method for Direct 
Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo. 
Nucleic Acid Ther. 2016 Apr;26(2):86-92. *Authors contributed equally to this 
work. 
13. Alterman JF, Hall LM, Coles AH, Hassler MR, Didiot MC, Chase K, Abraham J, 
Sottosanti E, Johnson E, Sapp E, Osborn MF, Difiglia M, Aronin N, Khvorova A. 
Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons 
and Mouse Brain. Mol Ther Nucleic Acids. 2015 Dec 1;4:e266. 
14. Osborn MF, Alterman JF, Nikan M, Cao H, Didiot MC, Hassler MR, Coles AH, 
Khvorova A. Guanabenz (Wytensin™) selectively enhances uptake and efficacy of 





APPENDIX C:  PATENTS AND PROVISIONAL PATENTS 
 
1. Khvorova, A., Aronin, N., Alterman, J. Oligonucleotide Compounds for 
Targeting Huntingtin mRNA. US Patent US9809817, Nov 7, 2017. 
2. Khvorova, A., Aronin, N., Hassler, M., Alterman, J. Fully Stabilized Asymmetric 
siRNA. US Provisional Patent Application No. 62/142,786, 4/3/2015 
3. Khvorova, A., Hassler, M., Alterman, J. Branched Oligonucleotides. US 
Provisional Patent Application No. 62/289,268, 1/31/2016 
4. Khvorova, A., Alterman, J, Hassler, M.  Two-tailed Self-Delivering siRNA.  U.S. 
Provisional Patent Application No. 62/523,949, 6/23/17. 
5. Khvorova, A., Alterman, J., Davis, S., Turanov, A.  O-Methyl Rich Fully 
Stabilized siRNA.  U.S. Provisional Patent Application No. 62/721,993, 8/23/18. 
6. Khvorova, A., Conroy, F., Alterman, J., Pfister, E., Aronin, N., Chemically 
Modified Oligonucleotides Targeting SNPs. 
7. Sontheimer, E., Khvorova, A., Watts, J., Mir, A., Alterman, J., Hassler, M., 
Brodsky, M., Debacker, A.  Modified Guide RNAs for CRISPR Genome Editing.  





1. Khvorova, A. & Watts, J.K. The chemical evolution of oligonucleotide therapies 
of clinical utility. Nature biotechnology 35, 238 (2017). 
2. Levin, A.A. Treating Disease at the RNA Level with Oligonucleotides. New 
England Journal of Medicine 380, 57-70 (2019). 
3. Barrangou, R. Cas9 Targeting and the CRISPR Revolution. Science 344, 707-708 
(2014). 
4. Liu, J. et al. Recent developments in protein and cell-targeted aptamer selection 
and applications. Current medicinal chemistry 18, 4117-4125 (2011). 
5. Kordasiewicz, H.B. et al. Sustained therapeutic reversal of Huntington's disease 
by transient repression of huntingtin synthesis. Neuron 74, 1031-1044 (2012). 
6. Havens, M.A. & Hastings, M.L. Splice-switching antisense oligonucleotides as 
therapeutic drugs. Nucleic acids research 44, 6549-6563 (2016). 
7. Kurreck, J., Wyszko, E., Gillen, C. & Erdmann, V.A. Design of antisense 
oligonucleotides stabilized by locked nucleic acids. Nucleic acids research 30, 
1911-1918 (2002). 
8. Bauman, J., Jearawiriyapaisarn, N. & Kole, R. Therapeutic Potential of Splice-
Switching Oligonucleotides. Oligonucleotides 19, 1-13 (2009). 
9. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in 
Caenorhabditis elegans. nature 391, 806 (1998). 
10. Elbashir, S.M., Lendeckel, W. & Tuschl, T. RNA interference is mediated by 21-
and 22-nucleotide RNAs. Genes & development 15, 188-200 (2001). 
11. Elbashir, S.M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference 
in cultured mammalian cells. Nature 411, 494-498 (2001). 
12. Salomon, W.E., Jolly, S.M., Moore, M.J., Zamore, P.D. & Serebrov, V. Single-
molecule imaging reveals that Argonaute reshapes the binding properties of its 
nucleic acid guides. Cell 162, 84-95 (2015). 
13. Wilson, R.C. & Doudna, J.A. Molecular mechanisms of RNA interference. Annu 
Rev Biophys 42, 217-239 (2013). 
14. Khvorova, A., Reynolds, A. & Jayasena, S.D. Functional siRNAs and miRNAs 
Exhibit Strand Bias. Cell 115, 209-216 (2003). 
15. Song, J.-J., Smith, S.K., Hannon, G.J. & Joshua-Tor, L. Crystal Structure of 
Argonaute and Its Implications for RISC Slicer Activity. Science 305, 1434-1437 
(2004). 
16. Liu, J. et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305, 
1437-1441 (2004). 
17. Layzer, J.M. et al. In vivo activity of nuclease-resistant siRNAs. RNA 10, 766-771 
(2004). 
18. Behlke, M.A. Chemical Modification of siRNAs for In Vivo Use. 
Oligonucleotides 18, 305-320 (2008). 
19. Jensen, S. & Thomsen, A.R. Sensing of RNA Viruses: a Review of Innate 
Immune Receptors Involved in Recognizing RNA Virus Invasion. Journal of 
Virology 86, 2900-2910 (2012). 
 176 
20. Foster, D.J. et al. Advanced siRNA Designs Further Improve In Vivo 
Performance of GalNAc-siRNA Conjugates. Molecular Therapy 26, 708-717 
(2018). 
21. Damha, M.J. et al. Properties of arabinonucleic acids (ANA & 20'F-ANA): 
implications for the design of antisense therapeutics that invoke RNase H 
cleavage of RNA. Nucleosides Nucleotides Nucleic Acids 20, 429-440 (2001). 
22. Zhao, X. et al. Structure variations of TBA G-quadruplex induced by 2'-O-methyl 
nucleotide in K+ and Ca2+ environments. Acta Biochim Biophys Sin (Shanghai) 
46, 837-850 (2014). 
23. Schirle, N.T. et al. Structural analysis of human Argonaute-2 bound to a modified 
siRNA guide. Journal of the American Chemical Society 138, 8694-8697 (2016). 
24. Robbins, M. et al. 2'-O-methyl-modified RNAs Act as TLR7 Antagonists. 
Molecular Therapy 15, 1663-1669 (2007). 
25. Judge, A.D., Bola, G., Lee, A.C. & MacLachlan, I. Design of noninflammatory 
synthetic siRNA mediating potent gene silencing in vivo. Molecular Therapy 13, 
494-505 (2006). 
26. Eckstein, F. Phosphorothioates, essential components of therapeutic 
oligonucleotides. Nucleic acid therapeutics 24, 374-387 (2014). 
27. Wu, S.Y. et al. 2′-OMe-phosphorodithioate-modified siRNAs show increased 
loading into the RISC complex and enhanced anti-tumour activity. Nature 
Communications 5, 3459 (2014). 
28. Hall, A.H.S., Wan, J., Shaughnessy, E.E., Ramsay Shaw, B. & Alexander, K.A. 
RNA interference using boranophosphate siRNAs: structure-activity 
relationships. Nucleic acids research 32, 5991-6000 (2004). 
29. Monia, B.P., Johnston, J.F., Sasmor, H. & Cummins, L.L. Nuclease resistance and 
antisense activity of modified oligonucleotides targeted to Ha-ras. The Journal of 
biological chemistry 271, 14533-14540 (1996). 
30. Brown, D.A. et al. Effect of phosphorothioate modification of 
oligodeoxynucleotides on specific protein binding. The Journal of biological 
chemistry 269, 26801-26805 (1994). 
31. Miller, C.M. et al. Stabilin-1 and Stabilin-2 are specific receptors for the cellular 
internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) 
in the liver. Nucleic Acids Res 44, 2782-2794 (2016). 
32. Bijsterbosch, M.K. et al. In vivo fate of phosphorothioate antisense 
oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial 
liver cells. Nucleic acids research 25, 3290-3296 (1997). 
33. Butler, M. et al. Phosphorothioate oligodeoxynucleotides distribute similarly in 
class A scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther 
292, 489-496 (2000). 
34. Benimetskaya, L. et al. Binding of phosphorothioate oligodeoxynucleotides to 
basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin 
is P-chirality independent. Nucleic Acids Res 23, 4239-4245 (1995). 
35. Haraszti, R.A. et al. 5΄-Vinylphosphonate improves tissue accumulation and 
efficacy of conjugated siRNAs in vivo. Nucleic acids research 45, 7581-7592 
(2017). 
 177 
36. Parmar, R. et al. 5′‐(E)‐Vinylphosphonate: A Stable Phosphate Mimic Can 
Improve the RNAi Activity of siRNA–GalNAc Conjugates. ChemBioChem 17, 
985-989 (2016). 
37. Hassler, M.R. et al. Comparison of partially and fully chemically-modified siRNA 
in conjugate-mediated delivery in vivo. Nucleic Acids Res 46, 2185-2196 (2018). 
38. Janas, M.M. et al. Selection of GalNAc-conjugated siRNAs with limited off-
target-driven rat hepatotoxicity. Nature Communications 9, 723 (2018). 
39. Sewing, S. et al. Assessing single-stranded oligonucleotide drug-induced effects 
in vitro reveals key risk factors for thrombocytopenia. PLoS One 12, e0187574 
(2017). 
40. Henry, S.P. et al. Assessment of the Effects of 2′-Methoxyethyl Antisense 
Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates. Nucleic 
Acid Therapeutics 27, 197-208 (2017). 
41. Adams, D. et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin 
Amyloidosis. New England Journal of Medicine 379, 11-21 (2018). 
42. Biswas, S. & Torchilin, V.P. Dendrimers for siRNA Delivery. Pharmaceuticals 
(Basel, Switzerland) 6, 161-183 (2013). 
43. Nemati, H. et al. Using siRNA-based spherical nucleic acid nanoparticle 
conjugates for gene regulation in psoriasis. Journal of Controlled Release 268, 
259-268 (2017). 
44. Guo, S. et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles 
coated with charge-reversal polyelectrolyte. ACS nano 4, 5505-5511 (2010). 
45. Ding, Y. et al. Gold Nanoparticles for Nucleic Acid Delivery. Molecular Therapy 
22, 1075-1083 (2014). 
46. Melamed, J.R., Kreuzberger, N.L., Goyal, R. & Day, E.S. Spherical Nucleic Acid 
Architecture Can Improve the Efficacy of Polycation-Mediated siRNA Delivery. 
Molecular Therapy - Nucleic Acids 12, 207-219 (2018). 
47. Lee, Y.C. et al. Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc 
lectin. Dependence on fine structural features. The Journal of biological chemistry 
258, 199-202 (1983). 
48. Willoughby, J.L.S. et al. Evaluation of GalNAc-siRNA Conjugate Activity in Pre-
clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression. 
Mol Ther 26, 105-114 (2018). 
49. Huang, Y. Preclinical and Clinical Advances of GalNAc-Decorated Nucleic Acid 
Therapeutics. Molecular therapy. Nucleic acids 6, 116-132 (2017). 
50. Tushir-Singh, J. Antibody-siRNA conjugates: drugging the undruggable for anti-
leukemic therapy. Expert Opin Biol Ther 17, 325-338 (2017). 
51. Cuellar, T.L. et al. Systematic evaluation of antibody-mediated siRNA delivery 
using an industrial platform of THIOMAB–siRNA conjugates. Nucleic acids 
research 43, 1189-1203 (2014). 
52. Kruspe, S. & Giangrande, P.H. Aptamer-siRNA Chimeras: Discovery, Progress, 
and Future Prospects. Biomedicines 5 (2017). 
53. Sivakumar, P., Kim, S., Kang, H.C. & Shim, M.S. Targeted siRNA delivery using 
aptamer-siRNA chimeras and aptamer-conjugated nanoparticles. Wiley 
Interdiscip Rev Nanomed Nanobiotechnol 11, e1543 (2019). 
 178 
54. McNamara II, J.O. et al. Cell type–specific delivery of siRNAs with aptamer-
siRNA chimeras. Nature biotechnology 24, 1005 (2006). 
55. Nikan, M. et al. Docosahexaenoic acid conjugation enhances distribution and 
safety of siRNA upon local administration in mouse brain. Molecular Therapy-
Nucleic Acids 5 (2016). 
56. Nikan, M. et al. Synthesis and Evaluation of Parenchymal Retention and Efficacy 
of a Metabolically Stable O-Phosphocholine-N-docosahexaenoyl-l-serine siRNA 
Conjugate in Mouse Brain. Bioconjugate chemistry 28, 1758-1766 (2017). 
57. DiFiglia, M. et al. Therapeutic silencing of mutant huntingtin with siRNA 
attenuates striatal and cortical neuropathology and behavioral deficits. 
Proceedings of the National Academy of Sciences 104, 17204-17209 (2007). 
58. Alterman, J.F. et al. Hydrophobically modified siRNAs silence huntingtin mRNA 
in primary neurons and mouse brain. Molecular Therapy-Nucleic Acids 4 (2015). 
59. Byrne, M. et al. Novel hydrophobically modified asymmetric RNAi compounds 
(sd-rxRNA) demonstrate robust efficacy in the eye. Journal of Ocular 
Pharmacology and Therapeutics 29, 855-864 (2013). 
60. Khan, T. et al. Silencing myostatin using cholesterol-conjugated siRNAs induces 
muscle growth. Molecular Therapy-Nucleic Acids 5 (2016). 
61. Duan, L. et al. Target delivery of small interfering RNAs with vitamin E-coupled 
nanoparticles for treating hepatitis C. Scientific reports 6, 24867-24867 (2016). 
62. Nishina, K. et al. Efficient in vivo delivery of siRNA to the liver by conjugation 
of α-tocopherol. Molecular Therapy 16, 734-740 (2008). 
63. Osborn, M.F. et al. Hydrophobicity drives the systemic distribution of lipid-
conjugated siRNAs via lipid transport pathways. Nucleic acids research 47, 1070-
1081 (2018). 
64. Biscans, A. et al. Diverse lipid conjugates for functional extra-hepatic siRNA 
delivery in vivo. Nucleic acids research 47, 1082-1096 (2018). 
65. Osborn, M.F. et al. Efficient Gene Silencing in Brain Tumors with 
Hydrophobically Modified siRNAs. Mol Cancer Ther 17, 1251-1258 (2018). 
66. Finkel, R.S. et al. Nusinersen versus Sham Control in Infantile-Onset Spinal 
Muscular Atrophy. The New England journal of medicine 377, 1723-1732 (2017). 
67. Tabrizi, S. et al. Effects of IONIS-HTTRx in Patients with Early Huntington’s 
Disease, Results of the First HTT-Lowering Drug Trial (CT.002). Neurology 90, 
CT.002 (2018). 
68. Hua, Y. et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis 
in a type III SMA mouse model. Genes & development 24, 1634-1644 (2010). 
69. Hickerson, R.P. et al. Gene Silencing in Skin After Deposition of Self-Delivery 
siRNA With a Motorized Microneedle Array Device. Mol Ther Nucleic Acids 2, 
e129 (2013). 
70. Hu, Q. et al. Therapeutic application of gene silencing MMP-9 in a middle 
cerebral artery occlusion-induced focal ischemia rat model. Experimental 
Neurology 216, 35-46 (2009). 
71. Thakker, D.R. et al. siRNA-mediated knockdown of the serotonin transporter in 
the adult mouse brain. Molecular Psychiatry 10, 782 (2005). 
 179 
72. Ferrés-Coy, A. et al. Therapeutic antidepressant potential of a conjugated siRNA 
silencing the serotonin transporter after intranasal administration. Molecular 
Psychiatry 21, 328 (2015). 
73. Chen, Q. et al. Lipophilic siRNAs mediate efficient gene silencing in 
oligodendrocytes with direct CNS delivery. J Control Release 144, 227-232 
(2010). 
74. Milstein, S. in RNA Therapeutics (Cold Spring Harbor Laboratories; 2019). 
75. Querbes, W. et al. Direct CNS delivery of siRNA mediates robust silencing in 
oligodendrocytes. Oligonucleotides 19, 23-29 (2009). 
76. Abbott, N.J., Patabendige, A.A.K., Dolman, D.E.M., Yusof, S.R. & Begley, D.J. 
Structure and function of the blood–brain barrier. Neurobiology of Disease 37, 
13-25 (2010). 
77. Gao, Y. et al. RVG-peptide-linked trimethylated chitosan for delivery of siRNA 
to the brain. Biomacromolecules 15, 1010-1018 (2014). 
78. Wiley, D.T., Webster, P., Gale, A. & Davis, M.E. Transcytosis and brain uptake 
of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. 
Proceedings of the National Academy of Sciences of the United States of America 
110, 8662-8667 (2013). 
79. Godinho, B. et al. Transvascular Delivery of Hydrophobically Modified siRNAs: 
Gene Silencing in the Rat Brain upon Disruption of the Blood-Brain Barrier. Mol 
Ther 26, 2580-2591 (2018). 
80. Passini, M.A. et al. Antisense oligonucleotides delivered to the mouse CNS 
ameliorate symptoms of severe spinal muscular atrophy. Science translational 
medicine 3, 72ra18-72ra18 (2011). 
81. Weiner, G.M. et al. Ommaya reservoir with ventricular catheter placement for 
chemotherapy with frameless and pinless electromagnetic surgical 
neuronavigation. Clin Neurol Neurosurg 130, 61-66 (2015). 
82. Dickerman, R.D. & Eisenberg, M.B. Preassembled method for insertion of 
Ommaya reservoir. Journal of Surgical Oncology 89, 36-38 (2005). 
83. Mangiarini, L. et al. Exon 1 of the HD gene with an expanded CAG repeat is 
sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 
87, 493-506 (1996). 
84. Anderson, E., Boese, Q., Khvorova, A. & Karpilow, J. in RNAi 45-63 (Springer, 
2008). 
85. Schwarz, D.S. et al. Asymmetry in the assembly of the RNAi enzyme complex. 
Cell 115, 199-208 (2003). 
86. Keeler, A.M. et al. Cellular Analysis of Silencing the Huntington's Disease Gene 
Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of 
Q140/Q140 Mice. J Huntingtons Dis 5, 239-248 (2016). 
87. DiFiglia, M. et al. Huntingtin is a cytoplasmic protein associated with vesicles in 
human and rat brain neurons. Neuron 14, 1075-1081 (1995). 
88. Coles, A.H. et al. A high-throughput method for direct detection of therapeutic 
oligonucleotide-induced gene silencing in vivo. nucleic acid therapeutics 26, 86-
92 (2016). 
89. Mullen, R.J., Buck, C.R. & Smith, A.M. NeuN, a neuronal specific nuclear 
protein in vertebrates. Development 116, 201-211 (1992). 
 180 
90. Weyer, A. & Schilling, K. Developmental and cell type‐specific expression of 
the neuronal marker NeuN in the murine cerebellum. Journal of neuroscience 
research 73, 400-409 (2003). 
91. Imai, Y., Ibata, I., Ito, D., Ohsawa, K. & Kohsaka, S. A novel geneiba1in the 
major histocompatibility complex class III region encoding an EF hand protein 
expressed in a monocytic lineage. Biochemical and biophysical research 
communications 224, 855-862 (1996). 
92. Garden, G.A. & Möller, T. Microglia biology in health and disease. Journal of 
Neuroimmune Pharmacology 1, 127-137 (2006). 
93. Shitaka, Y. et al. Repetitive closed-skull traumatic brain injury in mice causes 
persistent multifocal axonal injury and microglial reactivity. Journal of 
Neuropathology & Experimental Neurology 70, 551-567 (2011). 
94. Brown, G.C. & Neher, J.J. Inflammatory neurodegeneration and mechanisms of 
microglial killing of neurons. Molecular neurobiology 41, 242-247 (2010). 
95. Damha, M.J., Giannaris, P.A. & Zabarylo, S.V. An improved procedure for 
derivatization of controlled-pore glass beads for solid-phase oligonucleotide 
synthesis. Nucleic acids research 18, 3813-3821 (1990). 
96. Zamore, P.D. RNA interference: listening to the sound of silence. Nature 
Structural and Molecular Biology 8, 746 (2001). 
97. Castanotto, D. & Rossi, J.J. The promises and pitfalls of RNA-interference-based 
therapeutics. Nature 457, 426 (2009). 
98. Davidson, B.L. & McCray Jr, P.B. Current prospects for RNA interference-based 
therapies. Nature Reviews Genetics 12, 329 (2011). 
99. Miller, V.M., Paulson, H.L. & Gonzalez-Alegre, P. RNA interference in 
neuroscience: progress and challenges. Cellular and molecular neurobiology 25, 
1195-1207 (2005). 
100. Sah, D.W. & Aronin, N. Oligonucleotide therapeutic approaches for Huntington 
disease. The Journal of clinical investigation 121, 500-507 (2011). 
101. Boudreau, R.L. et al. Nonallele-specific silencing of mutant and wild-type 
huntingtin demonstrates therapeutic efficacy in Huntington's disease mice. 
Molecular Therapy 17, 1053-1063 (2009). 
102. Ramachandran, P.S., Boudreau, R.L., Schaefer, K.A., La Spada, A.R. & 
Davidson, B.L. Nonallele specific silencing of ataxin-7 improves disease 
phenotypes in a mouse model of SCA7. Molecular Therapy 22, 1635-1642 
(2014). 
103. Kumar, P. et al. Transvascular delivery of small interfering RNA to the central 
nervous system. Nature 448, 39 (2007). 
104. Huo, H. et al. Polyion complex micelles composed of pegylated 
polyasparthydrazide derivatives for siRNA delivery to the brain. Journal of 
colloid and interface science 447, 8-15 (2015). 
105. Thakker, D.R. et al. Neurochemical and behavioral consequences of widespread 
gene knockdown in the adult mouse brain by using nonviral RNA interference. 
Proceedings of the National Academy of Sciences 101, 17270-17275 (2004). 
106. Burgess, A., Huang, Y., Querbes, W., Sah, D.W. & Hynynen, K. Focused 
ultrasound for targeted delivery of siRNA and efficient knockdown of Htt 
expression. Journal of controlled release 163, 125-129 (2012). 
 181 
107. Stiles, D.K. et al. Widespread suppression of huntingtin with convection-
enhanced delivery of siRNA. Experimental neurology 233, 463-471 (2012). 
108. Dass, C.R. Cytotoxicity issues pertinent to lipoplex‐mediated gene therapy in‐
vivo. Journal of pharmacy and pharmacology 54, 593-601 (2002). 
109. Karra, D. & Dahm, R. Transfection techniques for neuronal cells. Journal of 
Neuroscience 30, 6171-6177 (2010). 
110. Song, H. & Yang, P.-C. Construction of shRNA lentiviral vector. North American 
journal of medical sciences 2, 598 (2010). 
111. Tomar, R.S., Matta, H. & Chaudhary, P.M. Use of adeno-associated viral vector 
for delivery of small interfering RNA. Oncogene 22, 5712 (2003). 
112. Bell, H., Kimber, W.L., Li, M. & Whittle, I.R. Liposomal transfection efficiency 
and toxicity on glioma cell lines: in vitro and in vitro studies. Neuroreport 9, 793-
798 (1998). 
113. Masotti, A. et al. Comparison of different commercially available cationic 
liposome–DNA lipoplexes: Parameters influencing toxicity and transfection 
efficiency. Colloids and Surfaces B: Biointerfaces 68, 136-144 (2009). 
114. Zou, L. et al. Liposome-mediated NGF gene transfection following neuronal 
injury: potential therapeutic applications. Gene Therapy 6, 994 (1999). 
115. Birmingham, A. et al. A protocol for designing siRNAs with high functionality 
and specificity. Nature protocols 2, 2068 (2007). 
116. Reynolds, A. et al. Rational siRNA design for RNA interference. Nature 
biotechnology 22, 326 (2004). 
117. Geary, R.S., Norris, D., Yu, R. & Bennett, C.F. Pharmacokinetics, biodistribution 
and cell uptake of antisense oligonucleotides. Advanced drug delivery reviews 87, 
46-51 (2015). 
118. Khvorova, A., Kamens, J, Samarsky, D, Woolf, T, Cardia, J  (2014). 
119. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic 
administration of modified siRNAs. Nature 432, 173 (2004). 
120. Dolga, A.M. et al. TNF‐α‐mediates neuroprotection against glutamate‐
induced excitotoxicity via NF‐κB‐dependent up‐regulation of KCa2. 2 
channels. Journal of neurochemistry 107, 1158-1167 (2008). 
121. De Paula, D., Bentley, M.V.L. & Mahato, R.I. Hydrophobization and 
bioconjugation for enhanced siRNA delivery and targeting. Rna 13, 431-456 
(2007). 
122. Watts, J.K., Deleavey, G.F. & Damha, M.J. Chemically modified siRNA: tools 
and applications. Drug discovery today 13, 842-855 (2008). 
123. Watts, J.K. & Corey, D.R. Silencing disease genes in the laboratory and the clinic. 
The Journal of pathology 226, 365-379 (2012). 
124. Deleavey, G.F. & Damha, M.J. Designing chemically modified oligonucleotides 
for targeted gene silencing. Chemistry & biology 19, 937-954 (2012). 
125. Li, S.-H. et al. Huntington's disease gene (IT15) is widely expressed in human and 
rat tissues. Neuron 11, 985-993 (1993). 
126. Foster, D.J. et al. Comprehensive evaluation of canonical versus Dicer-substrate 
siRNA in vitro and in vivo. Rna (2012). 
127. Marques, J.T. & Williams, B.R. Activation of the mammalian immune system by 
siRNAs. Nature biotechnology 23, 1399 (2005). 
 182 
128. Ferrazzano, P. et al. Age-dependent microglial activation in immature brains after 
hypoxia-ischemia. CNS & Neurological Disorders-Drug Targets (Formerly 
Current Drug Targets-CNS & Neurological Disorders) 12, 338-349 (2013). 
129. Koshinaga, M. et al. Rapid microglial activation induced by traumatic brain injury 
is independent of blood brain barrier disruption. Histology and histopathology 22, 
129-136 (2007). 
130. Ouimet, C., Miller, P., Hemmings, H., Walaas, S.I. & Greengard, P. DARPP-32, a 
dopamine-and adenosine 3': 5'-monophosphate-regulated phosphoprotein enriched 
in dopamine-innervated brain regions. III. Immunocytochemical localization. 
Journal of Neuroscience 4, 111-124 (1984). 
131. Bartlett, D.W. & Davis, M.E. Insights into the kinetics of siRNA-mediated gene 
silencing from live-cell and live-animal bioluminescent imaging. Nucleic acids 
research 34, 322-333 (2006). 
132. Carroll, J.B. et al. Potent and selective antisense oligonucleotides targeting single-
nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing 
of mutant huntingtin. Molecular Therapy 19, 2178-2185 (2011). 
133. Southwell, A.L. et al. In vivo evaluation of candidate allele-specific mutant 
huntingtin gene silencing antisense oligonucleotides. Molecular Therapy 22, 
2093-2106 (2014). 
134. Southwell, A.L. et al. Ultrasensitive measurement of huntingtin protein in 
cerebrospinal fluid demonstrates increase with Huntington disease stage and 
decrease following brain huntingtin suppression. Scientific reports 5, 12166 
(2015). 
135. Alvarez-Erviti, L. et al. Delivery of siRNA to the mouse brain by systemic 
injection of targeted exosomes. Nature biotechnology 29, 341 (2011). 
136. Marcus, M. & Leonard, J. FedExosomes: engineering therapeutic biological 
nanoparticles that truly deliver. Pharmaceuticals 6, 659-680 (2013). 
137. Deleavey, G.F. et al. Synergistic effects between analogs of DNA and RNA 
improve the potency of siRNA-mediated gene silencing. Nucleic acids research 
38, 4547-4557 (2010). 
138. Allerson, C.R. et al. Fully 2 ‘-modified oligonucleotide duplexes with improved 
in vitro potency and stability compared to unmodified small interfering RNA. 
Journal of medicinal chemistry 48, 901-904 (2005). 
139. Choung, S., Kim, Y.J., Kim, S., Park, H.-O. & Choi, Y.-C. Chemical modification 
of siRNAs to improve serum stability without loss of efficacy. Biochemical and 
biophysical research communications 342, 919-927 (2006). 
140. Czauderna, F. et al. Structural variations and stabilising modifications of synthetic 
siRNAs in mammalian cells. Nucleic acids research 31, 2705-2716 (2003). 
141. Chen, Q. et al. Lipophilic siRNAs mediate efficient gene silencing in 
oligodendrocytes with direct CNS delivery. Journal of Controlled Release 144, 
227-232 (2010). 
142. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic 
siRNAs. Nature biotechnology 25, 1149 (2007). 
143. Dohmen, C. et al. Defined folate-PEG-siRNA conjugates for receptor-specific 
gene silencing. Molecular Therapy-Nucleic Acids 1 (2012). 
 183 
144. Nair, J.K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in 
hepatocytes and elicits robust RNAi-mediated gene silencing. Journal of the 
American Chemical Society 136, 16958-16961 (2014). 
145. Nair, J.K. et al. Impact of enhanced metabolic stability on pharmacokinetics and 
pharmacodynamics of GalNAc–siRNA conjugates. Nucleic acids research 45, 
10969-10977 (2017). 
146. Yu, D. et al. Single-stranded RNAs use RNAi to potently and allele-selectively 
inhibit mutant huntingtin expression. Cell 150, 895-908 (2012). 
147. Lima, W.F. et al. Single-stranded siRNAs activate RNAi in animals. Cell 150, 
883-894 (2012). 
148. Prakash, T.P. et al. Identification of metabolically stable 5′-phosphate analogs 
that support single-stranded siRNA activity. Nucleic acids research 43, 2993-
3011 (2015). 
149. Prakash, T.P. et al. Synergistic effect of phosphorothioate, 5′-vinylphosphonate 
and GalNAc modifications for enhancing activity of synthetic siRNA. Bioorganic 
& medicinal chemistry letters 26, 2817-2820 (2016). 
150. Matranga, C., Tomari, Y., Shin, C., Bartel, D.P. & Zamore, P.D. Passenger-strand 
cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme 
complexes. Cell 123, 607-620 (2005). 
151. Ly, S. et al. Visualization of self-delivering hydrophobically modified siRNA 
cellular internalization. Nucleic acids research 45, 15-25 (2016). 
152. Godinho, B.M. et al. Pharmacokinetic profiling of conjugated therapeutic 
oligonucleotides: a high-throughput method based upon serial blood 
microsampling coupled to peptide nucleic acid hybridization assay. nucleic acid 
therapeutics 27, 323-334 (2017). 
153. Jackson, A.L. et al. Position-specific chemical modification of siRNAs reduces 
“off-target” transcript silencing. Rna 12, 1197-1205 (2006). 
154. Dahlman, J.E. et al. In vivo endothelial siRNA delivery using polymeric 
nanoparticles with low molecular weight. Nature nanotechnology 9, 648 (2014). 
155. Dass, C.R. & Burton, M.A. Modified microplex vector enhances transfection of 
cells in culture while maintaining tumour‐selective gene delivery in‐vivo. 
Journal of pharmacy and pharmacology 55, 19-25 (2003). 
156. Wee, L.M., Flores-Jasso, C.F., Salomon, W.E. & Zamore, P.D. Argonaute divides 
its RNA guide into domains with distinct functions and RNA-binding properties. 
Cell 151, 1055-1067 (2012). 
157. Roehl, I., Schuster, M. & Seiffert, S.  (Google Patents, 2011). 
158. Rozema, D.B. et al. Dynamic PolyConjugates for targeted in vivo delivery of 
siRNA to hepatocytes. Proceedings of the National Academy of Sciences 104, 
12982-12987 (2007). 
159. Deleavey, G.F. et al. The 5′ binding MID domain of human Argonaute2 
tolerates chemically modified nucleotide analogues. Nucleic acid therapeutics 23, 
81-87 (2013). 
160. Manoharan, M. et al. Unique Gene‐Silencing and Structural Properties of 2′‐
Fluoro‐Modified siRNAs. Angewandte Chemie International Edition 50, 2284-
2288 (2011). 
 184 
161. Schirle, N.T., Sheu-Gruttadauria, J. & MacRae, I.J. Structural basis for 
microRNA targeting. Science 346, 608-613 (2014). 
162. Østergaard, M.E. et al. Efficient Synthesis and Biological Evaluation of 5′-
GalNAc Conjugated Antisense Oligonucleotides. Bioconjugate Chemistry 26, 
1451-1455 (2015). 
163. Rajeev, K.G. et al. Hepatocyte-specific delivery of siRNAs conjugated to novel 
non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in 
vivo. Chembiochem 16, 903-908 (2015). 
164. Crooke, S.T., Wang, S., Vickers, T.A., Shen, W. & Liang, X.H. Cellular uptake 
and trafficking of antisense oligonucleotides. Nat Biotechnol 35, 230-237 (2017). 
165. Manoharan, M. in TIDES (https://www.alnylam.com/web/assets/ALNY-ESC-
GalNAc-siRNA-TIDES-May2014-Capella.pdf, 2014). 
166. Coelho, T. et al. Safety and efficacy of RNAi therapy for transthyretin 
amyloidosis. The New England journal of medicine 369, 819-829 (2013). 
167. Osborn, M.F. & Khvorova, A. Improving Small Interfering RNA Delivery In 
Vivo Through Lipid Conjugation. Nucleic Acid Ther (2018). 
168. Fitzgerald, K. et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. The 
New England journal of medicine 376, 41-51 (2017). 
169. Ray, K.K. et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated 
LDL Cholesterol. New England Journal of Medicine 376, 1430-1440 (2017). 
170. Prakash, T.P. et al. Comprehensive Structure-Activity Relationship of 
Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for 
Targeted Delivery to Hepatocytes. J Med Chem 59, 2718-2733 (2016). 
171. Flierl, U. et al. Phosphorothioate backbone modifications of nucleotide-based 
drugs are potent platelet activators. J Exp Med 212, 129-137 (2015). 
172. Behlke, M.A. Progress towards in vivo use of siRNAs. Mol Ther 13, 644-670 
(2006). 
173. Winkler, J., Stessl, M., Amartey, J. & Noe, C.R. Off-target effects related to the 
phosphorothioate modification of nucleic acids. ChemMedChem 5, 1344-1352 
(2010). 
174. Amarzguioui, M., Holen, T., Babaie, E. & Prydz, H. Tolerance for mutations and 
chemical modifications in a siRNA. Nucl. Acids Res. 31, 589-595 (2003). 
175. Harborth, J. et al. Sequence, Chemical, and Structural Variation of Small 
Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene 
Silencing. Antisense & Nucleic Acid Drug Development 13, 83-105 (2003). 
176. Liu, C.C., Liu, C.C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and 
Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118 
(2013). 
177. Mahley, R.W., Weisgraber, K.H. & Huang, Y. Apolipoprotein E4: a causative 
factor and therapeutic target in neuropathology, including Alzheimer's disease. 
Proc Natl Acad Sci U S A 103, 5644-5651 (2006). 
178. Zetterberg, H., Jacobsson, J., Rosengren, L., Blennow, K. & Andersen, P.M. 
Association of APOE with age at onset of sporadic amyotrophic lateral sclerosis. 
J Neurol Sci 273, 67-69 (2008). 
179. Didiot, M.C. et al. Nuclear Localization of Huntingtin mRNA Is Specific to Cells 
of Neuronal Origin. Cell Rep 24, 2553-2560 e2555 (2018). 
 185 
180. Ito, D. et al. Microglia-specific localisation of a novel calcium binding protein, 
Iba1. Molecular Brain Research 57, 1-9 (1998). 
181. Achuta, V.S. et al. Tissue plasminogen activator contributes to alterations of 
neuronal migration and activity-dependent responses in fragile X mice. J 
Neurosci 34, 1916-1923 (2014). 
182. Gu, X. et al. N17 Modifies mutant Huntingtin nuclear pathogenesis and severity 
of disease in HD BAC transgenic mice. Neuron 85, 726-741 (2015). 
183. Herndon, E.S. et al. Neuroanatomic profile of polyglutamine immunoreactivity in 
Huntington disease brains. J Neuropathol Exp Neurol 68, 250-261 (2009). 
184. Southwell, A.L. et al. Huntingtin suppression restores cognitive function in a 
mouse model of Huntington's disease. Science translational medicine 10 (2018). 
185. Takala, R.S. et al. Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal 
Hydrolase-L1 as Outcome Predictors in Traumatic Brain Injury. World Neurosurg 
87, 8-20 (2016). 
186. Taylor, J.P., Brown, R.H., Jr. & Cleveland, D.W. Decoding ALS: from genes to 
mechanism. Nature 539, 197-206 (2016). 
187. De Lahunta, A., Glass, E.N. & Kent, M. Veterinary Neuroanatomy and Clinical 
Neurology-E-Book. (Elsevier Health Sciences, 2014). 
188. Lind, D., Franken, S., Kappler, J., Jankowski, J. & Schilling, K. Characterization 
of the neuronal marker NeuN as a multiply phosphorylated antigen with discrete 
subcellular localization. J Neurosci Res 79, 295-302 (2005). 
189. Dou, C.L., Li, S. & Lai, E. Dual role of brain factor-1 in regulating growth and 
patterning of the cerebral hemispheres. Cereb Cortex 9, 543-550 (1999). 
190. Birmingham, A. et al. 3' UTR seed matches, but not overall identity, are 
associated with RNAi off-targets. Nature methods 3, 199-204 (2006). 
191. Jeong, S.J. et al. Huntingtin is localized in the nucleus during preimplanatation 
embryo development in mice. Int J Dev Neurosci 24, 81-85 (2006). 
192. Wang, G., Liu, X., Gaertig, M.A., Li, S. & Li, X.J. Ablation of huntingtin in adult 
neurons is nondeleterious but its depletion in young mice causes acute 
pancreatitis. Proc Natl Acad Sci U S A 113, 3359-3364 (2016). 
193. Zuccato, C., Valenza, M. & Cattaneo, E. Molecular mechanisms and potential 
therapeutical targets in Huntington's disease. Physiol Rev 90, 905-981 (2010). 
194. Evers, M.M. et al. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution 
and Strong Human Mutant Huntingtin Lowering in a Huntington’s Disease 
Minipig Model. Molecular Therapy 26, 2163-2177 (2018). 
195. Pfister, E.L. et al. Artificial miRNAs Reduce Human Mutant Huntingtin 
Throughout the Striatum in a Transgenic Sheep Model of Huntington's Disease. 
Hum Gene Ther 29, 663-673 (2018). 
196. Grondin, R. et al. Six-month partial suppression of Huntingtin is well tolerated in 
the adult rhesus striatum. Brain 135, 1197-1209 (2012). 
197. Schoch, K.M. & Miller, T.M. Antisense Oligonucleotides: Translation from 
Mouse Models to Human Neurodegenerative Diseases. Neuron 94, 1056-1070 
(2017). 
198. Bhagat, L. et al. Novel oligonucleotides containing two 3'-ends complementary to 
target mRNA show optimal gene-silencing activity. J Med Chem 54, 3027-3036 
(2011). 
 186 
199. Malcolm, D.W., Sorrells, J.E., Van Twisk, D., Thakar, J. & Benoit, D.S. 
Evaluating side effects of nanoparticle-mediated siRNA delivery to mesenchymal 
stem cells using next generation sequencing and enrichment analysis. Bioeng 
Transl Med 1, 193-206 (2016). 
200. Pfister, E.L. et al. Five siRNAs targeting three SNPs may provide therapy for 
three-quarters of Huntington's disease patients. Current biology : CB 19, 774-778 
(2009). 
201. Knauf, M.J. et al. Relationship of effective molecular size to systemic clearance in 
rats of recombinant interleukin-2 chemically modified with water-soluble 
polymers. The Journal of biological chemistry 263, 15064-15070 (1988). 
202. Suk, J.S., Xu, Q., Kim, N., Hanes, J. & Ensign, L.M. PEGylation as a strategy for 
improving nanoparticle-based drug and gene delivery. Advanced drug delivery 
reviews 99, 28-51 (2016). 
203. Fiszer, A., Mykowska, A. & Krzyzosiak, W.J. Inhibition of mutant huntingtin 
expression by RNA duplex targeting expanded CAG repeats. Nucleic acids 
research 39, 5578-5585 (2011). 
204. Skotte, N.H. et al. Allele-specific suppression of mutant huntingtin using 
antisense oligonucleotides: providing a therapeutic option for all Huntington 
disease patients. PloS one 9, e107434-e107434 (2014). 
205. Sathasivam, K. et al. Aberrant splicing of HTT generates the pathogenic exon 1 
protein in Huntington disease. Proceedings of the National Academy of Sciences 
of the United States of America 110, 2366-2370 (2013). 
206. Maday, S., Twelvetrees, A.E., Moughamian, A.J. & Holzbaur, E.L.F. Axonal 
transport: cargo-specific mechanisms of motility and regulation. Neuron 84, 292-
309 (2014). 
 
 
